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Summary 
The recent progress in biotechnological disciplines, such as metabolic engineering or 
synthetic biology, increased the interest of chemical and pharmaceutical industries to 
implement microbial processes for the synthesis of chemicals. However, most 
microorganisms, e.g., Escherichia coli or Saccharomyces cerevisiae, used in biotechnological 
applications are not evolved by nature for the production of industrially relevant compounds, 
which are often hydrophobic, non-charged, volatile, or toxic to the microbial organisms. 
Bioprocess design relies on an integrated approach addressing pathway, cellular, reaction, and 
process engineering to combine the results of natural evolution with the demands of industrial 
applicability.  
In this thesis, the microbial de novo production and selective oxyfunctionalization of the 
highly volatile isoprenoid limonene was investigated as a model system featuring reactants 
with challenging physicochemical characteristics. The cyclic monoterpene limonene and its 
oxygenated adducts are extensively used in the fragrance, food, and cosmetic industries due to 
their olfactory and antimicrobial properties. Key constraints that limit (S)-(-)-limonene 
biosynthesis in recombinant E. coli, related to genetics, physiology, and reaction engineering, 
were identified. A recombinant limonene overproducing E. coli strain expressing the yeast 
mevalonate pathway genes alongside plant derived genes for geranyl diphosphate and 
limonene synthase was constructed. An aqueous-organic high cell density fermentation 
allowed for gram-scale production of limonene (2.7 g Lorg-1) and the facile purification of 
enantiomerically pure (S)-(-)-limonene.  
This and other reported isoprenoid fermentation processes rely on growing recombinant 
microbial biocatalysts, which are typically robust and self-regenerating. However, the 
fermentative production of isoprenoids has to compete with carbon fluxes and energy supply 
for cellular maintenance and growth. The potential of an alternative biocatalyst configuration 
using non-growing, but metabolically active E. coli cells was evaluated to increase the 
availability of cellular resources for the formation of limonene. The use of non-growing cells 
resulted in more than fivefold increased specific limonene yields with respect to cell dry 
weight and glucose as compared to the approach featuring growing cells. The stability of the 
resting cell biocatalyst was initially limiting, but could be enhanced by optimization of the 
fermentation medium leading to high and stable limonene production rates for up to eight 
hours and a high specific yield of more than 50 mg per gram cell dry weight.  
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A bacterial cytochrome P450 limonene hydroxylase was incorporated into the limonene 
producing strain to synthesize the pharmaceutically active limonene adduct perillyl acetate. 
Cultivation of this strain in a batch-fermentation resulted in ineffective limonene synthesis 
and poor cytochrome P450 gene expression. Three strategies of genetic engineering, 
including the optimization of cytochrome P450 gene expression, the use of a translational 
fusion between limonene synthase and cytochrome P450, and the application of a membrane 
bound hydroxylase, did result in the production of (S)-(-)-perillyl acetate using growing 
E. coli. However, the titers remained low, probably as a consequence of fast limonene 
extraction into surrounding environment. Therefore, the concept of mixed-culture resting cell 
fermentation was introduced. Both, a limonene producing strain and a strain containing the 
monooxygenase components were grown separately and combined as resting cells in a 
defined ration. Mixed-culture resting cell fermentations resulted in the effective production of 
oxygenated monoterpenoids.  
The efficiency of many biocatalytic reactions involving industrially interesting reactants is 
constrained by toxification of the applied biocatalyst. Solvent-tolerant Pseudomonas putida 
GS1, catalyzing selective limonene oxidation via the p-cymene degradation pathway, and 
recombinant P. taiwanensis VLB120 were evaluated for continuous perillic acid production. 
Here, toxicity limitations during the multi-step oxyfunctionalization of limonene to perillic 
acid were overcome by the combination of biological and technological strategies. A tubular 
segmented-flow biofilm reactor enabling membrane mediated substrate supply and efficient 
in situ product removal was used. The productivity of P. putida GS1 was highly dependent on 
the carbon source and reached 35 g Ltube day-1 when glycerol was supplied. 10-fold lower 
productivities, irrespective of the applied carbon source, were reached when the recombinant 
P. taiwanensis VLB120 harboring p-cymene monooxygenase and p-cumic alcohol 
dehydrogenase was cultivated as a biofilm under segmented flow conditions. The preparative 
perillic acid synthesis was verified by purification of product from the outlet stream.  
The described strategies are complementary to and can be combined with metabolic and 
pathway engineering approaches aiding in developing sustainable and efficient bioprocesses 
for the de novo synthesis of valuable and pharmaceutically active isoprenoids from renewable 
resources. Furthermore, the strategies can be transferred to other microbial syntheses that 
feature reactants with similar physicochemical properties and, therefore, require similar 
efforts in pathway, cell, reaction, and process engineering. 
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Zusammenfassung 
Das Interesse der chemischen und pharmazeutischen Industrie, traditionelle chemische 
Verfahren durch mikrobielle Produktionsprozesse für die Synthese von 
Gebrauchschemikalien zu ersetzen, wächst zunehmend. Diese Entwicklung wird insbesondere 
durch den Fortschritt in den biotechnologischen Disziplinen, wie Metabolic Engineering oder 
Synthetische Biologie unterstützt. Eine besondere Herausforderung stellt dabei die Produktion 
hydrophober, ungeladener, flüchtiger und toxischer Chemikalien dar, da die meisten 
industriell eingesetzten Mikroorganismen, wie zum Beispiel Escherichia coli oder 
Saccharomyces cerevsiae, evolutiv nicht für die Synthese von Substanzen mit den genannten 
physikochemischen Eigenschaften optimiert sind. Um das Ergebnis der natürlichen Evolution 
mit den Anforderungen der industriellen Anwendbarkeit zu vereinen ist ein integrierter 
Ansatz, der die verschiedenen Ebenen der Bioprozessentwicklung adressiert, notwendig. 
Dieser Ansatz beruht auf der aufeinander abgestimmten Optimierung des metabolischen 
Stoffwechselweges, der Zelle als Biokatalysator, sowie der beteiligten Reaktions- und 
Prozesstechnik. 
In dieser Arbeit wurde die mikrobielle de novo Synthese und selektive Funktionalisierung des 
aliphatischen und flüchtigen Isoprenoids Limonen als Modellsystem für die Synthese und 
Prozessierung von Reaktanden mit, in Bezug auf den mikrobiellen Biokatalysator, nicht 
natürlichen physikochemischen Eigenschaften, untersucht. Das zyklische Monoterpen 
Limonen und dessen oxygenierte Addukte finden aufgrund ihrer olfaktorischen und 
antimikrobiellen Eigenschaften vielfache Verwendung in der Duftstoff-, Nahrungsmittel- und 
Kosmetikindustrie. 
Ein Hauptziel der vorliegenden Arbeit war es, Schlüsselbedingungen, welche die Biosynthese 
von (S)-(-)-Limonen in rekombinanten E. coli Stämmen in Bezug auf genetische, 
physiologische und reaktionstechnische Faktoren limitieren, zu identifizieren und aufzuheben. 
Dazu wurde zunächst, durch die heterologe Überexpression des Mevalonat 
Stoffwechselweges der Bäckerhefe, einer Geranylpyrophosphat und einer Limonene Synthase, 
ein (S)-(-)-Limonen produzierender Stamm entwickelt. In einer organisch-wässrigen 
Hochzelldichtefermentation konnte Limonen im Gramm-Maßstab (2.7 g Lorg-1) produziert und 
in entantiomerenreiner Form aufgereinigt werden. 
Dieser und alle bisher publizierten Produktionsprozesse für Isoprenoide nutzen wachsende 
Zellen als Biokatalysatoren, da diese eine vergleichsweise hohe Robustheit und die Fähigkeit 
zur Selbsterneuerung aufweisen. Dabei dient die Kohlenstoffquelle sowohl zur Synthese der 
Zusammenfassung 
   
 
X 
Isoprenoide, als auch zum Aufbau der Biomasse, wodurch es zu einer Kompetition beider 
Nutzungswege kommt. Um den Anteil des Kohlenstoffes zugunsten der Limonen Synthese zu 
verschieben, wurde das Potential ruhender, aber metabolisch aktiver Zellen als alternative 
Biokatalysator-Konfiguration evaluiert. Die Limonen Ausbeute in Bezug auf die eingesetzte 
Biomasse und Glukose konnte hiermit um das Fünffache erhöht werden. Die anfänglich 
limitierende Stabilität des nicht-wachsenden Biokatalysators, wurde durch die Optimierung 
des Fermentationsmediums verbessert. Schließlich wurde in MgSO4-freiem Minimalmedium 
eine hohe und über acht Stunden stabile Limonen-Produktionsrate erzielt, wodurch eine sehr 
hohe spezifische Ausbeute (50 mg gcdw-1) erreicht werden konnte. 
Zur Synthese des pharmazeutisch aktiven, oxygenierten Limonen Adduktes Perillyl Acetat 
wurde zusätzlich zum Limonen Biosyntheseweg eine bakterielle Cytochrom P450 
Monooxygenase co-exprimiert. Beim Einsatz des rekombinanten Stammes in einer Batch-
Fermentation war die Produktbildung anfänglich durch eine verringerte Limonen Synthese 
und ein niedriges Cytochrom P450 Expressionslevel limitiert. Daraufhin wurden drei 
unterschiedliche genetische Optimierungsstrategien angewendet, die auf der Erhöhung der 
Cytochrom P450 Expression, der Nutzung eines Fusionsproteins aus Limonen Synthase und 
Cytochrom P450, sowie der Verwendung einer membrangebundenen Monooxygenase 
basierten. Dennoch wurden dabei nur sehr geringe finale Konzentrationen erreicht, was auf 
die diffusive Ausschleusung von Limonen aus der Zelle, kinetisch der intrazellulären 
Oxidation überliegend, zurückgeführt wurde. Daher wurde ein neuartiges 
Fermentationskonzept enwickelt, welches auf der Mischung zweier ruhender 
Zellpopulationen beruht. Sowohl der Limonen-produzierende, als auch der Limonen-
oxidierende Stamm wurden getrennt voneinander kultiviert und in definierten Verhältnissen 
in Form ruhender Zellen vereint. Diese Gemischtkulturfermentation führte schließlich zu 
einer effizienten Produktion des Monoterpenoids Perillyl Acetat.  
Die Effizienz vieler biokatalytischer Reaktionen wird durch die Toxifizierung des 
verwendeten mikrobiellen Biokatalysators durch eingesetzte oder entstehende Reaktanden 
limitiert. In dieser Arbeit wurden der Lösungsmittel-tolerante Organismus Pseudomonas 
putida GS1, der die selektive Oxidation von Limonen zur Perillasäure über den nativen  
p-Cymol Abbauweg katalysiert, und ein entsprechend rekombinanter Organismus 
(P. taiwanensis VLB120) in Bezug auf ihre Fähigkeit zur kontinuierlichen Produktion von 
Perillasäure untersucht. Durch die Kombination biologischer und technischer Methoden 
konnte die Toxifizierung des Biokatalysators während dieser Mehrschrittoxidation vermieden 
werden. Es wurde ein tubulärer Biofilmreaktor eingesetzt, der auf einer Membran-
Zusammenfassung 
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vermittelten Substratversorgung und der kontinuierlichen Entfernung des toxischen 
Reaktionsproduktes beruht. Die Produktivität des katalytischen P. putida GS1 Biofilmes war 
abhängig von der eingesetzten Kohlenstoffquelle und erreichte einen Maximalwert von 
35 g LReaktor d-1. Die maximale Produktivität des rekombinanten Biofilmes war um etwa das 
Zehnfache geringer und wurde nicht durch die Art der eingesetzten Kohlenstoffquelle 
beeinflusst. Die Aufreinigung der produzierten Perillasäure zeigte die präparative 
Anwendbarkeit des Systems. 
Die in dieser Arbeit angewendeten Strategien sind komplementär zu und kombinierbar mit 
Methoden des Metabolic Engineerings. Sie tragen durch neuartige Ansätze dazu bei, 
nachhaltige und effiziente biologische Prozesse zur industriellen Produktion von Isoprenoiden 
aus erneuerbaren Rohstoffen zu entwickeln und zu verbessern. Weiterhin können diese 
Strategien für andere Verbindungen eingesetzt werden, die ähnliche physikochemische 
Eigenschaften aufweisen und dessen mikrobielle Produktion daher entsprechende 
Optimierung des Stoffwechselweges, der Zelle als Biokatalysator sowie der Reaktions- und 
Prozesstechnik benötigt. 
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1.1 Microbial cell factories for sustainable industrial processes  
What is sustainable industry? The Organization for Economic Co-operation and Development 
(OECD) adapted the initial definition of the broad and multifaceted term sustainability for 
industrial processes and conceived a general definition of a sustainable industry: 
 
“Industry is sustainable when it produces goods and services in such a manner as to meet the 
needs and aspirations of the present without compromising the ability of future generations to 
meet their own needs” (Jaworski, 2001). 
 
Consequently, a sustainable industry, as does the sustainable development in general, requires 
to be economically viable, environmentally compatible, and socially responsible (Jaworski, 
2001).  
The prime example of a sustainable system is Nature itself in which highly efficient chemical 
production systems and closed material streams function concertedly. The translation of this 
evolutionary natural optimum into technical solutions of similar efficiency is one of the key 
objectives in the development of sustainable industry. Already in the end of the last century, 
the OECD stated that following the path towards industrial sustainability inevitably requires 
the implementation of biotechnological processes into existing classical manufacturing routes 
for the synthesis of commodity, fine, and pharmaceutical chemicals (Bull, 1998). Thereby, the 
term “biotechnological process” can be interpreted as any kind of biological or biologically-
derived system that is employed to catalyze chemical reactions. This may cover any 
biological system ranging from isolated enzymes in various configurations catalyzing 
individual reactions in a chemical process to microbial cell factories for the one-pot 
biosyntheses of complex compounds that cannot be accessed by traditional chemical synthesis. 
In view of that, utilization of and research on microbial cell factories that use renewable and 
readily available resources, i.e., sugars or CO2 and sunlight, for manufacturing industrially 
relevant molecules for food, feed, pharma, or biofuel applications, ideally featuring closed 
material streams, appear as integral constituents on the way towards a truly sustainable 
industry. Therefore, a sustainable industry necessarily comes alongside a world “where 
biotechnology contributes to a significant share of the economic output” and can be therefore 
also associated with the term bioeconomy (Arundel and Sawaya, 2009).  
Since Louis Pasteur postulated the role of microorganisms in alcoholic fermentation for the 
production of wine (Barnett, 2003), many biotechnological production methods were 
Chapter 1: General introduction 
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employed resulting in bioprocesses at a multi-million ton scale per year for the production of, 
e.g., amino acids, proteins, or short-chain alcohols. With emerging modern disciplines such as 
synthetic or systems biology (including, e.g., omics-technologies) and the advent of 
recombinant DNA technologies and DNA synthesis, design, construction, and 
characterization of heterologous biological cell factories became feasible, fast, and affordable. 
Consequently, biotechnological de novo production routes towards a vast variety of 
compounds including drug precursors (e.g., (S)-reticuline (DeLoache et al., 2015; Nakagawa 
et al., 2011), taxadiene (Ajikumar et al., 2010), artemisinic acid (Paddon and Keasling, 2014), 
hydrocortisone (Szczebara et al., 2003)), fine chemicals (e.g., γ-aminobutyric acid (Park et al., 
2013), p-coumaric acid (Kang et al., 2012), ω-hydroxy carboxylic acids (Clomburg et al., 
2015)), polymers (e.g., polyhydroxyalkanoates (Agnew et al., 2012)), and commodity 
chemicals (e.g., alkanes (Schirmer et al., 2010), alkenes (Howard et al., 2013), fatty acids 
(Zhang et al., 2012), fatty alcohols (Cao et al., 2015; Steen et al., 2010), fatty acid ethyl esters 
(Kalscheuer et al., 2006; Steen et al., 2010)) were invented. Many of the reported syntheses 
require the implementation of complex foreign genetic pathways, fine tuning with respect to 
expression levels, and metabolic and regulatory interventions as the heterologous hosts are 
not optimized by evolution for the fabrication of these compounds. Despite the immense 
methodological and technical progress, our knowledge on the regulatory network, genetic and 
metabolic dynamics, and system wide energy/carbon fluxes and interconnections is still 
restricted. Thus, the majority of the reported processes is rather ineffective with respect to 
carbon yield and titer, rarely moves beyond the proof-of-principle stage, and is, thus, far away 
from economic competitiveness. In addition, the development of required reaction and 
process technologies (for, e.g., scalability) is often neglected in academic research. 
Bioprocess development, however, can only be effective when following a systematic and 
system-oriented biotechnology approach that covers research on both the biocatalyst and 
integrated reaction/process technologies (Bechtold et al., 2006; Kuhn et al., 2010; Lima-
Ramos et al., 2014; Park et al., 2008; Woodley, 2008). Nowadays, roughly 90% of 
commodity or fine chemicals are still produced from petrochemical feedstocks (Kircher, 
2012), but the anticipated decline of fossil resources fuels the development of alternative, 
biotechnological production processes as part of a sustainable industry (Murphy, 2011). 
The microbial bioproduction of isoprenoids, a large class of industrially relevant natural 
products, from renewable resources can be used to exemplify the progress regarding 
microbial cell factories for sustainable chemical synthesis. The diversity of isoprenoids with 
regard to physicochemical properties, biological functions, and potential industrial utilization 
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purposes is tremendous. This diversity and the accessibility of isoprenoid natural products via 
(at least) three different routes, namely isolation from natural sources, chemical (semi-
)synthesis, and microbial biofabrication renders this class of chemicals a well-suited indicator 
reflecting the current status on the way to a bio-based economy. This introductory chapter 
focusses on reviewing the state of the art research on isoprenoid microbial cell factories and 
their implementation into sustainable chemical manufacturing processes. The following 
sections provide a brief overview of biological function, biosynthesis, and technological 
utilization of isoprenoids. Subsequently, the above named three access routes for isoprenoids 
are presented. Current microbial isoprenoid production processes are emphasized by 
highlighting selected examples. These processes, operated at small lab- or large industrial 
scale, are evaluated within the framework of different but mutually interrelated bioprocess 
design levels (pathway-, cellular-, reaction-, process engineering). Finally, after assessing the 
different access routes to isoprenoids with respect to efficiency, environmental impact, and 
future prospects, section 1.7 provides the scope of the present dissertation and outlines how 
the results contribute to the development of sustainable industrial manufacturing processes. 
1.2 Isoprenoids – Biological function, biosynthesis, and technological 
utilization 
Definition and biological function. Isoprenoids, also often referred to as terpenoids, constitute 
the largest group of natural products. To date, the estimated number of identified isoprenoids 
fluctuates between 30,000 and more than 55,000 structurally different compounds (Dickschat, 
2011; Maimone and Baran, 2007). As the chemical structures of terpenoids vary substantially 
from rather simple and aliphatic (e.g., isoprene, limonene) to highly diverse and 
functionalized with heteroatoms (e.g., artemisinin, cholesterol, paclitaxel) (Figure 1.1), so do 
the chemical properties, biological functions, and (potential) industrial applications. 
Terpenoids are ubiquitous in organisms of all taxonomic kingdoms and can be assigned to the 
group of secondary metabolites. They play key roles in signal transduction (as hormones) 
(Gershenzon and Dudareva, 2007), intra- or inter-species communication (as attractants, 
repellents, pheromones) (Breitmaier, 2006; Hung et al., 2015), as chemical mediators (e.g., as 
photopigments) (Pattanaik and Lindberg, 2015), or as stress regulators (e.g., as antioxidants) 
(Graßmann, 2005). Many sesquiterpenes from e.g., the drimane superfamily and most 
monoterpenes show severe toxicity towards a variety of different organisms (Gershenzon and 
Dudareva, 2007) such as bacteria (Friedman et al., 2002; Rastogi et al., 1998), fungi (Hammer 
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et al., 2003; Lunde and Kubo, 2000), insects (Justicia et al., 2005; Lee et al., 2002), or 
mollusks (Frank et al., 2002). 
 
Figure 1.1: Schematic representation of some industrially relevant isoprenoids exemplarily selected 
from different classes (hemi- (C5), mono- (C10), sesqui- (C15), diterpenoids (C20)). 
Biosynthesis. The immense chemical repertoire of biological systems is built from a relatively 
low number of central metabolic intermediates. This is also reflected in the chemical class of 
isoprenoids. All isoprenoids are synthesized by sequential condensation of the two universal 
C5 building blocks dimethylallyl diphosphate (DMAPP) and isopentenyl diphosphate (IPP) 
(George et al., 2015). Two biosynthetic pathways, the mevalonate (MEV) pathway and 2-C-
methyl-D-erythritol 4-phosphate (MEP, non-mevalonate pathway) pathway, have evolved to 
supply the two building blocks from intermediates of the central carbon metabolism. Until the 
end of the 20th century the mevalonate pathway was believed to be the only biosynthetic route 
toward IPP and DMAPP as it was found in many organisms (Rohdich et al., 2001). The MEP 
pathway, discovered in the late 1990s by Rohmer and coworkers (Rohmer et al., 1993; 
Rohmer, 1999), is native to plants, which possess, although spatially separated, both the MEV 
and the MEP pathway. The MEP pathway was also found to be native to the largest portion of 
bacteria, some algae, and protozoa (Gräwert et al., 2011; Rohdich et al., 2001). 
Staphylococcus aureus and Enterococcus faecalis are some of the very few eubacteria that 
utilize the MEV pathway for isoprenoid biosynthesis (Wilding et al., 2000).  
The MEV pathway leads to the production of IPP and DMAPP via the central intermediate 
mevalonate and starts with the Claisen-type condensation of two acetyl-CoA molecules by the 
acetyl-CoA-acetyltransferase (Figure 1.2). Two moles of NADPH and three moles of ATP are 
required for the synthesis of one mole IPP (Gruchattka et al., 2013). IPP in turn is then 
isomerized to DMAPP (Ramos-Valdivia et al., 1997). The MEP pathway, in contrast, is 
initially fueled by the thiamine pyrophosphate-dependent transfer of an acetaldehyde moiety 
from pyruvate to glyceraldehyde-3-phosphate yielding 1-deoxy-D-xylulose 5-phosphate 
(Gräwert et al., 2011). The reaction is accompanied by carbon dioxide elimination. 
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Isomerization of IPP to DMAPP is not required as both compounds are concurrently formed 
during the last step of the MEP pathway (Figure 1.2).  
 
Figure 1.2: Schematic representation of the isoprenoid precursor (IPP, DMAPP) biosynthesis via the 
non-mevalonate (MEP) or the mevalonate (MEV) pathway. The sequential condensation and 
subsequent removal of the diphosphate group from these precursors is frequently followed by 
cyclization leading to of different isoprenoids. The number of C5 building blocks is the basis for the 
nomenclature and the assignment to different classes of isoprenoids, of which selected examples are 
shown. 
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Nevertheless, the isomerase enzyme is present in many organisms featuring the MEP pathway. 
In total, three moles of NADPH and two moles of ATP are harnessed in the MEP pathway for 
the synthesis of one mole IPP (Gruchattka et al., 2013). The condensation of the universal C5 
building blocks is catalyzed by the members of the “short-chain prenyltransferase” enzyme 
family and leads, depending on the chain-length specificity of the involved enzyme, to 
different prenyl diphosphates (Burke et al., 1999). Determined by the chain length of this 
prenyl diphosphates the corresponding aliphatic molecules, resulting from the carbocation 
mediated cyclization, are classified as hemi-(C5), mono-(C10), sesqui-(C15), di-(C20), tri-
(C30), or tetraterpenes (C40) (Figure 1.1) (Kirby and Keasling, 2008). The immense variety of 
different isoprenoid structures is achieved by further functionalization, decoration, 
rearrangement, or degradation of these terpenes.  
Technological utilization. Based on their multitude of biological functions and diverse 
chemical properties terpenoids are also ubiquitous in daily human life and therefore of great 
interest for the pharmaceutical, food, cosmetic, and fine chemical industries. Paclitaxel 
(TaxolTM) and artemisinine are probably the most prominent examples for pharmaceutically 
active terpenoids and already regularly applied in cancer chemotherapy (Johnson et al., 2006) 
and malaria treatment (Plowe, 2014), respectively. Besides these rather famous examples, 
numerous other terpenes such as the monoterpenoid menthol or the triterpenoic acid fusidic 
acid feature pharmaceutically promising analgesic (Guimarães et al., 2014; Kamatou et al., 
2013) or antimicrobial (Jones et al., 2010) properties, respectively. The monoterpenoids 
limonene and perillyl alcohol (besides many others) for instance provoke antiproliferative 
effects in various types of cancer cells (Gelb et al., 1995; Gould, 1997) and are currently 
evaluated in clinical phase I or II trial studies.  
Many volatile isoprenoids typically also possess characteristic olfactory properties. Limonene 
for example exhibits, depending on the stereochemical configuration, either a turpentine-like 
(S-enantiomer) or a fresh citrus-like (R-enantiomer) odor, is classified as GRAS (general 
recognized as safe) compound, and is, thus, exceptionally suited as additive for household 
chemicals (e.g., cleaning agents), cosmetics (e.g., deodorants), or food products (Ciriminna et 
al., 2014). More recently some branched terpenes or terpene-related compounds such as 
bisabolene (Peralta-Yahya et al., 2011), pinene, sabinene, farnesane, and limonane (Renninger 
et al., 2011; Ryder, 2009) also gained interest as potential novel biofuels of biofuel additives. 
Commercially available bisabolane (50% bisabolane, 20% farnesane, 7% aromatized 
bisabolene) has a cetane number of around 42 and thus can be used as alternative to D2 diesel 
fuel (cetane number between 40 and 55) (Peralta-Yahya et al., 2011).  
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These examples impressively demonstrate that terpenes and terpene-derived (natural) 
products have become an omnipresent and integral part of our daily live and comprise a 
multibillion US$ market (Schewe et al., 2015). Given the large number of different 
isoprenoids it seems to be obvious that further exploiting this plethora of chemical structures 
will reveal many more interesting and desirable compounds.  
 
1.3 Access to isoprenoids - Isolation from natural sources 
The most traditional route for gaining access to pharmaceutically or industrially attractive 
isoprenoids is the isolation from their natural sources (Monteiro and Veloso, 2004). Many 
hemi-, mono-, and sesquiterpenoids are major ingredients of plant essential oils. (R)-(+)-
limonene is the predominant component (90–94%) of orange oil, which is obtained by steam 
distillation of orange peels remaining as waste from the manufacturing process of orange 
juice. The worldwide annual production in 2013 exceeded 70,000 tons (Ciriminna et al., 
2014). Thus, the isolation of (R)-(+)-limonene from natural sources can be considered 
economic, but is constrained by climatic or geopolitical conditions. A sub-standard harvest 
and the huge amounts of limonene used as cleanser component after the Deepwater Horizon 
catastrophe in 2010 caused the limonene price to rise to $4-5 from approximately $1 per 
pound in 2009 (Moon, 2011). This demonstrates that price and steady supply of raw materials 
isolated from natural sources can be highly fluctuating and that novel production routes may 
be necessary to complement the traditional manufacturing processes. 
Such a complementation of traditional procedures by novel biotechnological routes has been 
established for the production of the antimalarial drug artemisinin. Since 2013 the traditional 
heat-based solvent extraction of artemisinin from the sweet wormwood (Artemisia annua) at 
an approximated annual scale of 200 metric tons is supplemented by the semisynthetic 
production of artemisinin (Paddon et al., 2013; Turconi et al., 2014). This approach employs a 
combined procedure relying on the microbial fermentation of artemisinic acid and a chemical 
reaction cascade yielding the final product artemisinin. The annual production of 
semisynthetic artemisinin was reported as 30 metric tons in 2013 (Turconi et al., 2014). 
Perillyl alcohol for instance, a valuable monoterpenoid alcohol, is a potent cytotoxic (Boon et 
al., 2000) and antimicrobial agent (Duelund et al., 2012) and naturally occurring in the leafs 
of Perilla frutescens and other plants. Perillyl alcohol (and its oxidized products perillyl 
aldehyde and acid) is part of the essential oil of this plant, which adds up to 0.05 to 1% of the 
total dry weight (Yu et al., 1997). Roughly 100 to 2000 tons of dried plant material would be 
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required for the production of 1 ton of perillyl alcohol assuming that the essential oil contains 
perillic alcohol as the sole terpenoic material. Noteworthy, this simplified calculation is based 
on the plant dry weight and does not take the chemodiversity of the plant essential oil into 
account. Also the resulting laborious separation of perillyl alcohol from the other oil 
components is neglected. The perillyl alcohol share in the Perilla essential oil is roughly 2% 
(Tabanca et al., 2015), which increases the required amount of plant material by a factor of 50 
to minimally 5000 tons. 
Therefore, the economic niche building the basis for the access to terpenoids by isolation 
from their natural sources is rather narrow. Isolation is only economically viable if the desired 
compound accumulates to rather high levels (more than 1% of the total dry weight for highly 
valuable products such as artemisinin) in the respective organisms. As illustrated by the 
example of perillyl alcohol it becomes obvious that for most isoprenoids quite the contrary is 
true, and, thus, other sources should be explored for the production of these value-added 
compounds. 
1.4 Access to isoprenoids - Chemical synthesis 
The low abundancy of several terpenoids in natural systems fueled the development of the 
second traditional route for the industrial production of valuable isoprenoids by chemical 
synthesis. The total synthesis of the relatively simple terpenoids pinene and racemic limonene 
can be readily realized at high yields by classical chemical methods such as alkylation 
(Thomas and Fallis, 1976) or Diels-Alder type cycloadditions (Thomas and Bessiere, 1989) 
starting from a benzalcyclohexanone derivative or isoprene, respectively. The current 
worldwide production of the C10 monoterpene (-)-menthol exceeds 19,000 metric tons per 
year (Schäfer, 2013). From that, approximately 6000 metric tons are manufactured chemically 
from m-cresol or myrcene/isoprene via the Haarman-Reimer or the Takasago process, 
respectively (Schäfer, 2013).  
Despite the impressive progress in the total synthesis of increasingly complex and highly 
functionalized chiral molecules such as the polyketide brevetoxin A featuring 10 rings and 22 
stereocenters (Crimmins et al., 2009; Nicolaou et al., 1998) or the alkaloid daphenylline (Lu 
et al., 2013), the total synthesis of terpenes and terpenoids is possible in some cases still 
remains challenging for countless brilliant chemists and often results in low yields (Maimone 
and Baran, 2007). Whereas the synthesis of unfunctionalized terpenes appeared to be more 
straightforward, the synthesis of complex terpenoids harboring multiple ring structures and 
stereocenters such as taxol (Nicolaou et al., 1994) is highly demanding. This is also 
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particularly valid for structurally less complex, though functionalized isoprenoids such as the 
oxygenated monoterpene perillyl alcohol. Chemical syntheses of perillyl alcohol have rarely 
been reported and the most efficient one has been described only recently (Geoghegan and 
Evans, 2014). Perillyl alcohol can be obtained via the naturally isolated or chemically 
synthesized limonene (both enantiomers) by the palladium(0)-mediated Claisen-type 
rearrangement of a secondary allylic acetate (Figure 1.3) (Geoghegan and Evans, 2014). 
However, this four step synthesis reaches only an overall yield of 39% and the rearrangement 
reaction could not be driven to completion (Geoghegan and Evans, 2014). This reaction 
profits from the two sp2 hybridized carbon atoms adjacent to the C7 methyl group of limonene 
for the initial formation of the allylic acetate and features a relatively environmentally benign 
palladium catalyst. Like for other aliphatic compounds, the regioselective oxygenation of 
terpenes yet appears demanding for synthetic chemistry and is often environmentally 
unfriendly (heavy metal catalysts, solvents etc.) (Kamata et al., 2010).  
 
Figure 1.3: Chemical synthesis of (R)-(+)-perillyl alcohol from limonene. m-CPBA: meta-chloro-
perbenzoic acid, LDA: lithium diisopropylamide, THF: tetrahydrofuran, Ac2O: acetic anhydride, Py: 
pyridine, Pd(PPH3): palladium(0) catalyst (Geoghegan and Evans, 2014). 
Taken together, the organic synthesis of industrially relevant isoprenoids covers the entire 
range from highly efficient to nearly impossible for economic manufacturing. Additionally, 
many syntheses still rely on naturally isolated terpenes as raw material, and are therefore 
facing the same challenges as described above. The availability of both fossil resources and 
agriculturally usable land area providing the raw material for chemical syntheses of higher 
isoprenoids is already restricted and, in view of the growing world population, will become 
severely limited in future. Therefore, the required diligent and sustainable use of natural 
resources necessitates research on novel ways for isoprenoid access and leverages the 
development of other economically feasible routes for production of terpenoids. 
Semisynthetic or fully biological syntheses using genetically engineered microbial factories in 
scalable and controlled systems would provide competitive ways for isoprenoid production if 
they could be operated to reach high product yields. 
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1.5 Microbial production of isoprenoids 
Early endeavors on the heterologous production of valuable isoprenoids with microorganisms 
have been undertaken already in the early 1990s (Yamano et al., 1994). Although the 
accumulation of carotenoids in recombinant microorganisms could be assessed easily by the 
formation of reddish or yellowish pigments, the yields of β-carotene and lycopene remained 
very low (~100 µg gcdw-1). Thus, industrial applications seemed to be out of scope. Frequently 
applied microorganisms in industrial biotechnology such as Escherichia coli or 
Saccharomyces cerevisiae feature also native terpene biosynthesis pathways, but flux via the 
isoprenoid biosynthesis pathways is inherently low and highly regulated. Biochemical 
engineers recognized that the preparative biotechnological production of isoprenoids in 
recombinant microorganisms cannot be accomplished by mere introduction of the respective, 
often plant derived, terpene synthases (Martin et al., 2003). 
From then on, designing and constructing microbial cell factories for isoprenoid synthesis 
developed into a prime example for diverse successful bottom-up synthetic and top-down 
systems biology strategies. The achievements in the microbial production of isoprenoids will 
be reviewed on the individual levels of bioprocess engineering in the following sections. After 
focusing on the optimization of the precursor supply by optimization by modulation of the 
directly involved pathway genes, strategies in cellular engineering (strategies that are not 
directly aiming at enhancing pathway gene expression), reaction engineering, and process 
engineering (e.g., downstream processing) are discussed. 
Precursor pathway engineering. The low flux through the MEP pathway in E. coli was 
identified as the major limitation for producing copious quantities of isoprenoids in 
(recombinant) microorganisms. Initially, research on increasing the isoprenoid precursor 
supply in E. coli focused on the optimization of the native MEP pathway by overexpression of 
putatively rate-limiting enzymes. Overexpression of dxs (DOXP synthase), catalyzing the 
initial step of the MEP pathway, followed by optimization of promotor strength and plasmid 
copy number, indeed moderately increased lycopene production six fold as compared to the 
control strain (Kim and Keasling, 2001). Additional overexpression of dxr (DOXP 
reductoisomerase) again resulted in a further 1.4-2-fold increased lycopene levels (Kim and 
Keasling, 2001). The DMAPP/IPP isomerase (idi1) has been also identified as a promising 
engineering target. Overexpression of idi1 alongside the two rate limiting enzymes dxs and 
dxr was shown to be most efficient for the production of isoprenoids via the MEP pathway in 
numerous cases (Boghigian et al., 2012b; Du et al., 2014; Lee et al., 2004; Morrone et al., 
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2010). Although substantial progress was made by engineering the MEP pathway, harnessing 
and modulating this endogenous route for biotechnological isoprenoid synthesis only resulted 
in relatively low terpenoid levels and specific yields in the single-digit mg gcdw-1 range (Table 
1.1). In frequent cases this poor performance is attributed to the native MEP pathway being 
subject to the host intrinsic regulatory network (Chang et al., 2007; Vickers et al., 2014). 
Perturbation of this synchronized network by overexpressing the involved pathway genes 
might lead to unbalanced pathway fluxes, inhibitions or the accumulation of toxic 
intermediates.  
The breakthrough in engineering microbes for isoprenoid production was achieved in 2003, 
when Keasling and coworkers reported the introduction of the yeast mevalonate pathway into 
E. coli. Five heterologous (erg13, tHMGR1, erg12, erg8, erg19) and three homologous 
(thiolase (atoB), IPP/DMAPP isomerase, and FPP synthase) genes were overexpressed in the 
recipient E. coli strain to increase the biosynthesis of the universal isoprenoid precursors. Co-
expression of the Artemisia annua amorphadiene synthase resulted in sesquiterpene 
production levels exceeding 0.1 g L-1 (Martin et al., 2003). Besides the toxicity of some 
intermediates (IPP, 3-hydroxy-3-methyl-glutaryl-CoA (Hmg-CoA)), which can be relieved by 
the heterologous expression of a terpene synthase (Martin et al., 2003) or replacement of the 
initially applied S. cerevisiae HMG-CoA reductase by a kinetically superior variant (Pitera et 
al., 2007), the introduction of the mevalonate pathway seemed to be a preferred option for 
heterologous isoprenoid biosynthesis in E. coli.  
Since then, substantial efforts in several research groups have been undertaken to balance the 
expression levels of the individual pathway enzymes by proven pathway optimization 
approaches such as variation of transcriptional control elements (Anthony et al., 2009; Pitera 
et al., 2007), codon usage (Redding-Johanson et al., 2011), translation (Nowroozi et al., 2014), 
and gene selection (Ma et al., 2011; Yang et al., 2012a). Tremendous improvements in 
production yields (e.g., almost 170-fold improvement of limonene concentration as compared 
to a non-engineered system (Alonso-Gutierrez et al., 2013) of various terpenes have been 
reported to profit from the optimized precursor supply via the mevalonate pathway (Tsuruta et 
al., 2009; Yang et al., 2012a). An effective high-flux mevalonate pathway for isoprenoid 
production in E. coli is comprised of two separate operons on a medium copy number vector 
(p15A) that are controlled by the lacUV5 promotor and the trc promoter (Sarria et al., 2014; 
Tsuruta et al., 2009), respectively The first operon is composed of the E. coli thiolase atoB 
and (codon-optimized) variants of the Staphylococcus aureus genes encoding for the HMG-
CoA synthase (mvaS) and the HMG-CoA reductase (mvaA).  
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Table 1.1: Overview of process parameters of selected isoprenoid production processes with optimized precursor pathways (MEP or MEV) in shaking flasks or 
bioreactor cultivations. The column configuration (config.) refers to the configuration of the biocatalyst and the cultivation mode (B: batch, FB: fed-batch, C: 
continuous). ISPR refers to the applied in situ product removal strategy. All product concentrations are calculated for the volume of the aqueous phase to simplify 
the comparison among the studies. n/a: data not available. If applicable, the cell dry weight was retrieved from the reported OD600 values with previously published 
correlation factors (Myers et al., 2013; Sonderegger and Sauer, 2003; Wang et al., 2013; Wenzel et al., 2011). 
Product C-source/ Medium Organism Config. Pathway ISPR 
cproduct/ 
mg Laq-1 
biomass/ 
gcdw Laq-1 
yield/ 
mg gcdw-1 
STY/ 
mg Laq-1 h-1 
Ref. 
Hemterpenoids (C5) 
isoprene -/LB B. subtilis B, growing MEP gas phase n/a n/a 11 n/a (Xue and Ahring, 2011) 
isoprene glucose/M9 E. coli FB, growing MEV gas 
stripping 6300 41.4 152 158 
(Yang et al., 
2012a) 
isoprene glycerol/M9 E. coli B, growing MEV gas phase 320 0.7 457 10 (Zurbriggen et 
al., 2012) 
isoprene n/a E. coli n/a MEV gas 
stripping 60000 n/a 110 2000 
(Coelho et al., 
2014) 
Monoterpenoids (C10) 
α-pinene glucose/LB E. coli FB, growing MEV gas phase 970 17 124 30 (Yang et al., 2013) 
α/β-pinene glucose/CGXII C. glutamicum B, growing MEP 2-LP 0.2 6.5 0.03 0.004 (Kang et al., 2014) 
α/β-pinene glucose/EZ-rich E. coli B, growing MEV 2-LP 32 0.8 38 0.4 (Sarria et al., 2014) 
myrcene glycerol/EZ-rich E. coli B, growing MEV 2-LP 58 2.2 26 0.8 (Kim et al., 2015) 
(S)-(-)-limonene glucose/EZ-rich E. coli B, growing MEV 2-LP 425 1.4 295 6 (Alonso-Gutier-
rez et al., 2013) 
(S)-(-)-limonene -/LB E. coli B, growing / gas phase 5 n/a n/a 0.1 (Carter et al., 2003) 
(S)-(-)-limonene pyruvate, glycerol/2YT E. coli B, growing MEP 2-LP 33 5.8 5.7 0.7 
(Du et al., 
2014) 
(S)-(-)-limonene galactose/YNB S. cerevisiae B, growing / gas phase 0.5 n/a n/a 0.007 (Jongedijk et 
al., 2014) 
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Product Substrate/ Medium Organism Config. Pathway ISPR 
cproduct/ 
mg L-1 
biomass/ 
gcdw L-1 
yield/ 
mg gcdw-1 
STY/ 
mg L-1 h-1 
Ref. 
Monoterpenoids (C10) - continued 
(S)-(-)-limonene CO2/BG11 Synechocystis sp. PCC6803 growing MEP 
gas 
stripping 1 1.1 0.9 0.001 
(Kiyota et al., 
2014) 
perillyl alcohol glucose/EZ-rich E. coli B, growing MEV resin 78 1.3 58.4 1.1 (Alonso-Gutier-
rez et al., 2013) 
geranic acid glycerol/E2 + LB P. putida FB, growing MEV / 193 19.8 9.7 2.7 (Mi et al., 2014) 
geraniol -/YNB S. cerevisiae B, growing / / 5.4 n/a n/a n/a (Fischer et al., 2011) 
geraniol glycerol/2YT E. coli B, growing MEV 2-LP 183 1.8 100.0 3.8 (Zhou et al., 2014) 
geraniol glucose/YNB S. cerevisiae B, growing MEV / 36 n/a n/a 0.8 (Liu et al., 2013) 
sabinene glycerol/LB E. coli FB, growing MEV gas 
stripping 2,650 6 411.5 110.4 
(Zhang et al., 
2014) 
Sesquiterpenoids (C15) 
(+)-nootkatoone glucose, 
methanol/complex P. pastoris FB, growing MEV 2-LP 208 120 1.7 2 
(Wriessnegger 
et al., 2014) 
amorpha-4,11-
diene glycerol/complex E. coli B, growing MEV / 112.2 1.7 66.0 8.0 
(Martin et al., 
2003) 
amorpha-4,11-
diene glucose/minimal E. coli FB, growing MEV 2-LP 27400 90 304.4 170 
(Tsuruta et al., 
2009) 
amorpha-4,11-
diene 
glucose, 
ethanol/defined S. cerevisiae FB, growing MEV 2-LP 41000 127.2 322.3 335 
(Westfall et al., 
2012) 
artemisinic acid glucose, 
ethanol/defined S. cerevisiae FB, growing MEV 2-LP 25000 n/a n/a 178.6 
(Paddon et al., 
2013) 
cubeol galactose/minimal S. cerevisiae B, growing / 2-LP 0.6 10 0.06 0.007 (Asadollahi et 
al., 2009) 
bisabolene glucose/EZ-rich E. coli B, growing MEV 2-LP 208 n/a n/a 2.9 (Peralta-Yahya 
et al., 2011) 
bisabolene galactose, glucose/YEP S. cerevisiae B, growing MEV 2-LP 994 n/a n/a 13.8 
(Peralta-Yahya 
et al., 2011) 
patchoulol galactose/minimal S. cerevisiae B, growing / 2-LP 40.9 7.3 5.6 n/a (Albertsen et al., 2011) 
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Product Substrate/ Medium Organism Config. Pathway ISPR 
cproduct/ 
mg L-1 
biomass/ 
gcdw L-1 
yield/ 
mg gcdw-1 
STY/ 
mg L-1 h-1 
Ref. 
Sesquiterpenoids (C15) - continued 
α-santalene glucose/defined S. cerevisiae C, growing MEV 2-LP 80 38 2.1 1.0 (Scalcinati et 
al., 2012) 
farnesol glycerol/2YT E. coli B, growing MEV 2-LP 135.5 7.8 17.3 2.8 (Wang et al., 2010) 
Diterpenoids (C20) 
miltiradiene glucose/YPD S. cerevisiae FB, growing MEV / 488 43 11.3 2.9 (Dai et al., 2012) 
sclareol glycerol/defined E. coli FB, growing MEV 2-LP 1460 60 24.3 24.3 (Schalk et al., 2012) 
taxa.-4,11-diene glycerol/LB E. coli B, growing MEP 2-LP 92.5 18.5 5.0 0.7 (Boghigian et 
al., 2011) 
taxa-4,11-diene glycerol/complex E. coli FB, growing MEP 2-LP 250.5 16.6 15.1 2.1 (Ajikumar et 
al., 2010) 
fusicocca-
1,10(14)-diene glucose/defined S. cerevisiae FB, growing MEV resin 21.0 n/a n/a 0.2 
(Arens et al., 
2014) 
taxanes xylose/complex E. coli + S. cerevisiae 
FB, growing 
mixed MEP / 30.0 n/a n/a 0.3 
(Zhou et al., 
2015) 
levopimaradiene glycerol/complex E. coli FB, growing MEP 2-LP 175.0 14.7 11.9 1.0 (Leonard et al., 2010) 
Tetraterpenoids (C40) 
β-carotene glycerol/2YT E. coli B, growing both / 119.0 10.0 12.0 6.0 (Nguyen et al., 2012) 
β-carotene glucose, arabinose /2YT E. coli B, growing MEP / 48.0 8.7 5.5 1 
(Yoon et al., 
2007) 
β-carotene glycerol/complex E. coli FB, growing both / 663.0 25.0 26.5 24.6 (Kim et al., 2009) 
lycopene glucose/minimal E. coli FB, growing MEP / 221.6 27.0 8.2 9.2 (Alper et al., 2006) 
lycopene glucose, arabinose/ 
complex E. coli FB, growing MEV / 1350 42 32.1 33.8 
(Kim et al., 
2011) 
retinoids glycerol, arabinose/ 
complex E. coli FB, growing MEV 2-LP 122 12 10.2 2.5 
(Jang et al., 
2011) 
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The second operon contains the initially used genes for the mevalonate kinase, the 
phosphomevalonate kinase and the diphosphomevalonate decarboxylase all from S. cerevisiae 
alongside the E. coli idi1 gene, with the codon-usage of the yeast genes being adapted 
according to the E. coli preferences (Alonso-Gutierrez et al., 2013; Dunlop et al., 2011; Sarria 
et al., 2014; Tsuruta et al., 2009). This optimized mevalonate pathway plasmid is then, 
depending on the type of the desired isoprenoid, co-expressed with codon-optimized variants 
of heterologous short-chain prenyltransferases, terpene synthases, and further downstream 
genes. E. coli strains, transformed with these or similar plasmids, produced very high 
quantities of various terpenes such as limonene (~295 mg gcdw-1, (Alonso-Gutierrez et al., 
2013)), amorphadiene (~304 mg gcdw-1, (Tsuruta et al., 2009)), and sabinene (~412 mg gcdw-1, 
(Zhang et al., 2014)) (Table 1.1). As these compounds are assigned to different classes of 
isoprenoids it may be concluded that rather the supply of IPP/DMAPP than the activity of the 
prenyltransferases or the terpene synthases constrains the current isoprenoid production 
capacities. Currently, the highest specific yield is reported for the E. coli based production of 
isoprene (~457 mg gcdw-1, (Zurbriggen et al., 2012)). This result supports the hypothesis of 
limiting endogeneous IPP/DMAPP quantities as this strain features a modified mevalonate 
pathway where the respective genes from Enterococcus faecalis and 
Streptococcus pneumonia are located on a high copy-number plasmid under control of the 
very strong T7 promotors (Zurbriggen et al., 2012). This approach, however, might also result 
in impaired production caused by a significant metabolic burden for the production of more 
sophisticated isoprenoids that require the expression of more heterologous genes (Ceroni et al., 
2015) or if toxic mevalonate pathway intermediates accumulate. 
Pathway engineering can also be applied to cope with intermediate or end-product toxicity 
challenges. An interesting approach was presented in order to deal with the toxicity of 
farnesyl diphosphate. Dahl and coworkers performed a global transcript analysis of a 
heterologous FPP production strain and identified genes that are downregulated under 
productive conditions (Dahl et al., 2013). From that it was deduced that the promoters of the 
downregulated genes (e.g., gadE) might be controlled by FPP and convey the FPP-triggered 
stress/toxicity response. Heterologous strains in which the MEV pathway gene expression is 
dynamically controlled by the gadE promotor did not accumulate toxic FPP and the 
concentration of the final product amorphadiene was doubled. 
Besides the rational optimization of pathway gene expression which is rather limited in 
throughput and requires detailed knowledge about the system, so-called multivariate modular 
engineering strategies aiming at the modular and combinatorial pathway optimization have 
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been established for the MEP pathway (Biggs et al., 2014) and resulted in a 15,000-fold 
improvement of taxadiene titer as compared to a control strain. Furthermore, proteomics-
guided pathway optimization strategies such as targeted proteomics (Redding-Johanson et al., 
2011) or principal component analysis of proteomic data (Alonso-Gutierrez et al., 2014) were 
used to identify limiting modules or enzymes and improved the production of amorpha-4,11-
diene and limonene, respectively.  
These combinatorial and proteomics-based strategies can help to uncover global optima in the 
production landscape. In future these strategies will be complemented by synthetic biology 
tools (e.g., circuits, switches, oscillators), which enable engineering-like designs as found in, 
e.g., electronic systems, and support the rational metabolic pathway engineering approaches 
(Biggs et al., 2014; Khalil and Collins, 2010; Yadav et al., 2012). 
Pathway engineering for isoprenoid biosynthesis in E. coli required substantial efforts in 
balancing gene expression (promotors, ribosomal binding sites, gene origins etc.) and has 
been most successful for engineering and optimizing the mevalonate pathway, whereas the 
results obtained with the MEP pathway were less promising. The highest specific production 
for limonene using the MEP pathway is approximately 50-fold lower (~6 mglimonene gcdw-1, (Du 
et al., 2014)) as compared to the yield using a MEV pathway engineering strategy 
(~295 mglimonene gcdw-1, (Alonso-Gutierrez et al., 2013)) (Table 1.1). Consequently, the MEV 
pathway exhibits the highest potential for designing E. coli microbial isoprenoid factories, 
although theoretical calculations (elementary mode analyses) revealed that theoretical IPP 
yields are roughly 50% higher with the MEP pathway (Gruchattka et al., 2013). 
Cellular engineering. Cellular engineering can comprise any modulation within the microbial 
cell that is not directly associated with the pathway gene expression. Conceptual strategies 
include knock-out of competing/withdrawing reactions, enhancing of supportive reactions, 
improving of cofactor or energy balances, or spatiotemporal organization.  
For E. coli several approaches have been reported. Farmer and Liao aimed at channeling the 
carbon flux into the lycopene formation pathway (MEP-based) by modulating the ratio 
between the central carbon metabolites and starting compounds of the MEP pathway, 
pyruvate and glyceraldehyde-3-phosphate. Deletion of the pyruvate kinase and 
overexpression of the phosphoenolpyruvate synthase genes resulted in enhanced production 
of lycopene (Farmer and Liao, 2001). In 2005, Vadali et al. followed a similar approach and 
deleted the genes (ackA-pta, poxB) at the acetate production node in E. coli. Indeed, absence 
of acetate accumulation increased the final MEV pathway-based production of lycopene 
twofold (Vadali et al., 2005).  
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An impressive series of papers of Alper and Stephanopoulos describes the effects of several 
deletions in the central carbon metabolism on microbial lycopene production. In the first 
round flux balance analysis identified genetic targets, i.e., glutamate dehydrogenase (gdhA, 
putative increase of NADPH), pyruvate dehydrogenase (aceE), and formate dehydrogenase 
(fdhF), that were simultaneously deleted and lycopene production could be increased by 40% 
as compared to the wild type (Alper et al., 2005a). Two of the deletions (gdhA, aceE) were 
combined with a deletion in the promoter region of yjiD encoding a protein with unkown 
function in a second transposon-based deletion strategy. The resulting strain accumulated 
lycopene to 18 mg gcdw-1 (Alper et al., 2005b). Exhaustive screening of 800,000 different 
mutants in order uncover multiple beneficial knockouts in a combinatorial fashion and global 
approaches such as global transcription factor machinery engineering (gTME) further 
improved lycopene production (Alper and Stephanopoulos, 2007; Alper and Stephanopoulos, 
2008).  
The repression of the squalene synthase (encoded by erg9) in combination with other 
alterations such as the overexpression of the HMG-CoA reductase appeared to be crucial for 
effective sesquiterpene production in S. cerevisiae (Ro et al., 2006). Furthermore, successful 
attempts to increase the flux into the mevalonate pathway were made by engineering the 
pyruvate dehydrogenase bypass by overexpressing the acetaldehyde dehydrogenase and 
introduction of a Salmonella enterica acetyl-CoA synthetase. As a result, the specific yield 
was tripled to approximately 150 mg gcdw-1 (approximated with a conversion factor of 0.53 
gcdw L-1 for an OD600 value of 1 (Sonderegger and Sauer, 2003)) (Shiba et al., 2007). 
Other strategies of cellular engineering simply include the choice of appropriate production 
hosts. Already the type of the applied E. coli strain seemed to substantially influence terpene 
yields (Boghigian et al., 2012a). Alternative host organisms that may feature beneficial 
metabolic properties or chemical inventories were also applied for isoprenoid production. 
Although production of isoprene, pinene, or bisabolene with B. subtilis (Xue and Ahring, 
2011), C. glutamicum (Kang et al., 2014), or Streptomyces venezuelae (Phelan et al., 2014), 
respectively, is yet characterized by relatively low yields, this approach might be very 
promising in combination with established metabolic engineering tools. As many isoprenoids 
are toxic to typical microbial production strains, the utilization of strains that inherently 
tolerate higher concentrations of toxic substances (as it is described for various 
Pseudomonads) is an appealing approach (Mi et al., 2014).  
Despite single success stories in rerouting carbon flux and gene knock-outs for improving 
microbial isoprenoid production, the level of cellular engineering has been investigated with 
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less intensity as compared to the optimization of the heterologous precursor pathway. 
Nevertheless, exploiting the multiple rational and omics-based systems biology 
methodologies will contribute substantially to designing microbial isoprenoid factories. In 
that respect it is quite surprising, that there are only very few reports describing 13C-based 
flux analyses of isoprenoid producing heterologous strains (Suthers et al., 2007), although 
such studies typically convey crucial information content to uncover cellular optimization 
potential (Zamboni et al., 2009). 
Reaction engineering. The physicochemical properties such as volatility, hydrophobicity or 
toxicity to microbial production strains of many isoprenoids pose challenges with respect to 
the applied reaction technology. The most popular and most frequently applied concepts are 
multiphasic production systems (Stark and von Stockar, 2003). In these setups, the produced 
isoprenoid is removed in situ from the vicinity of the biocatalyst. The tendency of the 
produced isoprenoid to reside in the opposite phase as the biocatalyst is quantified by the 
partition coefficient of the respective isoprenoid between the two phases present. In two-
liquid phase systems, water immiscible organic phase overlays (typically aliphatic 
hydrocarbons) are used to capture both hydrophobic and moderately volatile isoprenoids such 
as limonene or amorpha-4,11-diene. The products can accumulate to significantly higher 
concentrations by altering the aqueous:organic phase ratio (i.e., lowering the volume of the 
organic phase), which prevents typical challenges of biotechnological processes such as dilute 
product streams (Schewe et al., 2015; Stark and von Stockar, 2003). Hence, downstream 
purification is also substantially facilitated. Dodecane is the most frequently used organic 
solvent as it is biocompatible, immiscible with water, and features a very low volatility and 
high partition coefficients for hydrophobic isoprenoids (Asadollahi et al., 2009). Other 
organic carrier phases that also exhibit similar beneficial properties include methyl oleat 
(Westfall et al., 2012) or isopropyl myristate (Paddon et al., 2013).  
Although the rapid extraction of volatile or toxic isoprenoids into the organic carrier phase is 
crucial in most cases, it can also hamper the efficiency of coupled downstream reactions. In 
that respect, the de novo synthesis of perillyl alcohol appeared not to be possible in a two-
liquid phase system (Alonso-Gutierrez et al., 2013). The extraction of limonene into the 
dodecane phase was kinetically favored over its oxidation by the applied P450 
monooxygenase. This limitation was partly resolved by a reaction setup consisting of a single 
aqueous phase or the application of a solid phase resin to selectively trap perillyl alcohol 
(Alonso-Gutierrez et al., 2013). Though, the largest part of limonene was not converted to 
perillyl alcohol pointing to a limitation of the process by limonene volatility. 
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Gas phase recovery or gas stripping was proven to be very effective for (highly) volatile 
isoprenoids such as isoprene (Yang et al., 2012b; Zurbriggen et al., 2012), pinene (Yang et al., 
2013), or limonene (Carter et al., 2003; Jongedijk et al., 2014). Although this approach 
requires a more sophisticated technical setup, it alleviates the need for tedious downstream 
separation processes. 
In general, however, the variety of reported in situ product removal strategies for isoprenoid 
production is not very diverse, which possibly owes to the fact that process settings or 
downstream processing strategies which are dependent on the properties of the carrier phase 
are not exploited frequently. 
The majority of reported isoprenoid production attempts rely on the cultivation of the 
recombinant microorganisms under aerobic batch conditions in shaking flasks with undefined 
complex media (Table 1.1). Relatively little work has been conducted on the reaction 
engineering level with respect to media modification, although it has been reported that the 
application of complex media results in impaired isoprenoid titers as compared to defined 
media (Kim et al., 2015). Furthermore, alteration of the carbon source towards glycerol 
(Gupta et al., 2014) and the supplementation with auxiliary carbon sources (Kim et al., 2011) 
were proven beneficial. In some instances also the rich defined EZ medium has been applied 
containing besides buffer salts also all amino acids, several cofactor precursors, and 
nucleotides. Very high specific isoprenoid yields based on biomass were achieved with this 
medium (Alonso-Gutierrez et al., 2013; Kim et al., 2015; Peralta-Yahya et al., 2011; Sarria et 
al., 2014). The metabolic load for anabolic reactions is significantly reduced as compared to 
cultivation in minimal medium leading to an improved availability of resources for isoprenoid 
formation. In industrial processes, however, minimal media are preferred because they are 
generally considered cost-effective. Minimal media are used surprisingly seldom for the 
heterologous terpene fermentation. However, minimal media allow an exact description of the 
microbial physiology (substrate uptake rates, by-product excretion rates etc.) which might be 
promising to guide other reaction engineering strategies. 
The major part of experiments for microbial isoprenoid production was performed at a small 
scale (typically up to 0.1 L), but some processes also include high cell density fermentations 
in stirred tank reactors (up to 2 L culture volume). Thereby, isoprene (Yang et al., 2012b), 
sabinene (Zhang et al., 2014), sclareol (Schalk et al., 2012), or lycopene (Kim et al., 2011) 
were produced at very high concentrations of up to several grams per liter of aqueous volume 
and high specific yields in (carbon-limited) fed-batch cultures. The high cell density fed-batch 
fermentation of E. coli harboring the amorphadiene production pathway yielded a final 
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amorphadiene concentration of 25 g Laq-1 by simultaneously restricting glucose and nitrogen, 
which is one of the highest isoprenoid titers reported to date (Tsuruta et al., 2009). Yet, the 
effect of carbon restriction required for both growth and product formation has to be 
investigated systematically. Specifically, alternative feeding strategies such as pulse feeding, 
or the restriction of growth by other elements such as magnesium, sulfur, or even oxygen 
might be interesting approaches. 
In future, exploiting so far neglected reaction technologies such as optimization of biocatalyst 
configuration (resting cells, immobilized cells) or alternative feeding strategies can unveil a 
yet hidden optimization potential for isoprenoid production. These technologies can then, 
dependent on the physicochemical properties of the respective isoprenoid, be combined with 
established reaction engineering strategies and subsequently integrated with suitable process 
settings.  
Process Engineering. The economically feasible production of isoprenoids requires the 
integration of previous optimization efforts with respect to genetic, cellular, and reaction 
engineering into an adequate process setting. In most cases, however, research on isoprenoid 
synthesis is limited to enhancing concentrations at the small laboratory scale and process 
design strategies such as scale-up and implementation of downstream processing are often 
neglected. Downstream processing has been so far only reported for the purification of 
artemisinic acid from isopropyl myristate (Westfall et al., 2012) or the gas phase recovery of 
isoprene (Whited et al., 2010).  
Furthermore, relatively little emphasis was dedicated to the type and properties of the 
employed bioreactor. So far only aerated stirred tank reactors (batch or fed-batch operation 
mode) that served the purpose of achieving high cell densities have been reported (Mi et al., 
2014; Schalk et al., 2012). The design of a suitable bioreactor for microbial isoprenoid 
synthesis (and also other applications), however, is guided by the specific demands of the 
whole-cell biocatalyst, physical parameters (hydrodynamics, mass transfer), and the 
physicochemical properties of the desired isoprenoids and has to be considered already during 
early phases of bioprocess development. Other reactor types such as fixed/fluidized bed or 
membrane reactors that allow for the decoupling of biomass and liquid dwelling times or 
compartmentalization, respectively, might be beneficial for the production of toxic 
isoprenoids (Lima-Ramos et al., 2014), but have not been investigated yet. 
Another decisive factor for successful bioprocess development is the scalability of the 
microbial production setup from the lab scale application to a multi cubic meter industrial 
setting. Frequently, the efficiency of a microbial bioprocess with respect to specific yield or 
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biomass concentration is impaired when the process is operated at a larger scale. At large 
scale, spatial nutrient (carbon source, oxygen etc.) inhomogeneities caused by inappropriate 
fluid dynamics or rheological conditions can lead to genotypic and phenotypic variability and 
thus reduced production performances as compared to lab scale proof-of-concept studies 
(Takors, 2012).  
Ultimately, the integration of appropriate process technologies in terms of scalability of the 
process defines the economic feasibility and should therefore be an integral aspect of the 
research on microbial isoprenoid production (Cuellar et al., 2013). Revisiting upscaling 
aspects at regular intervals during bioprocess development and even the development of 
alternative reactor designs that meet the specific requirements are therefore crucial for 
economically competitive bioprocesses. 
1.6 Summary and future prospects 
A qualitative assessment of different routes for accessing industrially relevant isoprenoids 
based on the reviewed processes is summarized in Table 1.2. Today, the gross of isoprenoids is 
obtained via the traditional routes of extraction from natural sources or chemical synthesis. 
However, due to the advances in synthetic and systems biology, the biotechnological 
production of isoprenoids is gaining increasing importance. Yet, specific yields, 
concentrations, and productivities for bio-based de novo isoprenoid manufacturing processes 
are rather low and limit their industrial implementation. Extensive effort is still required to 
develop bioprocesses that are competitive to traditional manufacturing procedures with 
respect to cost and efficiency. Thus, with exception of high-value compounds such as 
artemisinin produced by specialized companies (Amyris/Sanofi), the way to a sustainable 
isoprenoid industry that is based on recombinant microorganisms is still very challenging, but 
can benefit from research on the level of metabolic engineering, reaction engineering, as well 
as process engineering.  
Consequently, a sustainable industry for isoprenoid production is not foreseeable for the near 
future, although some examples showed that microbial production can compete with 
traditional production methods. In the end, microbial production of other industrially 
important natural products (e.g., alkaloids, polyketides, aromatic compounds) is facing the 
same problems and limitations, which might be overcome by combined efforts in genetic, 
cellular, reaction, and process engineering. 
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Table 1.2: Qualitative comparison of the different routes for accessing industrially relevant 
isoprenoids based on the literature reviewed in the previous sections with respect to process 
parameters and future potential. 
criterion/parameter 
strategy/route 
extraction from 
natural source 
chemical 
synthesis 
biotransformation/
semisynthesis 
microbial de novo 
fermentation 
significance for current 
production 
high moderate to 
high 
limited limited 
yield/productivity typically very low low to very 
high 
moderate to high low to moderate 
operational regime (pH, 
temperature, pressure) 
harsh typically 
harsh 
typically mild mild 
generalizability of 
strategies 
limited moderate to 
good 
moderate to good good to very good 
downstream processing complex moderate moderate moderate 
scalability limited good challenging challenging 
ecological 
efficiency/sustainability 
limited limited to 
moderate 
moderate to good good to very good 
RD requirement low very high very high very high 
future potential limited high high very high 
1.7 Scope of this thesis 
While some studies report the production of significant amounts of isoprenoids (exceeding 
one gram per liter of medium), the majority of isoprenoid production processes yielded titers 
in the lower mg L-1 range. These low yields might partly be attributed to the scarcity of 
integrated interdisciplinary process development strategies for biotechnological production. 
Studies on microbial isoprenoid production so far predominantly focused on genetic 
engineering of the heterologous biosynthesis pathway. This work explored the microbial 
isoprenoid production within the four different levels (pathway, cellular, reaction, and 
process) of bioprocess engineering on the basis of the exemplary monoterpene limonene and 
its oxygenated adducts. The aim of this work was to identify and address novel tunable 
constraints that limit the de novo fermentation of monoterpenoids on each level and finally to 
improve microbial production of oxygenated monoterpenoids.  
Chapter 2 details the construction and characterization of different limonene overproducing 
E. coli strains by the introduction and optimization of the S. cerevisiae mevalonate pathway 
for enhancing IPP/DMAPP supply and the functional expression of plant derived GPP and 
limonene synthases. After establishing a two-liquid phase production system, the quantitative 
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production parameters such as volumetric productivities, yields, and specific rates were 
assessed. The two-liquid phase cultivation system was transferred into a bioreactor setup to 
realize the preparative gram scale de novo production of (S)-(-)-limonene. The technical 
feasibility of the process was verified by downstream purification of the product. Chapter 3 
focuses on the coupling of a regiospecific hydroxylation step to the fermentative production 
of limonene. Low limonene production rates and the physicochemical properties of the 
intermediary limonene (volatility, hydrophobicity) led to low limonene availability for the 
monooxygenase and thus limited hydroxylation. The novel reaction engineering concept of 
mixed-culture resting cell fermentation is introduced. Both, a limonene producing strain and a 
strain containing the monooxygenase components are combined as resting, but metabolically 
active, cells in a defined ration. This novel mixed-culture resting cell fermentation resulted in 
the effective production of oxygenated monoterpenoids. Chapter 4 focuses on the detailed 
investigation of the resting-cell biocatalyst configuration. Optimization of the reaction 
conditions showed that decoupling of growth and product formation results in significantly 
increased yields and specific production rates as compared to the use of growing cells. 
Chapter 5 describes a process engineering approach that evaluates the potential of biofilms of 
native and recombinant solvent tolerant Pseudomonads for the regioselective hydroxylation of 
the toxic and volatile limonene. This work paves the way for coupling this biofilm-based 
hydroxylation to the previously established fermentative limonene production. 
In Chapter 6 the achievements of this work and other biotechnological processes similarly 
involving reactants with challenging physicochemical properties are put into a more global 
context by developing and discussing a framework for bioprocess design that is guided by 
these physicochemical properties. Finally, Chapter 7 provides a summary of the results of this 
work, integrates them into the current state-of-the-art context, and discusses prospective 
trends in research on microbial isoprenoid production processes. 
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2.1 Abstract 
The efficiency and productivity of cellular biocatalysts play a key role in the industrial 
synthesis of fine and bulk chemicals. This study focuses on optimizing the synthesis of (S)-
limonene from glycerol and glucose as carbon sources using recombinant Escherichia coli. 
The cyclic monoterpene limonene is extensively used in the fragrance, food, and cosmetic 
industries. Recently, limonene also gained interest as alternative jet fuel of biological origin. 
Key parameters that limit the (S)-limonene yield, related to genetics, physiology, and reaction 
engineering, were identified. The growth-dependent production of (S)-limonene was shown 
for the first time in minimal media. E. coli BL21 (DE3) was chosen as the preferred host 
strain, as it showed low acetate formation, fast growth, and high productivity. A two-liquid 
phase fed-batch fermentation with glucose as the sole carbon and energy source resulted in 
the formation of 700 mg Lorg-1 (S)-(-)-limonene. Specific activities of 75 mU gcdw-1 were 
reached, but decreased relatively quickly. The use of glycerol as a carbon source resulted in a 
prolonged growth and production phase (specific activities of ≥50 mU gcdw-1) leading to a 
final (S)-(-)-limonene concentration of 2700 mg Lorg-1. Although geranyl diphosphate (GPP) 
synthase had a low solubility, its availability appeared not to limit (S)-limonene formation 
in vivo under the conditions investigated. GPP rerouting towards endogenous farnesyl 
diphosphate (FPP) formation also did not limit (S)-limonene production. The two-liquid phase 
fed-batch setup led to the highest monoterpene concentration obtained with a recombinant 
microbial biocatalyst to date. 
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2.2 Introduction 
Recombinant whole-cell biocatalysts offer a broad range of possibilities for sustainable 
monoterpenoid synthesis based on the fermentation of renewable feedstocks. Monoterpenes 
are regarded as promising biosynthetic alternatives for jet fuel precursors (Bokinsky et al., 
2011; Dunlop et al., 2011; Harvey et al., 2010) and building blocks for chemical (Thomas and 
Bessiere, 1989; Wender et al., 2001) and biocatalytic (van Beilen et al., 2005; Mirata et al., 
2009) syntheses. The fermentative production of monoterpenes was previously demonstrated 
in recombinant E. coli strains with an orthologous monoterpene biosynthesis pathway and 
grown either on defined rich (Alonso-Gutierrez et al., 2013) or complex medium (Carter et 
al., 2003; Reiling et al., 2004; Yang et al., 2013). The successful implementation of bacteria 
as organic synthesis catalysts requires detailed knowledge of the entire production system, 
including strain development, biocatalyst characterization, reaction and process engineering, 
as well as downstream processing (Kuhn et al., 2010). Moreover, the definition and analysis 
of strategies for improving efficiency and productivity provide a frame-work for further 
targeted bioprocess optimization to overcome biocatalyst and reaction related limitations 
(Kuhn et al., 2010; Meyer et al., 2006). However, such a systematic approach has not yet been 
applied for the production of monoterpenes in E. coli. 
Studies targeting the production of terpenes with recombinant microorganisms have mainly 
dealt with the engineering of strains that produced sesqui- (Martin et al., 2003; Pitera et al., 
2007; Tsuruta et al., 2009), di- (Ajikumar et al., 2010) and, tetraterpenes (Alper and 
Stephanopoulos, 2008; Yoon et al., 2009). In contrast to sesquiterpenes and other larger 
terpenes, monoterpenes are almost exclusively found in plants rather than in microorganisms 
that are commonly used as biotechnological production strains (Fischer et al., 2011). This is 
due to the bacteria’s inability to produce the monoterpene precursor geranyl diphosphate 
(GPP). This obstacle has been overcome by the biotechnological introduction of GPP 
synthase and terpene cyclase genes into suitable E. coli strains (Carter et al., 2003). However, 
physicochemical properties of monoterpenes, such as the high volatility, poor solubility in 
water (Schmid et al., 1992), and toxicity (Brennan et al., 2012) have remained a challenge on 
the reaction and process levels. The addition of an otherwise inert organic phase was shown to 
have a positive effect on in situ extraction of the products (Cornelissen et al., 2013; Schewe et 
al., 2009). Finally, the impact of the microbial physiology on the performance of heterologous 
pathways involved in monoterpene formation – and vice versa – might be crucial (Kim and 
Copley, 2012). Recently, an in silicon profiling study using elementary mode analysis 
identified metabolic engineering strategies, beyond pathway engineering that have the 
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potential to increase the monoterpenoid quantity in E. coli and Saccharomyces cerevisiae 
(Gruchattka et al., 2013). Unfortunately, this potential has not yet been exploited 
experimentally for the formation of monoterpenes.  
The present study aims at defining and assessing engineering strategies for the intensification 
of fermentative limonene production in E. coli (Figure 2.1). A comprehensive multi-level 
analysis approach was used to investigate the properties of the biocatalyst as well as the 
reaction. The key parameters for engineering of the biotechnological monoterpene synthesis 
process were defined: (i) pathway construction, gene expression, and limited heterologous 
production of soluble and active proteins; (ii) kinetics of the enzymes involved; (iii) 
physiology (toxicity, competing reactions or pathways, intracellular fluxes); and (iv) 
technological aspects (limonene volatility, two-liquid phase bioreactor setup, downstream 
processing). The systematic approach included metabolic engineering and host strain 
selection, along with reaction engineering, and resulted in the highest monoterpene titer 
produced with renewable feedstocks in a recombinant bacterial strain to date. 
 
Figure 2.1: Schematic representation of the primary metabolism and the connection (via acetyl-CoA) 
to the heterologously introduced pathway for the production of (S)-limonene in recombinant E. coli. 
Abbreviations: PPP (pentose phosphate pathway), OXPHOS (oxidative phosphorylation), atoB 
(acetoacetyl-CoA thiolase), HMGS (3-hydroxy-3-methylglutaryl-CoA synthase), tHMGR (truncated 
HMG-CoA reductase), MK (mevalonate kinase), PMK (phosphomevalonate kinase), PMDC 
(diphosphomevalonate decarboxylase), idi (IPP/DMAPP isomerase), IPP (isopentenyl diphosphate), 
DMAPP (dimethyl allyl diphosphate), GPPS (geranyl diphosphate synthase), GPP (geranyl 
diphosphate), (S)-LS ((S)-limonene synthase). 
Chapter 2: Engineering E. coli for de novo limonene production 
   
29 
2.3 Materials & Methods 
Chemicals and bacterial strains. Anhydrous D-glucose was obtained from Alfa Aesar 
(Karlsruhe, Germany), and isopentenyl diphosphate (IPP) and dimethylallyl diphosphate 
(DMAPP) were purchased with a purity >95% from Echelon Biosciences (Salt Lake City, 
UT, USA). Custom synthesized oligonucleotides were purchased from Sigma-Aldrich 
(Steinheim, Germany). All other chemicals were obtained from AppliChem (Darmstadt, 
Germany), Sigma-Aldrich (Steinheim, Germany), or Carl Roth (Karlsruhe, Germany) in the 
highest purity available. All E. coli strains and plasmids used in this study are listed in Table 
2.1. The antibiotics ampicillin, kanamycin, and chloramphenicol were applied at 
concentrations of 100, 50, and 34 mg L-1, respectively. Thiamine (if appropriate) was added to 
a final concentration of 0.001% (w/v). Detailed information about primer design is provided 
in Table 2.2. 
Cultivation of bacterial strains. Five milliliters of LB medium were inoculated with E. coli 
from a frozen stock and incubated for 12 h at 37°C (200 rpm, 2.5 cm amplitude). Aliquots of 
500 µL of the LB culture were transferred to 50 mL M9* medium with US* trace elements 
solution (Panke et al., 1999), 2 mM MgSO4, and 0.5% (w/v) D-glucose and incubated for 16-
20 h at 30°C in a baffled Erlenmeyer flask (200 rpm, 2.5 cm amplitude). This preculture was 
then used to inoculate fresh M9* medium supplemented with US* trace elements solution, 
2 mM MgSO4, and 0.5% (w/v) D-glucose at an optical density of 0.2 at 450 nm (OD450). The 
culture was incubated at 30°C and gene expression was induced by adding 1.0 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) or 0.2% L-arabinose, respectively once an OD450 of 0.6 
(~0.1 gcdw L-1, cdw: cell dry weight) was reached. Incubation was continued at 20, 25, or 
30°C. 
Construction of the limonene pathway plasmids. The plasmids were constructed using either 
a restriction-ligation cloning approach or the sequence and ligation independent cloning 
method (SLIC) (Li and Elledge, 2007) using enzymes and reagents purchased from Fermentas 
GmbH (St. Leon-Rot, Germany). The accuracy of the procedure was assessed by sequence 
analysis (MWG Eurofins, Ebersberg, Germany).  
The pMVAidi plasmid was constructed by amplifying the operon containing the Plac promoter 
and the S. cerevisiae mevalonate kinase (erg12), phosphomevalonate kinase (erg8), and 
diphosphomevalonate decarboxylase (erg19) genes as well as the E. coli IPP/DMAPP 
isomerase (idi1) gene. The plasmid pMBIS (kindly provided by Jay Keasling from the 
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University of California, Berkeley, CA, USA via Addgene.com) was used as a template 
(Martin et al., 2003). PCR was performed using the primers PCW006 and PCW007, and the 
Phusion high-fidelity DNA polymerase (Thermo Fisher Scientific, Waltham, MA, USA). The 
annealing temperature was set to 60°C, and the extension time to 90 s. The PCR fragment was 
subsequently integrated into the SbfI-linearized pMevT plasmid (also from J. Keasling) 
(Martin et al., 2003), which contained the acetoacetyl-CoA thiolase (atoB) gene from E. coli, 
the S. cerevisiae HMG-CoA synthase (erg13) gene, and a truncated S. cerevisiae HMG-CoA 
reductase (tHMGR1) gene.  
Abies grandis and Streptomyces sp. strain KO-3988 GPP synthases and Mentha spicata 
limonene synthase were previously described (Burke and Croteau, 2002; Kawasaki et al., 
2006; Williams et al., 1998). The coding sequences of these enzymes were retrieved from the 
NCBI database (accession numbers: AF513112.1, AB212624.1, and L13459.1). All 
sequences were optimized for E. coli codon usage using the GeneDesigner software (version 
1.0.0.1, DNA 2.0, Menlo Park, CA, USA). Optimized (and truncated) versions of the 
A. grandis GPP synthase, M. spicata limonene synthase (combined in vector 
pMK:LSAGPPS2) and Streptomyces sp. GPP synthase (in vector pMA-T:KO) genes were 
purchased from GeneArt AG (Regensburg, Germany). Construction of pET24-AGPPS2 
involved the amplification of the optimized A. grandis GPP synthase gene using pMK-
LSGPPS as template and the primers pAG-fw and pAG-rev. The 910 bp PCR product and 
pET24a(+), both digested with NdeI/EcoRI, were ligated, and the recombinant plasmid was 
subsequently used to transform E. coli DH5α cells. Construction of pET24-KO involved the 
amplification of the optimized Streptomyces sp. strain KO-3988 GPPS gene using pMA-
T:KO as template and the primers pKO-fw and pKO-rev. The 1078 bp PCR product and 
pET24a(+) were digested with NdeI/EcoRI and ligated.  
pBAD:LS was constructed by amplifying the optimized M. spicata limonene synthase gene 
using pMK:LSAGPPS2 as template and the primers pLS-fw and pLS-rev. The 1655 bp PCR 
product and pBAD/Myc-HisA were digested with NdeI/SalI and ligated. The plasmid 
pTAC:LS was created by amplifying truncated (E57M) and codon optimized limonene 
synthase gene from pBAD:LS using the primers PCW014 and PCW015 (annealing 
temperature: 57.5°C, extension time: 60 s) followed by ligation into pMAL-p5x (purchased 
from New England Biolabs, Frankfurt a. M., Germany) digested with MunI and HindIII.  
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Table 2.1: List of E. coli strains and plasmids used and constructed in this study. 
Strains/Plasmids Characteristics Reference 
E. coli DH5α F–, Φ80dlacZ∆M15, ∆(lacZYA-argF)U169, deoR, recA1, endA1, 
sdR17(rK–mK+), phoA, supE44, λ–, thi-1, gyrA96, relA1 
(Hanahan, 
1983) 
E. coli BL21 (DE3) F–, ompT, hsdSB(rB–mB–), gal (c1875, ind1, Sam7, nin5, lacUV5-
T7 gene1), dcm (DE3) 
(Studier and 
Moffatt, 
1986) 
E. coli JM101 glnV44, thi-1, supE, ∆(lac-proAB), F’[lacIq lacZ∆M15 traD36 
proAB+] 
(Messing, 
1979) 
E. coli MG1655 F–, λ–, ilvG–, rfb-50, rph-1 (Bachmann, 
1996) 
E. coli MG1655 DE3 
(∆pta, ∆ldhA, ∆adhE) 
F–, λ–, ilvG–, rfb-50, rph-1, ∆pta, ∆ldhA, ∆adhE, (DE3) (Tseng and 
Prather, 
2012) 
E. coli SF7N ∆ispA::neo derivative of W3110, ∆(srl-recA) 306::Tn10 (Fujisaki et 
al., 2005) 
E. coli SF5 ∆(srl-recA) 306::Tn10 derivative of W3110 (Fujisaki et 
al., 2005) 
pMevT p15A, CmR, Plac, atoB, erg13, tHMGR1 (Martin et 
al., 2003) 
pMBIS pMB1, TetR , Plac, erg12, erg8, erg19, idi1, ispA (Martin et 
al., 2003) 
pMVAidi p15A, CmR, Plac, atoB, erg13, tHMGR1, erg12, erg8, erg19, idi1 this study 
pMA-T ColE1, KmR, holding vector GeneArta) 
pMK ColE1, KmR, holding vector GeneArta) 
pMA-T:KO ColE1, KmR, codon-optimized GPPS gene from Streptomyces sp. 
strain KO-3988 
this study 
pMK:LSAGPPS2 ColE1, KmR, trunc. and codon-optimized LS gene from M. spicata 
and trunc. and codon-optimized GPPS2 gene from A. grandis 
this study 
pET24a(+) ColE1, KmR, PT7, lacIq Novagenb) 
pET24:AGPPS2 ColE1, KmR, PT7, lacIq, truncated and codon-optimized GPPS2 gene 
from A. grandis 
this study 
pET24:KO ColE1, KmR, PT7, lacIq, codon-optimized GPPS gene from 
Streptomyces sp. strain KO-3988 
this study 
pBAD/Myc-HisA ColE1, AmpR, ParaBAD, araC Life 
Technol.c) 
pBAD:LS ColE1, AmpR, ParaBAD, araC, truncated and codon-optimized LS 
gene from M. spicata 
this study 
pMAL-p5x pMB1, AmpR, Ptac, lacIq, malE NEBd) 
pTAC:LS pMB1, AmpR, Ptac, lacIq, truncated and codon-optimized LS gene 
from M. spicata 
this study 
pTAC:LS:AGPPS2 pMB1, AmpR, Ptac, lacIq, trunc., codon-optimized LS gene from M. 
spicata and trunc., codon-optimized GPPS2 gene from A. grandis 
this study 
a)GeneArt (Regensburg, Germany); b)Novagen, Merck KGaA (Darmstadt, Germany); c)Life Technologies 
(Darmstadt, Germany); d)NEB, New England Biolabs (Frankfurt, Germany) 
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The malE gene, which was present on pMAL-p5x, was removed. The truncated (E86M) and 
codon-optimized GPP synthase 2 gene was amplified from pET24:AGPPS2 with the primers 
PCW020 and PCW021 (annealing temperature: 60.0°C, extension time: 30 s) and recombined 
with the pTAC:LS plasmid (linearized with HindIII). The resulting plasmid 
pTAC:LS:AGPPS2 contained the GPPS2 gene downstream of the limonene synthase gene. 
Table 2.2: Nucleotide sequences of oligonucleotides used in this study. The underlined nucleotides 
indicate the gene specific regions. 
Primer Sequence 5’-3’ 
PCW006 GCCAAAACAGCCAAGCTTGCATGCCCGTACGTGTACAGGCGCGCCTTATTTAAGCTGGGTAAATG 
PCW007 ACCTGCATTAAATCCTAAGTCGACCTTGTACACGGCCGCATAATCGAAATCCTGCA
GGAATTCTTGCGGAGAACTG 
pAG-fw GGTAATCCATATGTTCGACTTCAATAAATACATGG 
pAG-rev CCGGAATTCTTAGTTTTGGCGGAAAGCGACG 
pKO-fw GGTAATCCATATGACCACCGATACCGGTCAGGATG 
pKO_rev CCGGAATTCTTATGCGGTACGATATGCAACA 
pLS-fw GGTAATCCATATGGAACGCCGCTCCGGTAACTACA 
pLS-rev ACGCGTCGACTTAGGCGAATGGTTCGAACAG 
PCW014 TGCGAAGCTTTTAGGCGAATGGTTCGAAC 
PCW015 GTCGCAATTGACCAACAGGAGGAATTACATATGGAACG 
PCW020 CAATGATGATGATGATGATGGTCGACGGAGCTCGAATTCTTAG 
PCW021 TGTTCGAACCATTCGCCTAAAAGCTGAAGGAGATATACATATGTTCG 
Analytical procedures. Cell growth was monitored by measuring turbidity (Libra S11, 
Biochrom Ltd., Cambridge, UK, OD450 = 1 equals 0.166 gcdw L-1) (Blank et al., 2008). Acetate 
formation and C source utilization were determined with HPLC analysis as described 
elsewhere (Gross et al., 2010). In some instances, the glucose concentration was determined 
with a spectrophotometric assay kit (Enzytec, sciL Diagnostics, Viernheim, Germany). 
Limonene concentrations were determined by GC using either a TRACE GC Ultra or Focus 
GC instrument (both from Thermo Fisher Scientific Inc., Waltham, MA, USA) equipped with 
a flame ionization detector and a FactorFour-5ms column (30 m, 0.25 mm, 0.25 µm) (Varian, 
Inc., Palo Alto, CA, USA) and commercial (S)-limonene as standard (0.2 mM dodecane as 
internal standard). The settings were: injector temperature 250°C, splitless injection or split 
ratio 1:7, molecular nitrogen as carrier gas. Program: 80°C (5 min), 80-140°C (7.5°C min-1), 
140-300°C (40°C min-1), 300°C (5 min). Optical purity was determined by GC separation on 
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a Finnigan Focus GC instrument equipped with a chiral Supelco β-DEX 120 column (Sigma-
Aldrich, Steinheim, Germany). Program: 50°C (5 min), 80-140°C (5°C min-1), 140-230°C 
(40°C min-1), 230°C (5 min). Limonene and by-products were determined with GC-MS using 
a CP3800 GC coupled to a 1200 Quadrupole MS (Varian, Inc., Palo Alto, CA, USA) using 
the same column and settings as above. 1H NMR spectra were recorded in chloroform-d1 
using a Bruker DRX-400 spectrometer (Bruker, Billerica, MA, USA) with a 5 mm sample 
head (400.13 MHz). 
In vitro limonene formation assay. Fully induced E. coli cells were harvested by 
centrifugation (20 min, 4°C, 4618 g), resuspended in 5 mL buffer A (0.05 mM potassium 
phosphate buffer, pH 7.4, 5% (v/v) glycerol, 1 mM dithiothreitol, 15 mM MgCl2) and 
disrupted by three passages through a French press (5.5 MPa, SLM-Aminco, Rochester, NY, 
USA). The solution was subsequently diluted to 0.5 gprotein L-1 (Bradford assay (Zor and 
Selinger, 1996)) in buffer A, aliquoted and incubated (5 min, 30°C, 1000 rpm, Thermomixer 
Comfort, Eppendorf, Hamburg, Germany). Bioconversion was started by adding 60 µL of an 
equimolar mixture of IPP and DMAPP (0.5 g L-1 each in methanol). The reaction was 
terminated by adding a saturating amount of NaCl and ice-cold Et2O (containing 0.2 mM 
dodecane as internal standard), and mixing vigorously for 30 s. The organic and aqueous 
phases were separated by centrifugation (5 min, 4°C, 17000 g) and the organic phase was 
subsequently dried over anhydrous Na2SO4 prior to determining the limonene concentration 
by GC analysis 
In vivo limonene formation assay. E. coli strains were grown at 30°C as described above, but 
in screw-capped baffled flasks (250 mL). Together with 1 mM IPTG, 10 mL 
diisononylphtalate (DINP) were added as inert organic carrier phase to 40 mL of the culture. 
For sampling, the phases were separated by centrifugation (5 min, 4°C, 17000 g). Prior to GC 
analysis, the organic phase was diluted in Et2O with 0.2 mM dodecane and dried over 
anhydrous Na2SO4.  
Fermentative production of limonene in a stirred tank reactor. Two-liquid phase 
fermentations were carried out in 3.1 L stirred tank reactors (KLF 2000, Bioengineering, 
Wald, Switzerland) equipped with two Rushton turbine stirrers. For batch cultivation, 1.0 L 
M9 medium, supplemented with chloramphenicol, ampicillin, US* trace elements (Panke et 
al., 1999), 2 mM MgSO4, and 1.5% (w/v) carbon source (D-glucose or glycerol) was 
inoculated to an OD450 of 0.2 with an overnight M9* preculture of E. coli BL21 (DE3) 
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(pMVAidi, pTAC:LS:AGPPS2). The pH was set to 7.2 and automatically controlled by 
titration with either 15% (v/v) phosphoric acid or 25% (v/v) ammonium hydroxide solution. 
Batch cultures were incubated for 16 or 20 h until depletion of the carbon source (30°C, 
aeration rate 1 vvm, 1800 rpm). After the addition of 1 mL 1000-fold US* trace element stock 
solution, a carbon-limited and controlled exponential feed with either 73% (w/v) glucose or 
glycerol as carbon source (both containing 19.6 g L-1 MgSO4) was started to keep the 
exponential growth rates between 0.15 and 0.18 h-1. After reaching a biomass concentration of 
20 gcdw L-1 the feed rate was kept constant. The pO2 value was kept >30% saturation by 
adjusting the stirrer speed. After 2 h of exponential feed, 0.5 L of DINP were added and gene 
expression was induced by adding 1 mM IPTG. Immediate changes in the O2 saturation upon 
interruptions of the feed at regular intervals were taken as an indication that the carbon source 
was not accumulating in the medium. GC analysis samples were prepared as described above. 
Purification of (S)-limonene. For isolation of limonene, the fermentation broth was 
centrifuged (15 min, 4°C, 4618 g) and the aqueous phase was removed. The resulting 
emulsion was immediately frozen (-80°C, 1 h) and centrifuged again (20 min, 4°C, 4618 g) 
after thawing. 120 mL of the clear organic phase were distilled under reduced pressure (4-
6 mbar, ~160°C). 
2.4 Results 
Limonene synthesis in recombinant E. coli. The synthesis of limonene in recombinant E. coli 
requires the functional expression of two plant genes. The expression vectors pBAD:LS and 
pET24:AGPPS2 were equipped with the truncated and codon-optimized genes for limonene 
synthase (LS) from Mentha spicata and GPP synthase 2 (AGPPS2) from Abies grandis, 
respectively. These two expression systems were chosen, as their use previously led to 
functional expression of GPP synthase and limonene synthase without codon-optimization in 
E. coli (Carter et al., 2003). In addition, a putative bacterial GPP synthase (pET24:KO) from 
Streptomyces sp. strain KO-3988 (Kawasaki et al., 2006) was investigated.  
Membrane-free extracts were prepared from induced E. coli BL21 (DE3) cells that contained 
either pBAD:LS/ pET24:AGPPS2 or pBAD:LS/pET24:KO. With GPP as substrate, activities 
of 1.6 and 3.6 U gprotein-1 were observed. When using IPP and DMAPP, activities for the two-
step bioconversion were 0.13 and 0.15 U gprotein-1. Thus, the introduced genes were 
functionally expressed and there was no significant difference in performance between the 
GPP synthase enzymes from A. grandis and Streptomyces sp. strain KO3988.  
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Figure 2.2: Limonene production in different E. coli strains harboring pMVAidi and 
pTAC:LS:AGPPS2 during two-liquid phase fermentation experiments carried out in a batch culture 
(M9* medium, 1% (w/v) glucose) with an aqueous:organic phase ratio of 4:1. (A) E. coli DH5α (B) 
E. coli BL21 (DE3) (C) E. coli JM101 (D) E. coli MG1655. Glucose (●), acetate (♦), and 
limonene (▲) concentrations were determined at regular intervals. The glucose data points were 
subjected to a Boltzmann regression (dotted line). All concentrations relate to the aqueous phase 
(40 mL). Error bars relate to two independent cultures. 
E. coli BL21 (DE3) (pBAD:LS, pET24:AGPPS2) and E. coli BL21 (DE3) (pBAD:LS, 
pET24:KO) were tested subsequently for their ability to produce limonene with glucose as 
carbon source. No limonene was detected (detection limit ~0.3 mg L-1) in the culture 
supernatant of either strain after cultivation for 24 h in M9* medium, which was in contrast to 
an earlier study reporting the formation of ~6 mg L-1 limonene (Carter et al., 2003). Limonene 
evaporation may explain the negative result. Therefore, the non-toxic organic solvent DINP 
(Schewe et al., 2009) was added to the cultures during growth for the purpose of in situ 
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extraction. The organic phase subsequently accumulated limonene (~0.4 mg Laq-1 in 72 h for 
both strains), demonstrating that limonene was produced from glucose, albeit at low quantity. 
Host effects of different E. coli metabolic backgrounds. The first strategy to optimize the 
biocatalyst was to increase precursor supply, an optimization strategy that has been shown to 
be successful for the production of the sesquiterpene amorpha-4,11-diene in E. coli (Martin et 
al., 2003) and was very recently also applied to the production of limonene (Alonso-Gutierrez 
et al., 2013). In order to increase the intracellular availability of IPP and DMAPP, the 
orthologous mevalonate (MVA) pathway from S. cerevisiae was introduced (Martin et al., 
2003). All the genes of the MVA pathway, that convert endogenous acetyl-CoA into IPP and 
DMAPP (Figure 2.1), were assembled on the plasmid pMVAidi. A second plasmid, 
pTAC:LS:AGPPS2, contained the genes for LS and AGPPS2. Three K-12-derived E. coli 
strains (DH5a, JM101, and MG1655) and the B strain E. coli BL21 (DE3) were transformed 
with pMVAidi and pTAC:LS:AGPPS2 and cultivated in the presence of DINP. Limonene 
was produced in all strains with final concentrations ranging from 15 to 25 mg Laq-1 after 78 h 
(Figure 2.2). Introducing the MVA pathway and simultaneously putting the downstream genes 
under the control of a tac-promoter on one plasmid, resulted in over 60-fold higher limonene 
concentrations as compared to the E. coli strain BL21 (DE3) harboring the incompatible 
plasmids pBAD:LS and pET24:AGPPS2 that was initially used. These results clearly 
confirmed that endogenous precursor supply was a limiting factor for monoterpenoid 
synthesis in the four E. coli strains investigated.  
The specific limonene yield relative to the biomass after 50 h of cultivation was highest for 
E. coli DH5α (12.0 ± 2.2 mg gcdw-1) and for E. coli MG1655 (12.2 ± 0.5 mg gcdw-1) (Table 2.3). 
The yields relative to the carbon source for E. coli DH5α and E. coli MG1655 were 
1.9 ± 0.4 mg g-1 and 2.0 ± 0.1 mg g-1, respectively, which translate into approximately 0.6% 
of the theoretically achievable maximum (calculated to be ~0.32 glimonene gglucose-1 (Dunlop et 
al., 2011)) (Table 2.3).  
Different limonene formation kinetics were observed in the E. coli strains, and acetate 
concentrations appeared to correlate with the level of limonene formation. E. coli DH5α 
produced the highest amount of acetate (5.25 g L-1) and simultaneously also showed the 
highest limonene concentration after 30 h (19.53 ± 0.75 mg Laq-1) (Figure 2.2A). 
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Figure 2.3: Limonene production in E. coli MG1655 (DE3) (∆pta, ∆ldhA, ∆adhE) harboring 
pMVAidi and pTAC:LS:AGPPS2 during a two-liquid phase fermentation carried out in a batch 
culture (M9* medium, 1% (w/v) glucose) with an aqueous:organic phase ratio of 4:1. Glucose (●), 
acetate (♦), and limonene (▲) concentrations were determined at regular intervals. The glucose data 
points were subjected to a Boltzmann regression (dotted line). All concentrations relate to the aqueous 
phase (40 mL). Error bars relate to two independent cultures. 
In contrast, E. coli JM101 showed low amounts of acetate (3.22 g L-1) and also yielded the 
lowest limonene concentration after 30 h (10.88 ± 0.43 mg Laq-1) (Figure 2.2C). The biomass 
concentrations of 1.69 gcdw L-1 for E. coli JM101 and 1.54 gcdw L-1 for E. coli DH5α were 
similar for both strains, but the glucose uptake rate during logarithmic growth was highest for 
E. coli JM101 (~2.4 mmol gcdw-1 h-1). In order to test whether acetate formation had an 
influence on limonene formation, an E. coli strain that lacked the phosphotransacetylase (pta) 
gene that converts acetyl-CoA into acetylphosphate was investigated. E. coli MG1655 DE3 
(∆pta, ∆ldhA, ∆adhE) (pMVAidi, pTAC:LS:AGPPS2) produced less limonene 
(9.07 ± 0.34 g Laq-1) and less acetate (0.85 g L-1) than the strains with a functional pta gene 
under the same experimental conditions (Figure 2.3). The lack of a functional pta gene and the 
resulting physiological properties of the cell prevented an increased flux of metabolites 
towards limonene production. Thus, E. coli BL21 (DE3) was selected as the preferred host 
strain for subsequent experiments as it showed fast growth, a high limonene productivity 
(15.2 ± 2.4 mg L-1 in 30 h) and low formation of acetate, which is generally considered 
detrimental for growth and gene expression. 
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Table 2.3: Comparison of limonene production during batch cultivation of different recombinant 
E. coli strains containing the plasmids pMVAidi and pTAC:LS:AGPPS2.a 
E. coli strain 
µ/ 
h-1 
Limonene/ 
µmol Laq-1 
Limonene/ 
mg Laq-1 
Spec.yield/ 
mg gcdw-1 
Yp/s 
mg g-1 
Of max 
Yp/s/ % 
DH5αb 0.30 140.2 ± 25.8 19.1 ± 3.5 12.0 ± 2.2 1.9 ± 0.4 0.60 
BL21 (DE3)b 0.32 111.5 ± 17.7 15.2 ± 2.4 9.5 ± 1.5 1.5 ± 0.2 0.47 
JM101b 0.34 89.0 ± 2.3 12.2 ± 0.3 7.6 ± 0.2 1.2 ± 0.0 0.38 
MG1655 WTb 0.32 143.2 ± 5.4 19.5 ± 0.7 12.2 ± 0.5 2.0 ± 0.1 0.61 
MG1655 DE3 ∆b, c 0.34 81.3 ± 0.0 11.1 ± 0.0 7.0 ± 0.0 1.1 ± 0.0 0.35 
SF7Nd 0.16 139.9 ± 2.8 19.1 ± 0.4 15.1 ± 0.3 1.9 ± 0.0 0.60 
SF5d 0.16 151.4 ± 5.1 20.6 ± 0.7 17.6 ± 0.6 2.1 ± 0.1 0.64 
aThe growth rate µ was determined from the initial exponential phase. The theoretical stoichiometric maximum 
yield with glucose as C-source was previously calculated as 0.32 g limonene per g glucose (Dunlop et al., 
2011).b50 h; cMG1655 (DE3) (∆pta, ∆ldhA, ∆adhE); d 72 h. 
Native FPP synthase activity does not compete with GPP synthase for endogenous IPP and 
DMAPP. E. coli produces the sesquiterpene precursor farnesyl diphosphate (FPP) via an 
endogenous FPP synthase. FPP is required for the synthesis of essential compounds such as 
menaquinone and ubiquinone, which can be of benefit for terpenoid biosynthesis. However, 
as far as the production of monoterpenes is concerned, the introduction of a recombinant GPP 
synthase enzyme might have an impact on the cellular metabolism of the host, and render 
monoterpene production difficult due to ongoing endogenous sesquiterpene synthesis. The 
intracellular GPP concentration might be limited due to rerouting of IPP and DMAPP or GPP 
towards the formation of FPP by native FPP synthase (ispA). A literature search revealed that 
the Michaelis constant (KM) of the E. coli FPP synthase is 10-fold lower for IPP (two-fold for 
DMAPP) than the KM of the A. grandis GPP synthase (Table 2.4) (Burke and Croteau, 2002; 
Fujisaki et al., 1986). To investigate the possible competition between FPP synthase and GPP 
synthase, limonene formation was analyzed in an ispA (encoding FPP synthase) deficient 
E. coli W3110 SF7N and its isogenic control E. coli W3110 SF5 (Fujisaki et al., 2005), both 
harboring pTAC:LS:AGPPS2 and pMVAidi.  
After depletion of glucose, both strains reached similar biomass concentrations of 
1.19 ± 0.07 gcdw L-1 (SF7N) and 1.17 ± 0.09 gcdw L-1 (SF5) and similar product levels 
(19.05 ± 0.37 mg Laq-1 for E. coli SF7N and 20.6 ± 0.7 mg Laq-1 for E. coli SF5) (Figure 2.4). 
Different acetate levels were not expected, given the near 100% genetic identity of the two 
strains. Hence, despite favored kinetic parameters, endogenous FPP synthesis did not affect 
monoterpene yield by limiting the terpenoid precursors IPP, DMAPP, and GPP. 
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Figure 2.4: The specific limonene yields (dark gray bars) in E. coli SF7N and SF5 harboring 
pTAC:LS:AGPPS2 and pMVAidi after 72 h with glucose as sole C-source. The biomass 
concentrations (in gcdw L-1) are provided for comparison (light gray bars). Error bars relate to two 
independent cultures. 
Does GPP synthase activity limit limonene formation rate? SDS–PAGE analyses with 
protein extracts from fully induced strains showed that E. coli JM101 produced more GPP 
synthase than E. coli BL21 (DE3) (Figure 2.6). Additionally, lower (soluble) GPP synthase 
levels were observed in E. coli BL21 (DE3) at 30°C and 25°C compared to 20°C, 
demonstrating that the translation, protein folding, and/or protein stability was temperature-
dependent (Figure 2.6). Extracts derived from E. coli BL21 (DE3) (pTAC:LS:AGPPS2) 
(Figure 2.5A) and E. coli BL21 (DE3) (pMVAidi, pTAC:LS:AGPPS2) cultivated at 25°C 
showed specific activities of 1.0 ± 0.0 and 1.2 ± 0.0 U gprotein-1, respectively for the two-step 
bioconversion of IPP and DMAPP to limonene.  
Table 2.4: KM values for the respective synthases involved in terpenoid synthesis 
Enzyme 
KM(IPP)/ 
µM 
KM(DMAPP)/ 
µM 
KM(GPP)/ 
µM 
Reference 
FPP synthase  
(E. coli) 40 50 8.7 
(Fujisaki et al., 
1986) 
GPP synthase 2 
(A. grandis) 50 90 / 
(Burke and Croteau, 
2002) 
Limonene synthase 
(M. spicata) / / 6.0 
(Williams et al., 
1998) 
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Figure 2.5: In vitro limonene production using cell extracts from E. coli BL21 (DE3) (panel A) and 
JM101 (panel C) cultures, both harboring pTAC:LS:AGPPS2. 20°C expression temperature (■), 25°C 
(●) expression temperature. The temperature-dependence of in vivo limonene production is shown in 
panel B and D for strains with pTAC:LS:AGPPS2 (light gray bars), and strains with 
pTAC:LS:AGPPS2 and pMVAidi (dark gray bars). In vivo experiments were run for 48 h after 
induction in a two-liquid phase system with DINP as inert organic phase (phase ratio 1:4, 
organic:aqueous volume). Limonene concentrations were normalized to the values obtained at 30°C. 
After cultivation at 20°C, the extracts showed higher specific limonene formation rates of 
2.1 ± 0.0 U gprotein-1 (pTAC:LS:AGPPS2) (Figure 2.5A) and 4.0 ± 0.1 U gprotein-1 (pMVAidi, 
pTAC:LS:AGPPS2). Raising the expression temperature to 30°C led to a further reduction in 
limonene formation rates (data not shown), most likely caused by the decreasing level of 
soluble AGPPS2 as the temperature increased (Figure 2.6). In contrast, no significant 
temperature-dependent difference in limonene formation was observed with extracts derived 
from fully induced E. coli JM101 (pTAC:LS:AGPPS2) cells (Figure 2.5C). 
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Figure 2.6: SDS-PAGE analysis of E. coli strains BL21 (DE3) (grown at 20°C, 25°C (A), and 30°C 
(B)) and JM101 (grown at 20°C and 25°C (D)) harboring the plasmid pTAC:LS:AGPPS2. The figure 
shows the whole cell protein content at time of induction (0 h) and 22 h after induction, as well as the 
soluble fraction (SN) 22 h after induction, and the pellets (P) after cell lysis and ultracentrifugation. 
The GPPS2 protein was identified by comparison with a negative control (derived from E. coli 
BL21 (DE3) grown at 30°C, harboring an empty control plasmid) (C). The approximate theoretical 
size of A. grandis GPPS2 is 32 kDa. 
The presence of the additional pMVAidi plasmid did not obviously impair the expression of 
AGPPS2 and LS genes. In order to address the impact of different amounts of AGPPS2 on 
whole-cell limonene formation, the strains (with both plasmids) were cultivated at different 
temperatures. When using glucose as carbon source, the specific in vivo limonene yield 
increased with increasing temperature for E. coli BL21 (DE3), whereas it remained constant 
in E. coli JM101 (Figure 2.5B, D). The limonene yield of E. coli BL21 (DE3) at 20°C was 
only 33.1 ± 10.7% of the amount observed at 30°C. In contrast, E. coli JM101 produced at 
20°C 92.3 ± 7.7% of the quantity formed at 30°C. The biomass yields were similar in all 
cases, with averaged final concentrations of 1.19 gcdw L-1 (± 6%) for E. coli BL21 (DE3) and 
1.39 gcdw L-1 (± 14%) for E. coli JM101. Glucose was metabolized entirely in all 
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fermentations (Table 2.5). Since the quantity of soluble AGPPS2 in E. coli BL21 (DE3) was 
reduced at elevated temperatures (Figure 2.6), it did not correlate with the in vivo limonene 
formation yield. As the largest part of limonene was produced within 24 h after induction 
(Figure 2.2A), we therefore conclude that AGPPS2 activity did not limit overall limonene 
production under the selected experimental conditions. For E. coli BL21 (DE3), the ratio of 
the limonene yields achieved in strains with and without the MVA pathway 
(Yp/x(MVA)/Yp/x(nonMVA)) increased with rising temperatures from 11 (20°C) to 19 (30°C). The 
reduced in vivo limonene formation in E. coli BL21 (DE3) at 20°C and 25°C can therefore be 
explained by the reduced performance of one or more MVA pathway enzymes. However, the 
differences observed in AGPPS2 solubility at different temperatures and in different hosts, 
might allow for further optimization of the production process. 
Table 2.5: Supplementary data for the investigation of the effect of AGPPS2 expression on the in vivo 
limonene production (Figure 2.5B, D). All concentrations relate to the final concentrations observed 
48 h after induction of gene expression. pTAC is used as abbreviation for pTAC:LS:AGPPS2. 
E. coli 
strain 
Plasmid(s) Express. temp./ 
°C 
Limonene/ 
mg Laq-1 
Biomass/ 
mg L-1 
Glucose/ 
g L-1 
Acetate/ 
g L-1 
BL21 (DE3) pTAC 20 0.4 ± 0.1 1.30 ± 0.01 0 4.32 ± 0.42 
BL21 (DE3) pTAC 25 0.3 ± 0.0 1.10 ± 0.06 0 1.62 ± 0.00 
BL21 (DE3) pTAC 30 0.6 ± 0.2 1.24 ± 0.03 0 1.57 ± 0.06 
BL21 (DE3) pTAC, pMVAidi 20 4.0 ± 1.2 1.22 ± 0.03 0 4.38 ± 0.06 
BL21 (DE3) pTAC, pMVAidi 25 5.7 ± 0.6 1.17 ± 0.00 0 2.00 ± 0.03 
BL21 (DE3) pTAC, pMVAidi 30 11.1 ± 1.0 1.12 ± 0.06 0 1.90 ± 0.00 
JM101 pTAC 20 1.7 ± 0.0 1.22 ± 0.09 0 3.72 ± 0.31 
JM101 pTAC 25 1.8 ± 0.4 1.39 ± 0.08 0 3.60 ± 0.31 
JM101 pTAC 30 1.5 ± 0.1 1.21 ± 0.06 0 2.38 ± 0.51 
JM101 pTAC, pMVAidi 20 12.6 ± 0.6 1.43 ± 0.09 0 2.37 ± 0.10 
JM101 pTAC, pMVAidi 25 12.5 ± 0.6 1.76 ± 0.15 0 2.90 ± 0.01 
JM101 pTAC, pMVAidi 30 12.3 ± 0.0 1.30 ± 0.03 0 2.62 ± 0.00 
Gram-scale production and purification of (S)-limonene. With the aim of achieving gram-
scale amounts of (S)-limonene from cheap and renewable carbon sources, E. coli BL21 (DE3) 
(pMVAidi, pTAC:LS:AGPPS2) was cultivated in a technical-scale process (3.1 L) using a 
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two-liquid phase fed-batch approach with either glucose or glycerol as carbon source and 
DINP as organic carrier solvent (phase ratio 1:2).  
 
Figure 2.7: Two-liquid phase fermentation processes with E. coli BL21 (DE3) (pMVAidi, 
pTAC:LS:AGPPS2) cultivated under carbon-limited fed-batch conditions in a 3.1 L reactor (glycerol: 
panel A, glucose: panel B). Biomass concentration (■), glycerol or glucose (●), and acetate (♦) 
concentrations were monitored. The feed rate is given by the dashed line. The limonene concentration 
(▲) determined by GC relates to the organic phase (0.5 L), because of the changing volume of the 
aqueous phase during cultivation. The initial phase ratio was set to 1:2 (0.5 L DINP, 1 L M9 medium). 
The error bars of the biomass concentration are calculated from four measurements. Time point 0 
indicates the beginning of fed-batch fermentation. Limonene concentrations of repeated experiments 
differed by less than ±12%. Panel C: Time course of specific activity (closed symbols) and observed 
limonene concentration (open symbols) during the two-liquid phase fed-batch cultivation of E. coli 
BL21 (DE3) (pMVAidi, pTAC:LS:AGPPS2) under either glycerol- (●, ○) or glucose-limited (■, □) 
conditions The figure is based on data reported in the Diploma Thesis of Christian David (David, 
2013). 
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With glycerol as the sole carbon source, a final limonene concentration of 2.7 g Lorg-1 was 
achieved within 45 h (Figure 2.7A), which was 3.9-fold higher than the final limonene 
concentration achieved with glucose as the carbon source (0.69 g Lorg-1) (Figure 2.7B). 
Furthermore, a 26% higher final biomass concentration of 61.8 gcdw L-1 was achieved with 
glycerol than with glucose (49.1 gcdw L-1). The increased limonene concentration is therefore 
not just attributable to the increase in biomass formation. Since the protein levels of LS and 
AGPPS2 were similar in the glucose- and glycerol-based experiments (as indicated by PAGE 
analysis, data not shown), it was concluded that the higher limonene concentration under 
glycerol-limited growth was not caused by the higher activity of the heterologously expressed 
limonene synthesis pathway but by other metabolic factors, such as ATP and redox equivalent 
regeneration rates. 
The initial specific limonene formation rates were low in both fed-batch cultivation 
experiments but increased to approximately 70 mU gcdw-1 (with glucose) during the first 8 h 
(Figure 2.7C). During fed-batch cultivation with glucose as carbon source, the specific 
limonene formation rate remained constant during the subsequent 7 h before decreasing to 
7 mU gcdw-1 after 32 h. This decrease in the limonene formation rate is due an as yet 
unidentified metabolic inactivation of the cells (glucose accumulation). With glycerol as 
carbon source, the high limonene formation rate remained almost constant during the entire 
fermentation process (~45 h), reaching specific activities of more than 50 mU gcdw-1 (Figure 
2.7C). These fed-batch experiments demonstrate that the selection of the appropriate substrate 
and reaction setup is crucial for optimizing product yields. Limonene obtained in the fed-
batch experiment with glucose as carbon source was purified via distillation. The resulting 
distillate (42% isolation yield) had a characteristic odor, contained (S)-limonene with an 
enantiomeric excess (ee) of ≥99.8, and exhibited a purity of ≥96% as determined by GC and 
1H-NMR, respectively. Impurity traces of the monoterpenes β-pinene and myrcene were also 
identified. 
2.5 Discussion 
Whole-cell biocatalyst engineering for monoterpene production. Over the past decade, 
extensive research efforts have been undertaken to construct recombinant microbial platform 
organisms that enable the fermentative production of terpenoids. Recent achievements in 
synthetic biology and metabolic engineering constitute a first step towards the rational design 
of microbial cell factories that are able to produce the desired terpenoids from cheap and 
renewable resources (Keasling, 2012). However, knowledge about the regulatory mechanisms 
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involved at the genetic and protein levels, and potential limitations resulting from inhibitions, 
the toxicity of components or interference of substrates and products with transcription factors 
is still very limited. This is particularly true when genes or entire pathways of foreign 
organisms are utilized (Kim and Copley, 2012). Furthermore, with respect to monoterpenoid 
formation, previous studies have rarely addressed parameters such as productivity (mg L-1 h-
1), specific activity (U gcdw-1), or specific yield (mg gcdw-1), which are, however, also highly 
important.  
The presence of a competing pathway (FPP synthase) and a mainly insoluble GPPS at 30°C 
did not affect the amount of limonene produced in vivo. The main limitation of (mono-) 
terpene production in recombinant E. coli appeared to be the availability of the terpene 
precursors IPP and DMAPP. The limonene concentrations obtained in shake flasks with 
glucose as carbon source (15–25 mg Laq-1 of limonene) were of the same order of magnitude 
as those previously reported for the heterologous production of limonene in E. coli DH1 
(Alonso-Gutierrez et al., 2013) that was engineered in a similar way to the strains used in this 
study and that was grown in a defined rich medium. A significant optimization potential was 
documented when all required heterologous pathway genes were combined on one plasmid, 
and when the heterologous MVA pathway was further optimized with respect to codon usage, 
promoter strength, and selection of an appropriate source organism for the required genes 
(Alonso-Gutierrez et al., 2013). 
E. coli strains derived from K-12, harboring an optimized 2-C-methyl-D-erythritol 4-
phosphate (MEP) pathway, showed a 2.5-fold increased taxadiene (diterpene) production 
compared to the respective B strain variants (Boghigian et al., 2012a). In the present study, 
the selection of strains that were able to synthesize monoterpenoids via the heterologous 
MVA pathway does not appear to be the crucial factor, as all strains investigated produced 
similar amounts of limonene (±25%), (Figure 2.2, Table 2.3). One explanation might be that in 
contrast to the eukaryotic MVA pathway, the MEP pathway originates from E. coli and is 
thus better suited to meet the intrinsic regulatory requirements of the host. High levels of 
acetate and the highest limonene concentration were found for E. coli DH5α harboring the 
limonene formation pathway (Figure 2.2). This was unexpected, as acetate formation is a sink 
for acetyl-CoA and was therefore assumed to be a competing pathway for the production of 
terpenoids. Nevertheless, a reasonable explanation for the correlation between acetate 
(leading to the generation of 1 mole ATP per mole acetate) and limonene formation may be 
seen in the activity of the exogenously introduced MVA pathway. This pathway requires 
6 moles of ATP for the formation of 1 mole limonene, which might cause a significant 
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metabolic burden. Although the final limonene concentration might seem low, the 
accumulation of (toxic) intermediates resulting from imbalances in the pathway, as well as the 
energy (and redox equivalents) required for expression of the genes involved, may increase 
the ATP demand even further. We therefore conclude that shortage of acetyl-CoA does not 
limit the limonene production rate in E. coli under these specific experimental conditions. A 
similar finding was recently published for the biosynthetic production of long-chain fatty 
acids in E. coli that also starts from acetyl-CoA (Li et al., 2012). The knocking out of the two 
key genes of the acetate formation pathway, ack-pta (acetate kinase/phosphotransacetylase) 
and poxB (pyruvate oxidase) did not result in increased fatty acid concentrations (Li et al., 
2012). 
Reaction engineering: Two-liquid Phase setup. Several studies have described a two-liquid 
phase approach for the in situ extraction of the terpenoids produced (Morrone et al., 2010; 
Newman et al., 2006). Although an earlier study reported the production of limonene in 
E. coli in an aqueous medium alone (Carter et al., 2003), the addition of a second organic 
phase appeared to be a mandatory requirement in our experiments that were aimed at avoiding 
evaporation and facilitating limonene quantification. Loss of product by evaporation was 
proven by the fact that exogenously added limonene (100 µM) could no longer be detected by 
means of GC analysis (detection limit ~0.3 mg L-1) after incubation for 4 h at 30°C and orbital 
shaking in M9* medium. DINP was found to be best suited for the two-liquid-phase setup, 
since it is reported to have no significant impact on the growth rate of E. coli (Schewe et al., 
2009) and shows a favorable limonene partition coefficient ((24.0 ± 2.7)·103). In fact, the 
addition of DINP was beneficial in our experiments with respect to the prevention of 
limonene evaporation. The efficient extraction of the product also facilitated downstream 
product purification by distillation and most likely also decreased the toxic effects of 
limonene on the host cell. 
Reaction Engineering: Glycerol as Carbon Source. Glycerol as carbon source in fed-batch 
cultivation yielded a four-fold higher limonene concentration compared to glucose (Figure 
2.7). The beneficial effect of glycerol as sole or supplementary carbon source has been 
reported before for the fermentative production of carotenoids in MEP- engineered E. coli 
strains (Jang et al., 2011; Kim et al., 2011; Lee et al., 2004) and for sesquiterpenes in a MVA-
engineered E. coli strain (Martin et al., 2003). However, the reasons for the reduced 
concentrations in the presence of glucose, remained unclear (Lee et al., 2004). In the present 
study, the stability of the whole-cell biocatalyst was shown to be responsible for the elevated 
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limonene concentration observed in the glycerol-based fermentation (Figure 2.7C). The 
stabilizing effect of glycerol on isolated enzymes is well known (Gekko and Timasheff, 1981; 
Jarabak et al., 1966). For whole-cell biocatalysis, however, metabolic effects rather than direct 
enzyme stabilization are to be expected. In general terms, glycerol exhibits a higher degree of 
reduction (κ = 0.47) per carbon atom as compared to glucose (κ = 0.40) (Durnin et al., 2009). 
It may therefore be beneficial for the formation of highly reduced compounds such as 
limonene (κ = 0.56). Furthermore, the incorporation of glycerol into biomass might result in 
the formation of additional reducing equivalents (Durnin et al., 2009). 
Production Rates and Yields. The total productivities (or space time yields, STY) over the 
entire fed-batch cultivation periods were calculated as 5.6 and 22.6 mg Laq-1 h-1 for cells 
grown with glucose or glycerol as carbon source, respectively. The productivity observed for 
the glycerol-based experiment equals roughly one fourth of the productivity that is considered 
a threshold for developing a profitable production process for fine chemicals (100 mg L-1 h-1) 
(Straathof et al., 2002). Considering the maximum space time yields observed (~40 mg Laq-
1
 h-1 for the glycerol-limited cultivation), the rates are only 2.5-fold lower than the required 
minimum proposed for industrial application.  
The specific limonene formation rates for E. coli BL21 (DE3) in fed-batch (approx. 
75 mU gcdw-1) and batch cultivation during exponential growth phase (approx. 85 mU gcdw-1) 
were similar. Despite these promising results, the limonene yields based on the carbon source 
utilized during fed-batch cultivation were still rather low and were calculated to be 1.31 and 
4.10 mg g-1 when using glucose or glycerol as carbon source, respectively. These values 
translate into 0.45 and 1.0% of the theoretically achievable maximum (stoichiometric 
calculation), and are thus also similar to the yields obtained for E. coli BL21 (DE3) in batch 
cultivation (Table 2.3). Nevertheless, it has to be taken into account that a large proportion of 
the carbon utilized is directed towards the production of biomass and by-products. It might 
therefore be useful for future applications to decouple product and biomass formation. 
2.6 Conclusions 
The optimization of whole-cell processes requires a systematic analysis of the biocatalyst, e.g. 
the microbial cell, in the reaction process. In order to optimize the fermentative production of 
(S)-limonene in recombinant E. coli, the key engineering parameters were defined and 
analyzed at the genetic (pathway engineering, gene expression), physiological (toxicity, 
competing pathways), and technological (volatility, two-liquid phase reactor set-up, 
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downstream processing) levels. This systematic approach allowed the identification of the 
parameters that play a key role in monoterpene production, and subsequently the development 
of strategies for bioprocess optimization. In accordance with earlier studies, orthologous 
pathway engineering was crucial to overcoming limiting quantities of terpene precursors. This 
potential was successfully exploited in earlier studies (Alonso-Gutierrez et al., 2013; Yang et 
al., 2013). Maximizing productivity and stability of the microbial biocatalyst is also highly 
important. This can be achieved by specifically engineering the host strain and by modifying 
the reaction conditions. The results of the present study furthermore showed that mass transfer 
rates of oxygen and glycerol into the cells were not restrictive. This provides a basis to further 
optimize productivity by exploiting the potential of the whole-cell biocatalyst. Future process 
improvement should also focus on the optimization of intracellular metabolite fluxes towards 
acetyl-CoA, the supply of sufficient redox and energy equivalents, as well as cultivation and 
production conditions. 
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3.1 Abstract 
Metabolic engineering strategies mark a milestone for the fermentative production of bulk and 
fine chemicals. Yet, toxic products and volatile reaction intermediates with low solubilities 
remain challenging. Prominent examples are artificial multistep pathways like the production 
of perillyl acetate (POHAc) from glucose via limonene. For POHAc, these limitations can be 
overcome by mixed-culture fermentations. A limonene biosynthesis pathway and cytochrome 
P450 153A6 (CYP153A6) as regioselective hydroxylase are used in two distinct recombinant 
Escherichia. coli. POHAc formation from glucose in one recombinant cell was hindered by 
ineffective coupling of limonene synthesis and low rates of oxyfunctionalization. The 
optimization of P450 gene expression led to the formation of 6.20 ± 0.06 mg gcdw-1 POHAc in 
a biphasic batch cultivation with glucose as sole carbon and energy source. Increasing the 
spatial proximity between limonene synthase and CYP153A6 by a genetic fusion of both 
enzymes changed the molar limonene/POHAc ratio from 3.2 to 1.6. Spatial separation of 
limonene biosynthesis from its oxyfunctionalization improved POHAc concentration 3.3-fold 
to 21.7 mg L-1 as compared to a biphasic fermentation. Mixed-cultures of E. coli BL21 DE3 
containing the limonene biosynthesis pathway and E. coli MG1655 harboring either 
CYP153A6, or alternatively a cymene monooxygenase, showed POHAc formation rates of 
0.06 or 0.11 U gcdw-1, respectively. This concept provides a novel framework for fermentative 
syntheses involving toxic, volatile, or barely soluble compounds or pathway intermediates. 
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3.2 Introduction 
Products and intermediates of central carbon metabolism are of limited structural complexity, 
hydrophilic and charged (http://www.ecocyc.org). The largest part of industrially relevant 
natural products, however, is structurally complex, hydrophobic, volatile, and not charged 
(Liese et al., 2006). Which concepts were evolved in nature to cope with these properties? 
Prominent examples are the modular polyketide synthases, assembling complex chemical 
structures by intermediate channeling through different subunits (Staunton and Weissman, 
2001), and the synthesis, production, and storage of volatiles in specialized plant cells or 
tissues containing designated cavities, ducts or vacuoles, or in organelles (Pichersky et al., 
2006).  
Specialized organisms and their parts like, e.g., plant cells, are seldom of industrial use as 
they are typically characterized by slow growth, fastidious nutrient requirements, and limited 
scalability (Zhang et al., 2011). Alternatively, recombinant microbial strains are applied, 
although their genetic repertoire and subcellular architecture are not optimized by evolution 
for natural product synthesis. The development of biotechnological production traditionally 
focuses on gene-based metabolic engineering strategies importing and synchronizing foreign 
genetic elements like genes or promotors. 
 
Figure 3.1: Biocatalytic de novo synthesis of (S)-(-)-perillyl acetate. Glucose is metabolized via the 
heterologous mevalonate pathway and the IPP/DMAPP isomerase to the terpene precursors 
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), which are then condensed by 
a geranyl diphosphate (GPP) synthase to form GPP. GPP in turn is cyclized via a cationic intermediate 
to (S)-(-)-limonene. The regioselective oxygenation of limonene to perillyl alcohol is catalyzed by the 
cytochrome P450 monooxygenase 153A6 (CYP153A6) or the cymene monooxygenase cymA. The 
free alcohol is converted to the respective acetic acid methyl ester perillyl acetate by the 
chloramphenicol acetyl transferase (CAT), which is present on the plasmid pMVAidi. 
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Successful implementations of biotechnological processes however, necessitate the concerted 
optimization of genetic, metabolic, reaction, and process related parameters, taking into 
account the properties of the intermediates and products of a given pathway. The 
biotechnological production of monoterpenoids, such as perillyl acetate or perillyl alcohol can 
serve as a model system for new process design concepts meeting these requirements. These 
compounds are of great interest for the cosmetic, food, and pharmaceutical industries due to 
their olfactory, antimicrobial, and anticarcinogenic properties (Schewe et al., 2011; van der 
Werf et al., 1997). 
The de novo formation of monoterpenes using engineered E. coli (Chapter 2, (Alonso-
Gutierrez et al., 2013; Sarria et al., 2014; Yang et al., 2013; Zhang et al., 2014)) was shown to 
be limited by the low solubility, volatility, and toxicity of the products (and intermediates) as 
well as a poor terpene precursor supply via the native methylerythritol phosphate pathway. An 
increase of terpene precursor concentrations was achieved by the introduction of the 
mevalonate (MVA) pathway in E. coli followed by optimization of promotor strength 
(Anthony et al., 2009), codon usage (Redding-Johanson et al., 2011), translation initiation 
(Nowroozi et al., 2014), and gene selection (Ma et al., 2011; Yang et al., 2012b) and resulted 
in the formation of (mono-) terpenes from glucose. Recombinant strains carrying cytochrome 
P450 monooxygenase 153A6 (CYP153A6) or cymene monooxygenase (cymA), both of 
bacterial origin, enabled the regioselective biotransformation of limonene to perillyl alcohol 
(POH) (van Beilen et al., 2005; Cornelissen et al., 2013; Mars et al., 2001). However, due to 
the inherent complexity of oxygenase systems (Bernhardt and Urlacher, 2014) and the 
physical properties of the (mono-) terpene educts, a direct coupling of the oxygenation 
reaction to the fermentation is very difficult (Alonso-Gutierrez et al., 2013). Gene-based 
engineering strategies, successful for the optimization of the heterologous MVA pathway, can 
be complemented with reaction engineering or novel fermentations concepts meeting the 
special requirements given by the involved compounds and enzymes. Typically, the toxicity 
of monoterpenes is counteracted by the use of biphasic setups, additionally facilitating 
downstream processing by in situ product removal (Frohwitter et al., 2014; Newman et al., 
2006). The fermentative production of monoterpenes was shown to profit from the addition of 
diisononyl phthalate (DINP) (Chapter 2) or dodecane (Sarria et al., 2014). However, for the 
direct microbial production of perillyl alcohol from glucose via limonene, the application of 
an aqueous:organic two-liquid phase system was counterproductive as the formed limonene 
was efficiently extracted into the organic carrier phase making it unavailable for 
oxyfunctionalization (Alonso-Gutierrez et al., 2013). The objective of this study was to 
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overcome factors preventing the de novo synthesis of perillyl acetate, which can be readily 
converted to perillyl alcohol by saponification (Štekrová et al., 2012), with engineered E. coli 
(Figure 3.1). Engineering strategies addressing parameters such as oxygenase concentration, 
spatial enzyme proximity, and enzyme kinetics or localization enabled coupling of the 
limonene oxygenation step to limonene production in a two-liquid phase system, but still 
identified the intracellular limonene availability as the main limiting factor. Inspired by the 
orthologous nature of the biosynthesis pathway, we finally developed a novel fermentation 
concept spatially separating limonene formation from glucose and its oxygenation using a 
defined mix of two distinct cultures of non-growing cells in a monophasic cultivation system. 
3.3 Materials & Methods 
Chemicals, oligonucleotides, and bacterial strains. Anhydrous D-glucose was obtained from 
Alfa Aesar (Karlsruhe, Germany), and isopentenyl diphosphate (IPP), dimethylallyl 
diphosphate (DMAPP), and geranyl diphosphate (GPP) were purchased from Echelon 
Biosciences (Salt Lake City, UT, USA) at a purity of >95%. Custom synthesized 
oligonucleotides were purchased from Sigma Aldrich (Steinheim, Germany). Perillyl acetate 
(>98.8% purity) was kindly provided by Hiroshi Tsuda (Nippon Terpene Chemicals, Inc., 
Tokyo, Japan). All other chemicals were obtained from AppliChem (Darmstadt, Germany), 
Sigma Aldrich (Steinheim, Germany), or Carl Roth (Karlsruhe, Germany) at the highest 
purity available. E. coli strains and plasmids used are listed in Table 3.1. The details of vector 
architecture and primer design are provided in Figure 3.2 and Table 3.2. 
Vector Construction. All production vectors were constructed by either using the in vitro 
assembling technology SLIC (sequence and ligation independent cloning) (Li and Elledge, 
2007) or the one-step isothermal assembling method described by Gibson et al. (Gibson et al., 
2009). Enzymes and materials were obtained from Thermo Scientific - Germany GmbH 
(Schwerte, Germany). The PCR conditions were designed according to the manufacturer's 
instructions. The accuracy of the cloning procedures was assessed by sequence analysis 
(MWG Eurofins, Ebersberg, Germany).  
The plasmid pTAlk:POH was constructed by amplifying the entire CYP expression unit 
(AlkS, PAlkS, PAlkB, CYP153A6, FdR, FdX) using the primers PCW070 and PCW071 (57°C 
annealing temperature, 120 s elongation time) from pCom8:PFR1500 (van Beilen et al., 2005) 
and subsequent integration of the resulting PCR fragment into RsrII linearized 
pTAC:LS:AGPPS2 (Chapter 2).  
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Table 3.1: List of bacterial strains and plasmids that were applied in this study. 
Strain Characteristics Reference 
E. coli DH5α F–, Φ80dlacZ∆M15, ∆(lacZYA-argF)U169, deoR, recA1, endA1, 
sdR17(rK–mK+), phoA, supE44, λ–, thi-1, gyrA96, relA1 
(Hanahan, 
1983) 
E. coli BL21 (DE3) F–, ompT, hsdSB(rB–mB–), gal (c1875, ind1, Sam7, nin5, lacUV5-
T7 gene1), dcm (DE3) 
(Studier and 
Moffatt, 
1986) 
E. coli JM101 glnV44, thi-1, supE, ∆(lac-proAB), F’[lacIq lacZ∆M15 traD36 
proAB+] 
(Messing, 
1979) 
E. coli MG1655 F–, λ–, ilvG–, rfb-50, rph-1 (Bachmann, 
1996) 
E. coli W3110 F-, λ-, ilvG-, rfb-50, rph-1 (Bachman, 
1972) 
P. putida DSM12264 Pseudomonas putida GS1 wild-type DSMZ 
Plasmid   
pMVAidi p15A, CmR, Plac, atoB, erg13, tHMGR1, erg12, erg8, erg19, idi1 Chapter 2 
pTAC:LS:AGPPS2 pMB1, AmpR, Ptac, lacIq, trunc. codon-optimized LS gene from M. 
spicata and trunc. codon-optimized GPPS2 gene from A. grandis Chapter 2 
pCom8:PFR1500 pMB1*, GmR, PalkB, alkS, genes encoding CYP153A6, FdR, and 
FdX from Mycobacterium sp. HXN1500 
(van Beilen 
et al., 2005) 
pCom8:PFR1500L pCom8:PFR1500 with gene encoding AlkL from P. putida GPo1 (Cornelissen 
et al., 2013) 
pTAlk:POH pTAC:LS:AGPPS2 with PalkB, alkS, and genes encoding 
CYP153A6, FdR, and FdX from Mycobacterium sp. HXN1500 this study 
pTAC:POH pTAC:LS:AGPPS2 with the CYP153A6 gene between the LS and 
GPPS2 genes and the FdX and FdR genes after the GPPS2 gene this study 
pTAC:POHf pTAC:POH, translational fusion between LS and CYP153A6 this study 
pTAC:CymA pMB1, AmpR, Ptac, lacIq, cymAa and cymAb genes from P. putida 
GS1 this study 
pTAC:POH:CymA pTAC:CymA with truncated and codon-optimized LS gene from 
M. spicata  this study 
Cultivation of bacterial strains. E. coli strains were cultivated as described before (M9* 
medium, baffled Erlenmeyer flasks, liquid:gas phase ratio of 1:4) (Chapter 2). Cultures were 
incubated at 30°C (200 rpm, 2.5 cm amplitude). Recombinant gene expression was induced 
by adding 1.0 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) or 0.025% (v/v) 
dicyclopropyl ketone (DCPK). If required, ampicillin, gentamicin, and/or chloramphenicol 
were added at concentrations of 100, 10, and 34 mg L-1, respectively. Thiamine (if 
appropriate) and δ-aminolevulinic acid (heme synthesis) were added to final concentrations of 
0.001% (w/v) and 0.5 mM, respectively. 
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Figure 3.2: A schematic drawing of the plasmids used and/or constructed in this study. References for 
the plasmids that were not constructed in this study are given in Table 3.1. Abbreviations: LS, 
Mentha spicata (S)-limonene synthase; AGPPS2, GPP synthase 2; atoB, E. coli acetyl-CoA 
acetyltransferase; HMGS, S. cerevisiae 3-hydroxy-3-methylglutaryl-CoA synthase; t-HMGR, 
truncated S. cerevisiae HMG-CoA reductase; MK, S. cerevisiae mevalonate kinase; PMK, 
S. cerevisiae phosphomevalonate kinase; PMDC, S. cerevisiae diphosphomevalonate decarboxylase; 
idi, E. coli IPP/DMAPP isomerase; CYP, Mycobacterium sp. HXN1500 alkane monooxygenase 
(CYP153A6); FdR, Mycobacterium sp. HXN1500 ferredoxin reductase; FdX, Mycobacterium sp. 
HXN1500 ferredoxin; AlkL, P. putida GPo1 AlkL; CymAa, monooxygenase subunit of P. putida 
GS1 CymA; CymAb, reductase subunit of P. putida GS1 CymA; AlkS, transcriptional activator of 
PalkB; lacIq, transcriptional repressor of Plac and Ptac. The scheme is not drawn to scale. 
For the construction of pTAC:POH and pTAC:POHf, the gene for the monooxygenase 
CYP153A6 was amplified from pCom8:PFR1500 (van Beilen et al., 2005) using the primers 
PCW072 and PCW074 (non-fusion) or PCW073 and PCW074 (fusion). The flexible amino 
acid linker (GGGGGGA) was introduced by primer PCW073. The PCRs were performed 
using a 2-step PCR protocol with combined annealing and elongation steps (60 s). The 
resulting PCR fragments were integrated into BstBI linearized pTAC:LS:AGPPS2. The 
obtained plasmids were then digested with EcoNI and combined with the PCR fragment 
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encoding FdR and FdX (obtained via PCR amplification from pCom8:PFR1500 with the 
primers PCW075 and PCW076, combined annealing and elongation for 60 s). 
The construction of the plasmid pTAC:CymA required the isolation of genomic DNA from 
P. putida GS1 (DSM 12264) via the peqGOLD Bacterial DNA Kit (PEQLAB Biotechnologie 
GmbH, Erlangen, Germany). 50 ng of genomic DNA were used as template for the PCR 
amplification (100 µL) of the genes cymAa (cymene monooxygenase) and cymAb (reductase 
subunit of cymene monooxygenase). The primers PCW077 and PCW078 (cymAa) as well as 
PCW079 and PCW080 (cymAb) were designed based on the publically available genome 
sequence of P. putida F1 (GenBank ID: CP000712.1). The PCR settings were adjusted to 
68°C annealing temperature and 40 s of elongation. The resulting DNA fragments were 
spliced together using the primers PCW077 and PCW080 (60°C annealing temperature, 40 s 
elongation time). The primers were added during the denaturation step of the third PCR cycle. 
The product of the fusion PCR (~2400 bp) was integrated into NdeI/HindIII linearized 
pTAC:LS (Chapter 2). The resulting nucleotide sequence was identical to the cymAab 
sequence of P. putida F1 (GenBank ID: CP000712.1). 
For the construction of pTAC:POH:CymA, the monooxygenase subunit gene (cymAa) of the 
P. putida cymene monooxygenase was amplified from pTAC:CymA using the primers 
PCW089 and PCW090 (59.1°C annealing temperature, 40 s elongation time) and integrated 
into BstBI linearized pTAC:LS:AGPPS2 (Chapter 2). The resulting plasmid was then digested 
with EcoNI and recombined with the PCR product encoding the reductase subunit gene 
(cymAb) of the P. putida cymene monooxygenase. This PCR product was obtained from 
amplification with primers PCW091 and PCW092 using pTAC:CymA as a template (59.1°C 
annealing temperature, 40 s elongation time). A schematic drawing (not to scale) of all 
vectors that were used and constructed in in this study is shown in Figure 3.2. 
Analytical procedures. Cell growth was monitored by measuring the optical density at 
450 nm (Libra S11, Biochrom Ltd., Cambridge, UK, OD450 = 1 equals 0.166 gcdw L-1) (Blank 
et al., 2008). For two-liquid phase fermentations, cells were washed once with potassium 
phosphate buffer (KPi, 0.1 M, pH 7.4) prior to OD450 determination, because the presence of 
DINP increased the OD450 value. The concentrations of (S)-(-)-limonene, (S)-(-)-perillyl 
alcohol, (S)-(-)-perillyl aldehyde, and perillic acid were determined using a GC method 
described previously (Chapter 2). GC-based quantification of (S)-(-)-perillyl acetate was done 
as follows: splitless injection, 80°C (5 min), 80 - 160°C (7.5°C min-1), 160 - 300°C 
(40°C min-1), 300°C (5 min). 
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Fermentatively produced limonene and POHAc were identified by comparison with authentic 
standards and by GC-MS using a CP3800 GC coupled to a 1200 Quadrupole MS (Varian, Inc., 
Palo Alto, CA, USA) using the same GC settings as described above. 
Table 3.2: Nucleotide sequences of the oligonucleotides used in this study. The underlined 
nucleotides indicate the template specific regions. Color code: Gibson/SLIC overlap to vector, Start 
codon, Stopp codon, ribosomal binding site, fusion protein linker sequences. 
Primer Sequence 5’-3’ 
PCW070 TGCGTTTCTACAAACTCTTTCGGTCCACCTATCAAGGTGTACTG 
PCW071 GTATTTAGAAAAATAAACAACGGACCAGGCTGCATTATTGAAG 
PCW072 CAGCAGATGACCCGCACCCTGTTCGAACCATTCGCCTAAGGATCTAGGAGGAAATAACCATGACGGTAGCCGCCAG 
PCW073 CAGCAGATGACCCGCACCCTGTTCGAACCATTCGCCGGCGGCGGCGGCGGCGGCGCCACGGTAGCCGCCAGCGAC 
PCW074 CTTCAGCTTTTAGGCGAATGGTTCGTTAGGCGTTGATGCGCAC 
PCW075 TCGCTTTCCGCCAAAACTAAGAATTAGGAGGAAATAACCATGATCCACACCGGCGTG 
PCW076 TTATTTGAAGCTCGGAGCTCGAATTTTAATGTTGTGCAGCTGGTGTC 
PCW077 ATTGACCAACAGGAGGAATTACATATGTGGGAATACATCAAGTAC 
PCW078 AGCGTGGGACAACACTTAC 
PCW079 CATGGAGTAAGTGTTGTCCCACGCTAGGAGGTTTCAATGAGAAGTTTC 
PCW080 TGAGCCTTTCGTTTTATTTGAAGCTCAATTAGCCTTTAGGAGTTCC 
PCW089 CAGCAGATGACCCGCACCCTGTTCGAACCATTCGCCTAAGGATCTAGGAGGAAATAACCATGTGGGAATACATCAAGTAC 
PCW090 CTTCAGCTTTTAGGCGAATGGTTCGACACTTACTCCATGTGATCAG 
PCW091 TCGCTTTCCGCCAAAACTAAGAATTAGGAGGAAATAACCATGAGAAGTTTCTTTCAATCC 
PCW092 TTATTTGAAGCTCGGAGCTCGAATTGCTCAATTAGCCTTTAGGAG 
Resting cell assays (biotransformation). Cells were grown in M9* medium at 30°C as 
described above. At desired time points after induction, the cells were harvested by 
centrifugation (4°C, 4,618 g, 20 min) and resuspended to approximately 1 gcdw L-1 (OD450 = 1 
equals 0.166 gcdw L-1) in 0.1 M potassium phosphate buffer pH 7.4 with 1.5% (w/v) glucose. 
Absence of growth was deduced from OD450 measurements. Limonene biotransformation 
assays were performed as described before (Cornelissen et al., 2011). Due to evaporation, 
limonene could not be quantified in monophasic resting cell assays. For two-liquid phase 
biotransformation resting cell assays, the preceding culture was supplemented with 
0.5% (w/v) yeast extract to accelerate growth. Resting cell suspensions of 1 mL were 
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incubated for 5 min (300 rpm, 30°C, Aquatron, Infors, Bottmingen, Switzerland), before 
addition of limonene in 0.5 mL DINP (initial concentrations are specified in results section). 
The reaction was terminated after 2 h by centrifugation (4°C, 4,618 g, 10 min). One 
hundred µL of the organic phase were diluted in 900 µL Et2O (with 0.2 mM dodecane as 
internal standard), dried over anhydrous Na2SO4, and analyzed for product formation via GC.  
CO difference spectra. The specific CYP153A6 content was determined as described 
previously (Cornelissen et al., 2011). Here, 0.5 mL of the cell suspension (~3.3 gcdw L-1 in 
0.05 M KPi, pH 7.4) were mixed with 0.4 mL KPi (0.05 M, pH 7.4) and 0.1 mL Na2S2O4 
solution (200 mM). 
In vitro activity assays. In vitro activity assays were performed as described elsewhere 
(Chapter 2), with the following modifications: The cells were harvested 20 h after induction 
of recombinant gene expression and the total protein content was either set to 5 gprotein L-1 
(IPP/DMAPP as substrates) or to 0.5 gprotein L-1 (GPP as substrate). Fifty µL from respective 
substrate stocks (in methanol) were added to 0.5 mL of the protein solution, resulting in final 
concentrations of 250 µM IPP and DMAPP or 500 µM GPP.  
Fermentative perillyl acetate production with growing cells. Recombinant E. coli strains 
were cultivated in screw-capped baffled flasks. If desired, DINP was added upon induction at 
an aqueous:organic phase ratio of 4:1 to avoid limonene evaporation. The organic phase was 
analyzed as described. Aliquots of the aqueous phase were extracted by the addition of an 
equal volume ice-cold Et2O (with 0.2 mM dodecane as internal standard), dried over Na2SO4, 
and analyzed by GC.  
Fermentative limonene and perillyl acetate production in mixed-strain resting cell assays. 
E. coli BL21 (DE3) (pMVAidi, pTAC:LS:AGPPS2), E. coli MG1655 (pTAC:POH), and 
E. coli MG1655 (pTAC:CymA) were cultivated as described above. Gene expression was 
induced at an OD450 of 0.6 to 0.8 and cultivation was continued for 12 h after induction. 
Subsequently, the cells were harvested (4°C, 4,618 g, 20 min), washed with ice-cold 
potassium phosphate buffer (0.1 M, pH 7.4), resuspended in the same buffer and combined at 
different cell densities (specified in text). To assess limonene formation in resting cell 
fermentations, different strains of E. coli (pMVAidi, pTAC:LS:AGPPS2) were used as single 
strains and DINP was added to avoid limonene evaporation (aqueous:organic phase ratio 4:1). 
The cell suspensions (25 mL in 250 mL screw-capped baffled flasks) were adapted for 15 min 
in a rotary incubator (30°C, 200 rpm, 2.5 cm amplitude). Product formation was initiated by 
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adding 0.75 mL glucose (50% (w/v)) and analyzed after extraction of the aqueous phase with 
Et2O or after dilution of the organic phase with Et2O (see above). 
3.4 Results 
Efficient extraction of limonene limits perillyl alcohol formation. The de novo biosynthesis 
of POHAc (and POH) was shown to be limited by efficient extraction of limonene in a two-
liquid phase fermentation system, which could be relieved by omission of the organic carrier 
phase partially (Alonso-Gutierrez et al., 2013). However, here batch cultivation of different 
limonene producing E. coli strains (DH5α, BL21 (DE3), MG1655) (Chapter 2) that were co-
transformed with a third plasmid harboring CYP153A6 (pCom8:PFR1500) (van Beilen et al., 
2005) did not lead to detectable amounts of POHAc. POHAc was neither detected in a 
monophasic nor in a biphasic cultivation system applying DINP as organic carrier phase. 
Limonene, however, accumulated in the organic phase (data not shown). The maximum 
specific CYP153A6 concentration was 40 nmol gcdw-1. Thus, all genes involved were 
expressed functionally, but, as described before, limonene was efficiently extracted into the 
organic phase (Alonso-Gutierrez et al., 2013) which seemed to result in a mass transfer 
limitation for the oxygenation. The high partition coefficient of (24.0 ± 2.7) x 103 for 
limonene in DINP/water supports this hypothesis. To determine the concentration of limonene 
in the organic phase enabling limonene hydroxylation, biotransformations with fully induced 
non-growing E. coli W3110 (pCom8:PFR1500) were performed in a DINP/medium mixture 
(organic:aqueous phase ratio 1:2) with different limonene concentrations (0.5, 1, 2, 4, 8, 16, 
32, 64, 128, 256 mM). Limonene hydroxylation started at limonene concentrations between 
64 and 125 mmol Lorg-1 (Figure 3.3). Using E. coli W3110 (pCom8:PFR1500L) with an 
improved uptake of hydrophobic molecules into the cell due to the presence of AlkL 
(Cornelissen et al., 2013; Julsing et al., 2012b), at least 16 to 32 mmol Lorg-1 of limonene were 
required for hydroxylation (Figure 3.3). As those minimally required concentrations are well 
above the reported 0.74 mmol Lorg-1 limonene produced from 1% (w/v) glucose (Chapter 2), 
POH and consequentially also POHAc formation in the applied experimental two-liquid 
phase setup, is infeasible and might be hindered by the amount or kinetic properties of the 
monooxygenase.  
Therefore, we here focused on the influence of the monooxygenase as a complementary 
strategy to the approach described by Alonso-Gutierrez et al. who aimed at increasing the 
terpene precursor supply by genetic pathway engineering (Alonso-Gutierrez et al., 2013). 
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Figure 3.3: Two-liquid phase biotransformation of limonene into perillyl alcohol with resting E. coli 
W3110 (pCom8:PFR1500) (■) and E. coli W3110 (pCom8:PFR1500L) (●). The reactions were started 
by adding 0.5 mL DINP with varying limonene concentrations (0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256 
mM) to 1mL of cell suspensions (~1 gcdw L-1) in glucose containing potassium phosphate buffer. After 
2 h, the perillyl alcohol concentration was determined via GC (detection limit: ~5 µM). The error bars 
relate to results obtained from two independent cultures. 
Three potential strategies were defined to achieve POHAc formation from glucose in a two-
liquid phase setup: (i) combination of all downstream pathway genes (for LS, AGPPS2, 
CYP153A6 with redox partners) in one operon to temporally couple their expression and 
potentially optimize the intracellular CYP153A6 concentration, (ii) generation of a 
translational fusion of LS and CYP153A6 to establish spatial proximity of limonene 
formation and oxygenation, and (iii) application of cymA from P. putida as an alternative 
limonene hydroxylase.  
First, we assessed each strategy individually with respect to the functional expression of the 
downstream genes converting the terpene precursors IPP and DMAPP to limonene and POH. 
In order to investigate recombinant strains for limonene hydroxylation capability, the POH 
formation rate in resting cells by externally adding limonene served as an important measure. 
Together with the CO difference spectra, revealing the specific CYP153A6 content, these 
activities allowed for reliable selection of optimal expression conditions for CYP153A6 with 
respect to expression time and host. Furthermore, in vitro assays supplying IPP and DMAPP 
were applied as a measure to investigate the formation of limonene and oxygenated adducts in 
an extracellular environment and to verify the successful expression of all downstream genes. 
Subsequently, the strains harboring the entire POHAc formation pathway (MVA pathway, 
LS; AGPPS2, monooxygenase) were tested for de novo POHAc synthesis. 
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Simultaneous expression controlled by the Ptac promotor improves CYP153A6 availability. 
In order to tackle the low specific CYP153A6 content of the three-plasmid system 
(max 40 nmol gcdw-1) as compared to the single plasmid system (163 nmol gcdw-1 (Cornelissen 
et al., 2013)), the genes encoding the CYP153A6 system, LS, and AGPPS2 were assembled 
in one operon. This modification resulted in high specific limonene hydroxylation activities 
(up to 6.8 U gcdw-1) and improved specific CYP153A6 concentrations (up to 183 nmol gcdw-1) 
for both E. coli MG1655 (pTAC:POH) and E. coli MG1655 (pTAC:POH, pMVAidi) (Figure 
3.4A, B). E. coli MG1655 was chosen as the preferred host, as it showed, compared to other 
E. coli strains, the highest maximum specific CYP153A6 content (data not shown) and was 
shown to be suitable for fermentative limonene production (Chapter 2). The limonene 
hydroxylation activity was coupled to the growth stage of the culture and could be sustained 
for as long as 20 h after induction.  
The specific CYP153A6 concentration (Figure 3.4A) and limonene hydroxylation activity 
(Figure 3.5) decreased after glucose depletion. During short term resting cell assays (5-10 min) 
to assess the limonene oxygenation rate, POH (and minor amounts of perillyl aldehyde) were 
the only limonene oxidation products. Possibly, the activity of the chloramphenicol 
acetyltransferase (CAT), encoded on pMVAidi and hypothesized to be responsible for the 
acetylation of POH (Figure 3.7, (Alonso-Gutierrez et al., 2013)), was too low to generate 
detectable amounts of POHAc in this short time frame. To verify the functionality of all 
downstream enzymes in concert, extracts from induced E. coli MG1655 (pTAC:POH) and 
E. coli MG1655 (pTAC:POH, pMVAidi) were analyzed for terpene formation after addition 
of terpene precursors in an aqueous single phase system. For MG1655 (pTAC:POH, 
pMVAidi) extracts supplied with IPP/DMAPP, a limonene formation rate of 
2.4 ± 0.0 U gprotein-1 (Figure 3.4C) and an initial POH formation rate of 0.72 ± 0.02 U gprotein-1 
were found. The latter rate, however, might have been limited by the availability of NADH, 
which was not externally supplied to the assay. A significantly higher limonene formation rate 
of 33.2 ± 0.2 U gprotein-1 was found with GPP as substrate (Figure 3.4C). Formation of POH 
was not observed in this experiment, due to the lower protein concentration applied. However, 
all proteins responsible for the formation of POH from IPP and DMAPP were synthesized 
simultaneously and functionally from pTAC:POH. 
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Figure 3.4: CYP153A6 synthesis and activity using the Ptac controlled expression of the downstream 
pathway genes on pTAC:POH. Limonene hydroxylation rates (grey bars in panels A and B), biomass 
concentrations (●), and specific CYP153A6 contents (■) in dependency of the cultivation time of 
E. coli MG1655 (pTAC:POH) (A) or E. coli MG1655 (pMVAidi, pTAC:POH) (B). The cells were 
cultivated in M9* minimal medium with an initial glucose concentration of 1% (w/v). In 
biotransformations with resting cells containing the plasmid pMVAidi with the substrate limonene 
supplied in excess, POHAc accumulation was not observed. Panel C: Specific terpenoid formation 
rates of crude cell extracts generated 20 h after induction of gene expression in E. coli MG1655 
(pTAC:POH) (-MVA: without mevalonate pathway) or E. coli MG1655 (pMVAidi, pTAC:POH) (+ 
MVA: with mevalonate pathway) for the conversion of IPP/DMAPP or GPP to limonene. The error 
bars were calculated from results obtained with two independently grown cultures. One unit (U) is 
defined as one µmol of product formed per minute. The units are either normalized to the total 
biomass concentration (U gcdw-1) or the total protein concentration (U gprotein-1). Panel D: Schematic 
drawing of the biocatalytic reactions and CYP153A6. The CYP153A6 structure was obtained via a 
homology model on the basis of CYP153A7 from Sphingopyxis macrogoltabida, PDB ID 3RWL 
(Pham et al., 2012). 
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Figure 3.5: Limonene hydroxylation capability of E. coli MG1655 (pTAC:POH) during batch growth 
on different amounts of glucose. E. coli MG1655 (pTAC:POH) was grown in M9* medium (30°C, 
200 rpm, 2.5 cm amplitude) with initial glucose concentrations of either 0.5% (w/v) (panel A) or 
2.0% (w/v) (panel B). At the indicated time points after induction of gene expression, cells were 
harvested from the cultures to determine biomass concentrations (■) and, in separate resting cell 
assays, specific limonene hydroxylation rates (grey bars).The deviations result from assay duplicates. 
Upon depletion of the carbon source (no further increase in biomass, panel A), the specific limonene 
seemed to decrease. The figure is based on data reported in the Master Thesis of Anna Hoschek 
(Hoschek, 2014). 
Functional fusion of LS and CYP153A6. To minimize limonene extraction prior to its 
hydroxylation, we brought LS and CYP153A6 into spatial proximity by generating a 
translational fusion connecting the two enzymes via a flexible amino acid linker 
(GGGGGGA). E. coli MG1655 (pTAC:POHf) showed similar growth as compared to the 
strain harboring pTAC:POH. Approximately 3-fold lower maximum specific CYP153A6 
concentrations were found for strains containing the hybrid LS-CYP153A6 compared to the 
non-fused enzymes (Figure 3.4A, B and Figure 3.6A, B). The maximum specific limonene 
hydroxylation activities were 6 U gcdw-1 for both strains with the LS-CYP153A6 fusion (Figure 
3.6A, B). Extracts from E. coli MG1655 (pTAC:POHf, pMVAidi) showed similar reaction 
rates for the two-step bioconversion (IPP/DMAPP to limonene) as compared to extracts from 
E. coli MG1655 (pTAC:POH, pMVAidi). The specific reaction rate for the one step 
bioconversion (GPP to limonene) was impaired and found to be approximately 2.8-fold lower 
for the LS-CYP153A6 hybrid (Figure 3.6C). The specific POH formation activity with 
IPP/DMAPP as substrates was 0.36 U gprotein-1 using extracts of E. coli MG1655 (pTAC:POHf, 
pMVAidi). Although no improvement of product formation was observed with this specific 
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linker connecting LS and CYP153A6 in the in vitro assays, the functional coupling of these 
enzymes was successful and had to be evaluated in vivo.  
 
Figure 3.6: CYP153A6 synthesis and activity as part of the LS-CYP hybrid using the Ptac controlled 
expression of the downstream pathway genes on pTAC:POHf. Limonene hydroxylation rates (grey 
bars in panels A and B), biomass concentrations (●), and specific CYP53A6 contents (■) in 
dependency of the cultivation time of E. coli MG1655 (pTAC:POHf) (A) or E. coli MG1655 
(pMVAidi, pTAC:POHf) (B). The cells were cultivated in M9* minimal medium with an initial 
glucose concentration of 1% (w/v). In biotransformations with resting cells containing the plasmid 
pMVAidi with the substrate limonene supplied in excess, POHAc accumulation was not observed. 
Panel C: Specific terpenoid formation rates of crude cell extracts generated 20 h after induction of 
gene expression in E. coli MG1655 (pTAC:POHf) (-MVA: without mevalonate pathway) or E. coli 
MG1655 (pMVAidi, pTAC:POHf) (+MVA:with mevalonate pathway) for the conversion of 
IPP/DMAPP or GPP to limonene. All error bars were calculated from results obtained with two 
independently grown cultures. One unit (U) is defined as one µmol of product formed per minute. The 
units are either normalized to the total biomass concentration (U gcdw-1) or the total protein 
concentration (U gprotein-1). Panel D: Schematic drawing of the biocatalytic reactions and the functional 
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LS-CYP153A6 fusion. The CYP153A6 structure was obtained as described in the legend of Figure 3.4. 
The structure of limonene synthase (upper protein) was obtained from PDB ID 2ONG (Hyatt et al., 
2007). 
 
Figure 3.7: Acetylation of perillyl alcohol to perillyl acetate (●, ○) in membrane-free crude cell 
extracts (5 gtotal protein L-1) obtained from fully induced cells of E. coli MG1655 (pMVAidi, pTAC:POH) 
in the presence (open symbols) and absence (closed symbols) of 3 mM chloramphenicol. Cells were 
grown as described in the methods section (30°C, M9* minimal medium, 1% (w/v) initial glucose, 
200 rpm, 2.5 cm amplitude). The preparation of crude cell extracts was performed as described 
elsewhere (Chapter 2), but in this case dithiothreitol was omitted and sodium acetate was added to a 
final concentration of 10 mM. At specified time points, the assay mixture was extracted with Et2O and 
analyzed for the sum of terpenoids (perillyl alcohol, perillyl acetate) (■, □) content via GC. Without 
chloramphenicol, perillyl alcohol is converted to low amounts of perillyl acetate, but the acetylation 
can be entirely prevented by adding chloramphenicol (closed symbols). Error bars relate to averaged 
concentrations from two assays (derived from the same main culture). 
CymA is a specific and highly active limonene hydroxylase. To investigate an alternative 
limonene hydroxylase with putatively improved properties, the genes for the monooxygenase 
cymAa and the respective reductase cymAb (Eaton, 1997) were amplified from the genomic 
DNA of P. putida GS1 and cloned behind the Ptac promotor of pTAC giving pTAC:CymA. 
High and stable limonene hydroxylation activities of approximately 10 U gcdw-1 (for ≥ 1 h) 
were observed with resting E. coli MG1655 (pTAC:CymA) cells harvested 4 h after induction 
(data not shown). 
After verification of the cymA activity in this bicistronic expression system, cymAa and 
cymAb were sub-cloned into pTAC:LS:AGPPS2 yielding pTAC:POH:CymA. To ensure 
comparability with the CYP153A6 containing strains, pTAC:POH:CymA was assembled with 
the similar gene order as pTAC:POH (LS, monooxygenase, AGPPS2, redox partner; see 
Supplemental Information for details). Resting E. coli MG1655 (pTAC:POH:CymA, 
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pMVAidi) showed very high limonene hydroxylation rates of 17.9 ± 0.9 U gcdw-1, 
demonstrating the functional expression of the cymA gene from pTAC:POH:CymA. A 
product mixture of POH and perillyl aldehyde (roughly 50:50) was obtained. 
 
Figure 3.8: Monoterpenoid production from glucose with different recombinant E. coli MG1655 
strains in monophasic (M9* medium) and biphasic (2LP: M9*, DINP, phase ratio 4:1) shake flask 
cultivations. Final limonene (Lim), perillyl acetate (POHAc), and total monoterpenoid (sum) 
concentrations are shown. Lim: E. coli MG1655 (pMVAidi, pTAC:LS:AGPPS2), CYP: E. coli 
MG1655 (pMVAidi, pTAC:POH), LS-CYP: E. coli MG1655 (pMVAidi, pTAC:POHf), CymA: 
E. coli MG1655 (pMVAidi, pTAC:POH:CymA). For comparability, all concentrations given are 
translated to the aqueous phase volume and were measured after glucose depletion (approximately 
after 48 h). Mean values and error bars given refer to three independent cultures. 
Perillyl acetate is synthesized from glucose. E. coli MG1655 harboring pMVAidi in 
combination with either pTAC:POH, pTAC:POHf, or pTAC:POH:CymA were tested for in 
vivo POHAc formation from glucose. Indeed, the accumulation of POHAc was observed as a 
result of POH acetylation catalyzed by the chloramphenicol acetyl transferase encoded on 
pMVAidi (Figure 3.7). Low amounts of POHAc (maximally ~37 µmol Laq-1 or ~6.6 mg Laq-1) 
were found for E. coli MG1655 (pTAC:POH, pMVAidi) 48 h after induction (Figure 3.8). 
Notably, a similar POHAc formation also was observed in the two-liquid phase setup, 
demonstrating that the intracellular CYP153A6 amount, in contrast to the 3 plasmid system, 
was sufficient to allow limonene hydroxylation prior to extraction into the organic carrier 
phase. The coexpression of the cymA genes led to significantly less formation of POHAc. 
This is caused by the significantly reduced limonene synthesis (Figure 3.8), possibly the result 
of impaired AGPPS2 synthesis (SDS-PAGE analysis, Figure 3.9). Further POH oxidation 
products (perillyl aldehyde and perillic acid) were also not observed. The highest specific 
POHAc yields were found for E. coli MG1655 (pMVAidi, pTAC:POH) in a two-liquid phase 
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system with 6.20 ± 0.06 mg gcdw-1 and 0.68 ± 0.03 mg gglucose-1. Despite successful 
hydroxylation of produced limonene, the titers obtained were low and make a detailed 
assessment of the product formation kinetics difficult. Furthermore, the majority of produced 
limonene accumulated in the organic phase or evaporated, pointing to intrinsic physical 
properties of limonene still limiting the hydroxylation in the experimental setup applied. As 
the extrusion of limonene could not be prevented, we sought to develop a fermentation setup 
that takes advantage of this obviously inevitable phenomenon.  
 
Figure 3.9: Downstream pathway enzyme synthesis in growing E. coli MG1655 harboring different 
expression plasmids (as indicated above the respective lanes) in combination with the plasmid 
pMVAidi analyzed by SDS PAGE. The lanes show protein patterns of whole cells at the time point of 
the induction of the gene expression with 1 mM IPTG (I) and after 24 h of induction (o: cultivation in 
an open flask with metal lid, c: cultivation in a screw-capped flask). MP: monophasic cultivation, 2LP: 
aqueous:organic cultivation. The approximated theoretical sizes of the visible heterologous proteins 
are: LS: 64 kDa, LS-CYP: 112 kDa, AGPPS2: 32 kDa, CymAa: 43 kDa, CymAb: 38 kDa. The cells 
were obtained from the same experiment as shown in Figure 3.8. 
Defined multi-strain mixed cultures of non-growing cells produce POHAc at high rates. In 
general, growing cells are applied for terpene production from glucose (Ajikumar et al., 2010; 
Martin et al., 2003). Resting (non-growing, but metabolically active) cells are frequently 
applied for biotransformations and often show higher product formation rates as their growing 
counterparts (Julsing et al., 2012a). Here, the potential of resting cells for the fermentative 
production of terpenes was investigated. In a preliminary experiment aiming at establishing 
the preconditions we observed that resting cells of different E. coli strains harboring 
pTAC:LS:AGPPS2 and pMVAidi showed higher limonene formation rates (~0.3 U gcdw-1, 
Figure 3.10A) as compared to growing cells (~0.1 U gcdw-1, Chapter 2). This preliminary 
experiment also identified E. coli BL21 (DE3) (pTAC:LS:AGPPS) as the most suitable host 
for resting cell limonene fermentation. E. coli BL21 (DE3), however, showed the lowest 
expression of functional CYP153A6 (data not shown). Therefore, we decided to directly 
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examine the best host for functional CYP153A6 synthesis E. coli MG1655 transformed with 
pTAC:POH and pMVAidi for fermentative POHAc formation with resting cells. Indeed, 
POHAc was observed, however, at very low final concentrations and specific formation rates 
(initially ~10 mU gcdw-1) (Table 3.3, Figure 3.10B).  
Surprisingly, limonene accumulation was not detected during this experiment, which raised 
question whether it would be possible to selectively increase limonene biosynthesis by 
increasing the amount of limonene producing biomass. For this, we developed a mixed-strain 
resting cell approach for the fermentative synthesis of limonene oxidation products by 
combining a strain producing limonene with a separate strain for limonene oxygenation. To 
this end, E. coli BL21 (DE3) (pTAC:LS:AGPPS2, pMVAidi) and E. coli MG1655 
(pTAC:POH), respectively, were cultivated in separate shaking flasks from which mixed-
strain cell suspensions with a ratio 10 gcdw L-1 (limonene producer) and 1 gcdw L-1 (limonene 
hydroxylation) were composed.  
 
Figure 3.10: Resting cell fermentations for limonene and perillyl acetate production. (A) Average 
specific limonene formation rates with resting cells of different E. coli strains harboring the limonene 
biosynthesis pathway (pTAC:LS:AGPPS, pMVAidi). Cells were incubated in a biphasic 
aqueous:organic (buffer/DINP, 4:1) system with 1.5% (w/v) glucose as sole carbon and energy source. 
The average rates relate to the increase of limonene during the first 4 h of the resting cell fermentation. 
(B) Time course of POHAc concentration in single strain resting cell fermentations using E. coli 
MG1655 (pTAC:POH, pMVAidi). The cells were grown in M9* medium and gene expression was 
induced for 12 h. Subsequently, the cells were harvested and resuspended to 8 gcdw L-1 in potassium 
phosphate buffer. 1.5% (w/v) glucose was added to initiate monoterpenoid formation. Mean values 
and error bars given refer to resting cells retrieved from two independent cultures. One unit (U) is 
defined as one µmol of product formed per minute. Panel A of the figure is based on data reported in 
the Master Thesis of Anna Hoschek (Hoschek, 2014). 
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POHAc accumulated as the sole limonene oxidation product. The specific product formation 
rate (Figure 3.12A) remained constant for ~3 h and decreased afterwards due to glucose 
depletion. The overall specific production rates were slightly higher when cell mixtures of 5, 
2.5, or 1 gcdw L-1 limonene producing and 1 gcdw L-1 limonene hydroxylating cells were 
applied, which is in contrast to the reduced volumetric activity for limonene formation (Figure 
3.12:A). Normalizing the POHAc formation rate to the applied biomass harboring the 
CYP153A6 enzyme (1 gcdw L-1) resulted in the highest specific limonene hydroxylation 
(which in this case is equal to the volumetric productivity) rate of 0.60U gcdw-1 in the 10:1 
system (Figure 3.12B). POHAc formation in the fermentations applying the 2.5:1 and the 1:1 
ratio ceased 120 minutes after beginning of the fermentation (data not shown) and therefore 
these low cell densities were rendered inappropriate for efficient POHAc synthesis due to 
limiting limonene availability. In all assay setups, limonene accumulated in the aqueous phase 
(and the headspace), though only trace amounts for the 2.5:1 and the 1:1 experiment.  
Table 3.3: POHAc production performance of E. coli MG1655 (pTAC:POH, pMVAidi) in different 
reaction setups: the two-liquid phase fermentation with growing cells (2-LP), the single-strain (RCA 
single) and the mixed-strain resting cell approach (RCA mixed). Means and standard deviations were 
retrieved from 2 (for 2-LP and RCA single) or 4 (for RCA mixed) independent experiments. 
Parameter 2-LPa RCA 
single 
RCA 
mixedb 
volume/ mLaq 80 25 25 
concentration/ mgPOHAc Laq-1  6.8 ± 0.3  1.8 ± 0.3 21.7 ± 5.0 
biomass concentration/ gcdw Laq-1 1.1 ± 0.1 8.0 ± 0.0 11.0 ± 0.0 
Yp/x/ mgPOHAc gcdw-1 6.2 ± 0.4 0.22 ± 0.03 2.0 ± 0.4 
Yp/s/ mgPOHAc gglucose-1 0.68 ± 0.03  0.02 ± 0.0c 0.26 ± 0.06c 
duration/ h 48 3 3 
averaged productivity/ mg L-1 h-1  ≥0.21d  0.60 ± 0.09 7.34 ± 1.68 
aFor comparability reasons, the POHAc concentrations for the 2-LP cultivation of E. coli MG1655 
(pMVAidi, pTAC:POH) are given as total product amount per aqueous phase volume (although 
the product resided in the organic phase).  
bMixed-strain data were taken from the 10:1 biomass ratio set-up (see text and Figure 3.12A, B). 
cFor the comparison of the POHAc yields on glucose, the amount of glucose which was consumed 
during the preceding biomass formation was added to the amount of glucose that was consumed 
during the resting cell fermentation. 
dThe productivity for the batch culture was approximated by assuming ~32 h POHAc production 
(4 h of pre-induction phase and ~12 h of late stationary phase were substracted as being non-
productive). 
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The observed limonene concentrations (altering over time, maximum 46 µM after 2 h, 
10 gcdw L-1 limonene producing cells) were well below the uptake constant KS (defined as the 
substrate concentration that results in the half-maximum product formation rate) of 
109 ± 3 µM (determined for E. coli MG1655 harboring pTAlk:POH, Figure 3.11). Thus, for 
the higher cell densities applied (10 or 5gcdw L-1 of limonene producing cells) POHAc 
formation might be limited by limonene uptake by the cells containing CYP153A6. 
Compared to the approach using growing cells, the mixed-strain fermentations achieved a 3.3-
fold higher final POHAc concentrations (~125 µmol Laq-1 or ~22 mg Laq-1) in a shorter time 
period of less than 3 h, but with significantly higher biomass concentrations (Table 3.3). The 
high biomass concentration and the excess of limonene producing cells were crucial to ensure 
sufficiently high limonene concentrations for the subsequent oxyfunctionalization over the 
entire fermentation time frame.  
In order to evaluate cymA in the mixed-strain resting cell setup, the combination of limonene 
producing cells and E. coli MG1655 (pTAC:CymA) (1 gcdw L-1) resting cells was investigated. 
The overall specific perillyl acetate formation rate and volumetric activity were increased 
when 10 instead of 5 gcdw L-1 limonene producing cells were applied (Figure 3.12C, D). 
Furthermore, limonene only accumulated when a cell concentration of 10 gcdw L-1 of the 
limonene producer was used. Obviously, cymA performed better in the mixed-strain approach 
as compared to CYP153A6. 
 
Figure 3.11: Resting cell activities of E. coli MG1655 harboring either pTAlk:POH (A) or 
pTAC:CymA (B) in dependency of different limonene concentrations. Cultures were grown in M9* 
minimal medium as described in the methods section and gene expression was induced for 4 h with 
either 0.025% (v/v) DCPK (A) or 1 mM IPTG (B). The apparent whole-cell kinetic constants were 
determined as Vmax, CYP = 5.7 ± 0.1 U gcdw-1, KS, CYP = 109 ± 3 µM, Vmax, cymA = 14.7 ± 1.0 U gcdw-1 and 
KS, cymA = 130 ± 30 µM. The results were obtained from resting cell assays (initial rates) and error bars 
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relate to results obtained from two independent cultures. The dotted line connecting the data points is 
derived from a Michaelis-Menten type fitting function. 
 
Figure 3.12: De novo perillyl acetate formation in the mixed-strain resting cell setup. Specific rates 
for the formation of perillyl acetate from glucose (light grey bars) by mixed-strain resting-cell 
suspensions composed of E. coli BL21 DE3 (pMVAidi, pTAC:AGPSS2:LS) and either E. coli 
MG1655 (pTAC:POH) (A, B) or E. coli MG1655 (pTAC:CymA) (C, D). The numbers on the x-axes 
refer to the applied cell dry weight (cdw) concentrations of E. coli BL21 (pMVAidi, 
pTAC:AGPSS2:LS), whereas the concentration of the MG1655 strains was 1 gcdw L-1 in all cases. 
Specific rates refer to the total CDW concentration (sum of both strains). Panels B and D represent the 
volumetric perillyl acetate formation rates for mixtures with CYP153A6 (B) or cymA (D). Means and 
error bars refer to two independent resting cell assays. One unit (U) is defined as one µmol of product 
formed per minute. The units are either normalized to the total biomass concentration (U gcdw-1) or to 
the reaction volume (U L-1). 
Chapter 3: Production of oxygenated monoterpenoids by mixed-culture resting cell fermentation 
   
72 
3.5 Discussion 
Production of oxygenated limonene derivatives in a two-liquid phase system. The 
fermentative production of monoterpenes has multiple challenges determined by their 
physico-chemical properties such as volatility (van der Werf et al., 1997), relatively low water 
solubility (11 - 53 µmol L-1 (Schmid et al., 1992)) and high toxicity towards typical microbial 
production hosts (logP values of around 4.5). Limonene concentrations exceeding 0.025% 
(v/v) were shown to completely inhibit the growth of E. coli (Dunlop et al., 2011). These 
drawbacks can be relieved by the use of a two-liquid phase fermentation setup. However, for 
the production of oxygenated derivatives the extraction of limonene into an organic carrier 
phase is kinetically favored over its oxygenation. Thus, the intracellular coupling of an 
oxygenation reaction to the synthesis of monoterpenes requires a tradeoff between 
monoterpene toxicity and sufficiently high intracellular monoterpene concentrations. At this 
point, metabolic engineering strategies aiming at the optimization of intracellular protein 
levels is a possible, but very challenging approach. Other potential approaches are channeling 
of intermediates or improvement of enzyme properties. 
CYP153A6 already shows a roughly 20-fold higher catalytic efficiency  
(kcat/KM = 0.111 µM-1 s-1 (Funhoff et al., 2006)), than LS (Williams et al., 1998). Thus, a 
strategy aiming at the optimization of kinetic parameters seems to be inappropriate and the 
focus should be on increasing the intracellular CYP153A6 concentrations. Indeed, increasing 
the intracellular CYP153A6 concentration (with pTAC:POH) did allow for the direct 
oxygenation of fermentatively synthesized limonene during batch fermentation of E. coli 
MG1655 (pTAC:POH, pMVAidi) in a two-liquid phase system, albeit at rather low titers. In 
this context, a further increase in specific CYP153A6 content in recombinant E. coli might be 
difficult as the obtained CYP153A6 concentration (187 nmol gcdw-1 for E. coli MG1655 
harboring pTAC:POH) is close to the highest values reported 200 nmol gcdw-1 (Olaofe et al., 
2013) and 249 nmol gcdw-1 (Cornelissen et al., 2013).  
Substantial amounts of limonene accumulated in the organic phase, showing that limonene 
extraction remained the most critical issue. Interestingly, the same POHAc levels (calculated 
per aqueous phase volume) were obtained for both mono- and biphasic batch cultivations of 
E. coli MG1655 (pTAC:POH, pMVAidi) suggesting that the extrusion of limonene into the 
extracellular environment prior to oxygenation is not facilitated by the addition of an organic 
phase. The extraction of limonene into the organic phase has been reported as the main 
obstacle for POH production (Alonso-Gutierrez et al., 2013). Here, we identified the 
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extraction of limonene into the organic and/or evaporation into the gaseous phase, and thus 
intracellular limonene availability, as the key issue for effective oxygenation. 
Although we intended to increase production of POHAc by the generation of a functional LS-
CYP hybrid protein, the total POHAc production was much lower in the final recombinant 
strain (pTAC:POHf, pMVAidi) as compared to the non-fusion control strain (pTAC:POH, 
pMVAidi) (Figure 3.8). A reduced synthesis of the fusion protein led to a reduced limonene 
synthesis rate and consequentially to a lower final POHAc concentration. Nonetheless, the 
molar limonene/POHAc ratio decreased from 3.2 for E. coli MG1655 (pTAC:POH, 
pMVAidi) to 1.6 for E. coli MG1655 (pTAC:POHf, pMVAidi), both in a two-liquid phase 
system, pointing at an improved coupling of limonene synthesis and its oxyfunctionalization. 
The applied oligo-Gly (GGGGGGA) linker was chosen based on its flexibility (Argos, 1990) 
and the length was kept short to minimize diffusion distance. In this context, a (rational) 
optimization of the linker sequence and length has potential as an approach to increase 
expression/activity of both fusion partners (Chen et al., 2013).  
Although considerable progress regarding the formation of oxygenated limonene derivatives 
in a two-liquid phase setup was achieved, the POHAc titers were rather low and a systematic 
quantitation of the production capacity and rates of the system was difficult. 
The construction of orthologous recombinant pathways is often performed in a 
straightforward manner using the advantage that the pathway typically is not influenced by 
the endogenous regulatory network. However, this and other studies (e.g., (Dahl et al., 2013; 
Nowroozi et al., 2014)) showed that orthologous pathway development requires more than the 
assembly of the necessary genes and functional modules. Fine-tuned enzyme synthesis, 
enzymatic properties, physical phenomena, such as mass transfer, and most importantly, the 
intrinsic properties of reaction intermediates and products have to be considered. 
Mixed-strain resting cells: A promising approach for difficult fermentations For redox 
biotransformations, the application of whole cells is beneficial in terms of enzyme 
stabilization in the cellular environment, redox-equivalent supply, and self-regeneration 
(Schrewe et al., 2013). Resting cells, however, typically show limited stability and self-
regeneration, but do not produce biomass as by-product that competes with the biocatalytic 
pathway for carbon and energy. Indeed, increased redox-cofactor regeneration and product 
formation rates have been observed in non-growing cells (Blank et al., 2008; Julsing et al., 
2012a). Approaches that use metabolically active non-growing cells harboring a heterologous 
pathway for the production of value-added compounds from cheap carbon sources 
(fermentation), however, are rare (Wittgens et al., 2011). We showed that the formation of 
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limonene, via the heterologous MVA pathway can be decoupled from biomass formation, and 
developed a novel fermentation concept using mixed strains for the coupling of an 
oxygenation reaction to fermentatively produce the limonene derivative POHAc.  
With the mixed-culture resting cell concept, a 3.3-fold higher POHAc concentration was 
achieved as compared to the single strain two-liquid phase fermentation (Table 3.3). The 
comparison of the productivity, however, is more difficult and suffers from the unknown 
POHAc formation kinetics during the batch cultivation, which could not be assessed 
quantitatively due to the low POHAc concentrations obtained. The calculated productivity 
should therefore be interpreted with care. If 4 h of pre-induction phase and 12 h of late 
stationary phase were subtracted as being non-productive for the batch fermentation an up to 
~34-fold (to ~7.3 mg L-1 h-1) improved productivity was observed for the mixed-culture 
resting cell setup. This seemed to be a consequence of the higher cell density applied and the 
relieved limonene availability limitation. Upscaling the batch fermentation from shake flasks 
to a bioreactor setup allows significantly increased biomass concentrations, which might 
enable a systematic analysis of POAHc formation with growing cells and thus an accurate 
determination of the productivity. This, however, was beyond the scope of the present study. 
The lower specific POHAc yield in the mixed-strain setup might be improved by additional 
glucose supplementation and continued production. For this, the stability of the resting cell 
activity has to be determined and possibly improved by the optimization of for example 
medium composition or temperature. Additionally, an oxygen limitation for both cellular 
maintenance (energy supply via respiration) and the oxygenation reaction cannot be excluded, 
especially when high cell concentrations are applied. Thus, it should be noted that the 
presented system is running at sub-optimal conditions offering multiple opportunities for 
optimization. 
The main advantages of the mixed-culture concept are the possibility to titrate production 
rates of different steps by adjusting the ratio of the respective cell numbers of each strain and 
selecting optimum expression conditions (host, expression time etc.) for the enzymes 
involved. This especially becomes evident when comparing to the single-strain resting cell 
performances. Taking advantage of the excess of limonene producing cells and the higher 
limonene biosynthesis rate of E. coli BL21 (DE3) as compared to MG1655 (Figure 3.10A), the 
final POHAc concentration and the specific POHAc yield could be improved 12 and 9-fold, 
respectively as compared to the single-strain resting cell fermentation (Table 3.3). By 
artificially increasing the volumetric limonene synthesis rate (increasing the amount of 
limonene producing cells) we could show that limonene availability is a limiting factor for 
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hydroxylation. In this experimental setup the limonene availability is influenced by (i) the rate 
of limonene biosynthesis, (ii) the rate of limonene evaporation into the headspace, and (iii) the 
rate of limonene hydroxylation, which in turn are determined by mass transfer rates and 
enzyme kinetics. By having the opportunity to manually control the biocatalyst stoichiometry 
and biomass concentrations one might be able to identify improved production conditions, 
which is part of ongoing research. Analogous advantages have been described for complex in 
vitro enzyme cascades (Bujara et al., 2011; Myung et al., 2014; Zhang et al., 2010), but not 
yet for fermentative whole-cell biocatalysis. The versatility of this approach was proven by 
the use of two different enzyme systems (CYP153A6 and cymA) catalyzing the regioselective 
limonene oxyfunctionalization. CymA performed significantly better than CYP153A6 in 
terms of the total POHAc formation. CymA is hypothesized to be located in the cytoplasmic 
membrane (Eaton, 1997). Increased local limonene concentrations in the cytoplasmic 
membrane may contribute to a better performance with cymA, which is also reflected by the 
whole-cell biotransformation kinetics. For both biocatalysts (harboring either CYP153A6 or 
cymA) similar substrate uptake constants (KS of approximately 100 µmol L-1) were observed, 
but a significantly higher Vmax was obtained with cymA (Figure 3.11). However, also the KS 
(and KM) value of the catalysts for oxygen must not be disregarded. 
Based on these findings, it is likely that the limonene mass transfer rate over the outer 
membrane limits the hydroxylation, as the outer membrane is believed to be an efficient 
barrier for hydrophobic molecules (Chen, 2007). This mass transfer issue could be 
counteracted by the introduction of alkL, featuring a hydrophobic pore, into the cell 
performing the oxygenation. AlkL was shown to increase the uptake of limonene, alkanes, 
and fatty acid methyl esters in whole cell biotransformations (Cornelissen et al., 2013; Julsing 
et al., 2012b). Finally, the electron transfer in the three component CYP153A6 system might 
be less efficient in terms of coupling as compared to the two component cymA enzyme 
system.  
Another optimization strategy aiming at the exchange of the chloramphenicol 
acetyltransferase gene for another selection marker might be considered, since omission of 
this gene would lead to the formation of POH as the sole oxygenation product. However, 
overexpression of CAT might generate a metabolic pull for more efficient POHAc synthesis. 
The spatial dissection of the fermentative formation of a terpene from its hydroxylation 
constitutes a modular approach which allows the assembly of different synthetic reaction 
cascades, e.g., using different hydroxylases, without the need for elaborate genetic pathway 
engineering and balancing. The presented approach has multiple benefits, but also downsides 
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and limitations. The long term stability (>3 h) and the artificial introduction of mass transfer 
barriers for the limonene intermediate (by separating limonene production and hydroxylation 
in different cells) are considered most critical. 
3.6 Conclusion 
The availability of highly volatile limonene for the monooxygenase was found to limit 
fermentative POH/POHAc production. Three strategies were evaluated for POHAc synthesis 
in a two-liquid phase system. Increasing the specific CYP153A6 concentration was found 
suitable to lower limonene extraction prior to its oxygenation. Furthermore, a novel mixed-
strain resting cell fermentation concept was developed with the cell number/strain ratio as a 
powerful and tunable parameter. This concept enabled effective POHAc production with two 
different limonene hydroxylase systems (CYP153A6 and cymA). The approach is 
complementary to and can be combined with metabolic engineering. Mixed-culture resting 
cell fermentations may serve as general tools to perform cascade reactions involving 
intermediates and products in multistep reactions with challenging properties like high 
volatility and toxicity or low solubility.  
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4.1 Abstract 
The microbial production of isoprenoids has recently developed into a prime example for 
successful bottom-up synthetic biology or top-down systems biology strategies. Respective 
fermentation processes typically rely on growing recombinant microorganisms. However, the 
fermentative production of isoprenoids has to compete with cellular maintenance and growth 
for carbon and energy. Non-growing but metabolically active E. coli cells were evaluated in 
this study as alternative biocatalyst configurations to reduce energy and carbon loss towards 
biomass formation. The use of non-growing cells resulted in more than fivefold increased 
specific limonene yields on cell dry weight and glucose as compared to the traditional 
growing-cell-approach. However, the stability of resting cells was limited. This instability 
was overcome via the optimization of the minimal fermentation medium enabling high and 
stable limonene production rates for up to 8 h and a high specific yield of ≥ 50 mg limonene 
per g cell dry weight. Omitting MgSO4 from the fermentation medium was very promising to 
reduce growth and allow high productivities. MgSO4-limitation also optimized limonene 
formation rates by growing cells during non-exponential growth, a reduced biomass yield on 
glucose, a fourfold increase in specific limonene formation rates and yields on biomass, as 
compared to non-limited cultures. The control of microbial growth was identified as a key but 
yet underrated strategy for efficient isoprenoid production.  
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4.2 Introduction 
The fermentative production of valuable compounds from renewable resources with 
genetically engineered or synthetic pathways in microorganisms relies on microbial 
metabolism and therefore on the integrity of intracellular anabolic and catabolic reactions 
(Lee et al., 2012; Paddon and Keasling, 2014; Zhang et al., 2011). Operational regeneration of 
redox and energy equivalents is often mandatory. Most current in silico optimization 
strategies for microbial cell factories producing such compounds aim at maximizing coupling 
of compound production to microbial growth using biomass objective functions 
(Campodonico et al., 2014). The use of growing cells can be advantageous with respect to the 
regeneration of cells as well as the efficient synthesis of energy carriers (Orth et al., 2011; 
Schrewe et al., 2013). This is especially true, when the involved products or intermediates 
feature physicochemical properties (volatility, hydrophobicity, toxicity) that do not directly 
match with the optimal microbial production environment (Chapter 6). 
However, non-growing, also called resting, cells decouple growth and biocatalyst synthesis 
from the production phase. They have been applied for a variety of redox biotransformations 
(Barghini et al., 2007; Bordeaux et al., 2011; Julsing et al., 2012a). The resting state of 
microorganisms is a natural phenomenon arising under conditions of nutrient limitation 
(Harder and Dijkhuizen, 1983). In a laboratory setting, the resting state can be induced by the 
depletion of an element compulsory for growth, e.g., nitrogen. Resting but metabolically 
active cells were shown to be beneficial in terms of both specific reaction rates (Bühler et al., 
2008; McIver et al., 2008; Panke et al., 2002) and practical concerns such as reusability 
(Barghini et al., 2007). However, biocatalytic activities of non-growing recombinant cells 
were found to decrease steadily for example due to limited protein stability (Gottesman, 2003) 
or altered product inhibition profiles (Julsing et al., 2012a), reflected by altered gene 
expression profiles (Ishihama, 1997). Decoupling of growth and product formation is 
beneficial for fermentative de novo syntheses of valuable compounds as it reduces the use of 
resources and energy for by-product formation (biomass, fermentation products) (Chubukov 
and Sauer, 2014; Julsing et al., 2012a). The physiological and practical advantages of resting 
cells were, for instance, harnessed for the efficient homologous production of volatile 
metabolites with Lactococcus lactis (van de Bunt et al., 2014) or ethanol, acetate (Cotter et al., 
2009), and butanol (Förberg et al., 1983; Loyarkat et al., 2013) with different Clostridium 
species.  
The potential of physiological advantages has not been explored systematically for de novo 
formation of natural products, such as isoprenoids. The efficient fermentative production of 
Chapter 4: Decoupling production from growth boosts limonene fermentation 
   
80 
isoprenoids requires the engineering of complex, partly heterologous biosynthesis pathways 
involving e.g., the yeast mevalonate pathway and terpene cyclases (Martin et al., 2003). 
Research on heterologous terpene production in E. coli has mainly focused on improving the 
supply of terpene precursors via optimization of promotor strength (Anthony et al., 2009), 
codon usage (Redding-Johanson et al., 2011), translation (Nowroozi et al., 2014), and gene 
selection (Ma et al., 2011; Yang et al., 2012a). This resulted in high titers for various terpenes. 
Typically, the production of terpenes, such as limonene (Chapter 2, (Alonso-Gutierrez et al., 
2013)), pinene (Sarria et al., 2014), or sclareol (Schalk et al., 2012), was based on growing 
E. coli cells, co-producing the terpene alongside major quantities of by-products (e.g., 
biomass). Resting cells only have been applied for a mixed-strain approach to produce perillyl 
acetate (Chapter 3).  
We exploit the microbial biosynthesis of the monoterpene limonene with recombinant E. coli 
under growth-prohibiting and growth-limiting conditions. Limonene has received much 
attention as scent or flavor component for perfume and food industries (Thomas and Bessiere, 
1989) and as precursor for a variety of fine chemicals such as perillyl alcohol or carvone 
(Marmulla and Harder, 2014). More recently limonene also gained attention as jet fuel 
additive (Ryder, 2009; Tracy et al., 2009). We demonstrate that limonene formation profits 
from both a resting-cell biocatalyst configuration and a reduction of microbial growth by 
omitting or restricting essential nutrients. Insight into the microbial physiology of the 
limonene producer by growth-prohibition guided the successful optimization of limonene 
production and resulted in significantly increased limonene yields. 
4.3 Materials & Methods 
Chemicals, oligonucleotides, and bacterial strains. Anhydrous D-glucose was obtained from 
Alfa Aesar (Karlsruhe, Germany). Custom synthesized oligonucleotides were purchased from 
Sigma Aldrich (Steinheim, Germany). All other chemicals were obtained from AppliChem 
(Darmstadt, Germany), Sigma Aldrich (Steinheim, Germany), or Carl Roth (Karlsruhe, 
Germany) at the highest purity available. For all experiments, E. coli BL21 (DE3) (Studier 
and Moffatt, 1986) harboring the plasmids pTAC:LS:AGPPS2 (limonene synthase (LS) and 
geranyl diphosphate synthase (GPPS)) and pMVAidi (mevalonate pathway genes) was 
applied (Chapter 2). 
Cultivation of E. coli. E. coli BL21 (DE3) (pMVAidi; pTAC:LS:AGPPS2) was cultivated as 
described before (M9* medium, baffled Erlenmeyer flasks with metal caps, liquid:gas phase 
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ratio of 1:4) (Chapter 2). If not stated otherwise, cultures were incubated at 30°C (200 rpm, 
2.5 cm amplitude, Multitron, Infors, Bottmingen, Switzerland). Recombinant gene expression 
was induced by adding 1.0 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Ampicillin 
and chloramphenicol were added at concentrations of 100 and 34 mg L-1, respectively. Cell 
growth was monitored by measuring the optical density of the aqueous phase at 450 nm 
(Libra S11, Biochrom Ltd., Cambridge, UK, OD450 = 1 equals 0.166 gcdw L-1) (Blank et al., 
2008). For two-liquid phase fermentations with diisononyl phthalate (DINP, organic:aqueous 
phase ratio 1:4) as organic carrier phase, cells were washed once with potassium phosphate 
buffer (KPi, 0.1 M, pH 7.4) prior to OD450 determination, in order to circumvent an OD450 
increase due to remaining DINP. 
Growing-cell fermentation. Eighty mL of M9* medium (0.5% (w/v) glucose) were 
inoculated at an optical density (OD450) of 0.2 using an appropriate volume of a M9* pre-
culture. Upon induction of gene expression in the early exponential growth phase (OD450 0.6-
0.8), the culture was overlaid with 20 mL DINP giving an aqueous:organic phase ratio of 4:1 
and incubation was continued. Aliquots of the two-liquid phase fermentation were retrieved 
from the culture at regular intervals and subjected to centrifugation (4°C, 4618 g, 10 min) for 
phase separation. One hundred µL of the organic phase were diluted in 900 µL Et2O (with 
0.2 mM dodecane as internal standard) and dried over anhydrous Na2SO4. The aqueous phase 
was analyzed by HPLC for the determination of glucose, acetate, and pyruvate concentrations 
and the cell density was assessed by measuring the OD450. Concentrations of glucose, acetate, 
and pyruvate or (S)-(-)-limonene (LIM) were determined via HPLC or GC, respectively, as 
described previously (Chapter 2). An exponential function was iterated to the limonene data 
points in the exponential production range (4-14 h) by the least squares method (coefficient of 
determination 0.98). 
Resting-cell fermentation. Cells were grown as described above, without the addition of 
DINP upon induction of gene expression. Cells were harvested by centrifugation (4°C, 4618 g, 
20 min) and resuspended to approximately 1 gcdw L-1 in desired media, i.e., 0.1 mM potassium 
phosphate buffer pH 7.4, nitrogen-free M9* (M9*
-N), or M9* medium lacking magnesium 
sulfate (M9*
-MgSO4) at different time points after induction (depending on the type of 
experiment). Absence of growth was deduced from OD450 measurements, which were 
confirmed via the determination of colony forming units. Twenty mL of the cell suspension 
were added to a baffled Erlenmeyer flask (250 mL total volume) and incubated at 30°C for 
10 min in a rotary shaker (200 rpm, 2.5 cm amplitude). Subsequently, the culture was overlaid 
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with 5 mL DINP and limonene formation was initiated by the addition of 0.4 mL 50% (w/v) 
glucose. Aliquots of the two-liquid phase fermentation were retrieved At defined time points 
and processed as reported for the quantitation of metabolites (Chapter 2). 
4.4 Results 
Limonene formation in growing cells is limited by physiological constraints. The achievable 
biomass concentration during batch cultivations is typically limited by the amount of glucose 
in the medium. In addition, oxygen mass transfer into the medium and release of toxic by-
products (e.g., acetate) can also restrict microbial growth and prevent the formation of high 
biomass concentrations in batch cultures. The formation of limonene from glucose in 
recombinant E. coli might be limited by these factors, because it is connected to cell growth 
(Chapter 2) and might thus be limited by the above mentioned factors as well. Furthermore, 
the carbon source is utilized for both limonene and biomass/by-product formation. 
The limonene formation capacity of resting cells was determined to investigate whether 
limonene synthesis competes with microbial growth. Resting cells were prepared by 
harvesting at different time points during cultivation, followed by resuspension in glucose-
containing buffer. This capacity was compared with the limonene formation activity of the 
growing cells during cultivation. E. coli BL21 (DE3) harboring the plasmids 
pTAC:LS:AGPPS2 (encoding the enzymes limonene synthase and GPP synthase) and 
pMVAidi (encoding the enzymes of the mevalonate pathway) was grown in shake flasks with 
0.5 % (w/v) glucose (Figure 4.1). The specific limonene formation rate was highest  
(0.21 U gcdw-1) within the first two hours after induction and decreased to 0.15 and 
0.06 U gcdw-1 in the late exponential phase and during the transition to the stationary phase, 
respectively. This decrease in limonene formation rates during the exponential phase is 
unexpected, especially considering the longer time available for heterologous gene expression. 
The limonene formation activities were assessed in short-term (<2 h) resting cell assays with 
cells retrieved from a growing culture in order to investigate whether the specific limonene 
formation rate decreased due to hampered enzyme synthesis or physiological constraints such 
as limiting precursor (e.g., acetyl-CoA) availability. Resting cell activities transiently 
increased depending on the expression time and, after 9 h of gene expression, were almost 
threefold higher (0.44 vs. 0.15 U g cdw-1) than the activity of their growing counterparts (Figure 
4.2A). The estimated specific glucose uptake rates of both growing and resting cells were 
similar (during the first 2 h, data not shown), suggesting at least initially similar metabolic 
capacities of the cells in both biocatalyst configurations.  
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Figure 4.1: Limonene production profile in batch cultivation of E. coli BL21 (DE3) harboring 
pMVAidi and pTAC:LS:AGPPS2 from 0.5% (w/v) glucose. Biomass (●), limonene (♦) glucose (■), 
and acetate (▲) concentrations were monitored throughout the cultivation. The specific limonene 
formation rate of growing cells is represented as grey bars. The error bars refer to the standard 
deviations retrieved from two independent cultivations (biological replicates). The figure was adapted 
from the Master Thesis of Anna Hoschek (Hoschek, 2014). 
The highest specific limonene formation activity of resting cells (0.47 U g cdw-1) was observed 
12 h after induction of gene expression. This was also the case when the exponential growth 
phase was prolonged by adding 2% (w/v) glucose in a pH controlled and aerated bioreactor 
(data not shown), where this activity remained constant until glucose depletion. Thus, under 
the applied conditions of batch cultivation, the use of growing cells appeared to be sub-
optimal for efficient limonene synthesis from glucose. We reason that the higher specific 
limonene formation activities of non-growing cells reflect a reduced competition with growth 
demands as glucose fueled the formation of both biomass and limonene. 
Pathway gene expression and limonene synthesis rate depend on temperature. The 
functional production of heterologous proteins is not only governed by genetic and cellular 
aspects, such as genetic regulatory elements and the intracellular environment of the 
heterologous host, but also by exogenous factors (e.g., temperature). Lowering the expression 
temperature has frequently been shown to improve the synthesis of soluble heterologous 
proteins (Rosano and Ceccarelli, 2014). The production of soluble geranyl diphosphate 
synthase (GPPS) was shown to profit from a reduced expression temperature, although the 
improved solubility of synthesized GPPS did not increase limonene titers accumulated by 
growing cells (Chapter 2). E. coli BL21 DE3 (pTAC:LS:AGPPS2, pMVAidi) was cultivated 
at different temperatures to modulate the heterologous expression of limonene biosynthesis 
pathway genes. The limonene formation capacity of resting cells derived from these cultures 
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after different expression times was assessed. The resting-cell fermentations were performed 
at 30°C to ensure comparability and exclude effects of intrinsic enzyme activities at different 
temperatures. Although the initial glucose uptake rate during the resting-cell fermentation 
were similar in either case (data not shown), resting cells grown at 30°C showed significantly 
higher maximal limonene formation rates as compared to biocatalyst production at 20, 25, and 
37°C (Figure 4.2B, Figure 4.3). Additionally, the maximal rates were reached faster at higher 
expression temperatures (Figure 4.2B). The tendency observed for limonene formation at 
different expression temperature resembles the earlier finding of maximal limonene yields at 
30°C with growing cells (Chapter 2). Here, an expression temperature of 30°C combined with 
an expression duration of 12 h can thus be considered optimal for the balanced synthesis of 
active GPPS, LS, and mevalonate pathway enzymes.  
 
Figure 4.2: (A) Specific resting-cell limonene formation activities (grey bars) of E. coli BL21 (DE3) 
(pMVAidi, pTAC:LS:AGPPS2) at 30°C in dependency of the expression time and microbial growth 
phase. Resting cells were retrieved from cultures actively growing at 30°C (●) by harvesting the cells 
at indicated time points of growth and subsequent resuspension in potassium phosphate buffer (0.1 M, 
pH 7.4) supplemented with 1% (w/v) glucose. (B) Maximal limonene formation activities of resting 
cells in dependency of the temperature during cultivation and expression. The time points after 
induction at which maximal activities were reached are given in parentheses. To ensure comparability, 
all resting-cell fermentations were conducted at 30°C. The limonene formation rates were obtained by 
linear regression of data points within the initial linear production phase (~2 h). The error bars refer to 
standard deviations obtained from two independent cultures (biological replicates). The figure is based 
on data reported in the Master Thesis of Anna Hoschek (Hoschek, 2014). 
Chapter 4: Decoupling production from growth boosts limonene fermentation 
   
85 
 
Figure 4.3: Specific resting-cell limonene formation rates (grey bars) of resting E. coli BL21 (DE3) 
(pMVAidi, pTAC:LS:AGPPS2) generated cultures (●) grown at 20°C (A), 25°C (B), or 37°C (C). The 
cells were harvested at indicated time points of growth and subsequently resuspended in potassium 
phosphate buffer (0.1 M, pH 7.4) supplemented with 1% (w/v) glucose. The limonene formation rates 
were obtained by linear regression of data points within the initial linear production phase (~2 h). The 
error bars refer to deviations obtained from two independent cultures (biological replicates). The 
figure is based on data reported in the Master Thesis of Anna Hoschek (Hoschek, 2014). 
Operational enzyme instability limits limonene production by resting cells. The resting-cell 
fermentations reported above were performed to assess the maximal initial limonene 
formation rate during a limited time window of maximally 2 h with low cell concentrations. 
However, up-scaling of both cell concentration and production period is required for 
productive limonene formation. The resting cell-approach was well scalable regarding 
biomass concentration (Figure 4.4). An increase in biomass concentration up to 10 gcdw L-1 
increased the in initial productivity and final yields proportionally. However, these 
fermentations suffered from limited biocatalyst stability. Resting-cell fermentations, for 
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which the cells were obtained under the above deduced optimal conditions were, performed at 
different temperatures (25, 30, 37°C) and followed for 8 h to investigate this instability in 
detail. The initial limonene formation rate was highest (0.55 U gcdw-1) for fermentation at 
37°C and lowest (0.25 U gcdw-1) at 25°C (data not shown). The final limonene concentrations 
were similar in all cases despite these differences in initial specific activities (Figure 4.5A). 
The limonene formation rate at 37°C decreased faster as compared to 30°C or 25°C (Figure 
4.5B). The glucose uptake rate was most stable at 37°C. This might be attributed to higher 
glycolytic flux at this temperature (Figure 4.5C). This indicates, in combination with the 
decreasing limonene yield over time at 37°C, instability of the heterologous limonene 
formation pathway rather than instability of the metabolic capacity of resting cells. In contrast, 
the specific limonene yield on glucose increased during the fermentation performed at 25°C 
(Figure 4.5D) indicating an improved pathway stability at lower temperatures, which is in 
good agreement the decreasing glucose uptake rate. 
 
Figure 4.4: Limonene concentrations (A) and volumetric productivities (B) of resting-cell 
fermentations using different biomass concentrations (10 gcdw L-1 (green), 5 gcdw L-1 (dark blue), 
2.5 gcdw L-1 (orange), or 1 gcdw L-1 (purple)) of E. coli BL21 (DE3) (pMVAidi, pTAC:LS:AGPPS2). 
The fermentations were performed at 30°C and with an initial glucose concentration of 1% (w/v). The 
error bars refer to deviations obtained from two resting-cell fermentations. 
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Figure 4.5: Time course of resting-cell fermentations in dependency of the temperature. Limonene 
yields on biomass (A), specific limonene synthesis rates (B), glucose uptake rates (C) and limonene 
yield on consumed glucose (D) are shown. The temperatures investigated were 25°C (♦), 30°C (■) and 
37°C (●). The error bars refer to standard deviations obtained from two independent cultures 
(biological replicates). The figure is based on data reported in the Master Thesis of Anna Hoschek 
(Hoschek, 2014). 
Resting cells were incubated at 30°C in presence or absence of glucose to investigate the 
reason for the rapidly decreasing specific limonene formation rates (Figure 4.5B). The specific 
limonene formation rate of the cells incubated in absence of glucose remained almost 
unaffected when glucose was added after an incubation time of 6 h (~0.3 U gcdw-1, Figure 4.6). 
The limonene formation rate after 6 h of continuous fermentation, however, was threefold 
lower (Figure 4.6). This suggests that the operational stability rather than thermal/temporal 
inactivation of one or more enzymes of the limonene formation pathway restricts limonene 
formation by resting cells.  
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Figure 4.6: Initial (~2h) specific resting-cell limonene formation rate after different times of 
incubation at 30°C in the presence (grey bars) or the absence of glucose (white bars). The error bars 
refer to standard deviations obtained from two independent cultures (biological replicates). The figure 
is based on data reported in the Master Thesis of Anna Hoschek (Hoschek, 2014). 
Limonene formation and biocatalyst stability as function of medium composition. The 
resting-cell fermentations were supplemented with 1 mM IPTG to overcome instability. The 
initial reaction rate was slightly increased approximately by 10% after addition of the inducer 
leading to 1.6-fold increased limonene concentrations after 9 h of fermentation (Figure 4.7A). 
This supports the hypothesis of an operational instability of the heterologous enzymes, but 
also indicates (limited) capability of protein re-synthesis of heterologous proteins under 
growth-prohibiting conditions. However, protein re-synthesis is likely limited by the 
availability free amino acids and only facilitated by the turnover of intracellular resources 
under growth-prohibiting conditions induced by the lack of nitrogen (Mandelstam, 1958). An 
additional 1.3-fold increase in limonene titer after 9 h of fermentation was observed when the 
resting-cell fermentation broth was supplemented with the two antibiotics used during normal 
batch cultivation (Figure 4.7A).  
Besides carbon and oxygen, which constitute 45 and 30% (w/w) of the dry biomass of E. coli 
B strains (Bauer and Ziv, 1976), respectively, nitrogen is the most important element for the 
synthesis of essential cellular macromolecules, such as nucleic acids and proteins. The 
utilization of a resting-cell fermentation medium containing all essential elements except 
nitrogen (M9*
-N) did not result in higher final limonene yields on biomass compared to 
potassium phosphate buffer supplemented with glucose (Figure 4.7A, C). 
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Figure 4.7: Course of limonene production under different nutrient limitations (A, C, E) in media 
either supplemented with IPTG (♦), IPTG, chloramphenicol, and ampicillin (■) or without 
supplementation (●). Resting-cell fermentations were performed either in potassium phosphate buffer 
(A), M9* medium lacking nitrogen (C), or M9* medium lacking magnesium sulfate (E). The panels B, 
D, F illustrate glucose (■), acetate (♦), and pyruvate (●) concentration profiles of the resting-cell 
fermentations supplemented with IPTG and antibiotics. The error bars refer to standard deviations 
obtained from two independent cultures (biological replicates).  
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The activity was less stable, though the observed initial rate for the nitrogen-deficient 
fermentation higher was 0.67 U gcdw-1 (vs. 0.48 U gcdw-1, both fermentations supplemented 
with IPTG and antibiotics). This underlines that nitrogen-free medium is does not improve 
terpenoid fermentation with resting cells. The glucose consumption and acetate production 
profiles were similar in both fermentations (Figure 4.7B, D, supplemented with IPTG and 
antibiotics). Low amounts of pyruvate accumulated additionally to acetate in the fermentation 
based on the nitrogen-free M9* medium, indicating either a saturated or inhibited activity of 
pyruvate dehydrogenase with respect to acetyl-CoA formation.   
Magnesium sulfate was omitted from the fermentation medium to obtain non-growing cells, 
which might be able to synthesize amino acids and proteins more efficiently. The initial 
specific limonene formation rate was very similar as compared to the rate observed in 
nitrogen-free medium (0.7 vs. 0.68 U gcdw-1), but strikingly, the limonene formation was much 
more stable, linear for more than 7 h and decreased only slightly afterwards. The high and 
stable specific limonene formation rates were accompanied by increased rates for glucose 
uptake and pyruvate accumulation (Figure 4.7E, F). Pyruvate accumulation possibly occurred 
as a consequence of the increased glucose uptake rate and a consequential glycolytic pathway 
overflow.  
Table 4.1: Characteristics of limonene biosynthesis in growing and non-growing E. coli BL21 (DE3) 
harboring pTAC:LS:AGPPS2 and pMVAidi under different experimental conditions.  
condition clim/  
µmol Laq-1 
clim/  
mg Laq-1 
Yp/s/ 
mglim gglc-1 
Yp/x/ 
mglim gcdw-1 
growing cellsa,b 111.5 ± 17.7 15.2 ± 2.4 1.5 ± 0.2 9.5 ± 1.5 
MgSO4 limited growing cellsa,b 200.5 ± 0.8 27.3 ± 0.1 2.7 ± 0.0 38.2 ± 3.9 
resting cells (KPi)c 164.8 ± 18.6 22.4 ± 2.5 11.6 ± 1.3 29.7 ± 3.4 
resting cells (M9*
-N)c 170.1 ± 0.1 23.2 ± 0.0 10.6 ± 1.2 30.7 ± 0.0 
resting cells (M9*MgSO4)c 277.1 ± 2.4 37.8 ± 0.3 8.0 ± 0.1 50.0 ± 0.4 
a the averaged values and deviations were obtained from at least two independent fermentations. The values 
for growing (Chapter 2) and MgSO4 limited growing cells refer to the data obtained after depletion of 
1% (w/v) glucose. 
b values refer to concentrations and yields obtained after glucose depletion 
c
 values refer to concentrations and yields obtained after 8.7 h of resting cell fermentation with IPTG and 
antibiotic supplementation  
In conclusion, we consider the application of magnesium sulfate deficient broth optimal for 
limonene formation by non-growing cells as it features the highest specific limonene yield on 
both glucose and biocatalyst after 9 h of fermentation (Table 4.1). These high yields and stable 
activities correlated with the increased and stabilized glycolytic activity (glucose uptake rate, 
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overflow metabolite formation), which might have allowed regeneration of both metabolic 
and heterologous proteins. 
Limonene formation benefits from magnesium sulfate limited growth. The optimized 
production system shows numerous advantages, though the generation of resting cells for 
production purposes involves laborious and potentially dispensable washing steps. Therefore, 
it is desirable to combine the simplicity of a typical batch cultivation and the superior 
potential of non-growing cells. Growth of E. coli in batch cultures is typically terminated by 
the depletion of the sole carbon and energy source, frequently glucose. Limonene formation 
during the subsequent stationary phase is, thus, substrate limited. Glucose remains available 
for limonene formation, but is barely consumed for biomass formation when another element, 
e.g., magnesium or sulfate, is depleted. Hence, resting cells are obtained in situ and can be 
applied for fermentative limonene production. 
The amount of magnesium sulfate in M9* was decreased (from the initial concentration of 
2 mmol L-1 to 0 mmol L-1) and the biomass yield on magnesium sulfate was determined. A 
constant yield was observed for magnesium sulfate concentrations up to 160 µmol L-1 
(0.008 gbiomass µmolMgSO4-1) (Figure 4.8A). This empirically determined yield was then used to 
limit microbial growth by MgSO4 (118 µmol L-1 magnesium sulfate was added) to obtain 
biomass concentrations at which oxygen availability was not limiting (approximately 1 gcdw L-
1). The growth profile did not show an exponential pattern and entered a stationary phase only 
after glucose depletion between 18 and 29 h fermentation time. Limonene accumulation, 
however, appeared to profit from MgSO4 limitation, as the highest specific limonene 
formation rate was determined at 0.67 U gcdw-1 (Figure 4.8B). This rate was not only 
significantly higher than the maximal rate observed for exponentially growing cells 
(0.21 U gcdw-1), but also comparable to the rate observed during resting-cell fermentation in 
MgSO4-deficient M9* medium (Figure 4.7E). Limonene is produced at a reduced rate 
putatively from storage compounds after glucose depletion and finally twofold and fourfold 
higher limonene yields on glucose and biomass, respectively, as compared to growing cells 
(Chapter 2) were obtained (Table 4.1). Thus, limonene formation profits from the sub-optimal 
(non-exponential) growth conditions and the MgSO4 limitation, putatively by increased 
availability of carbon and/or energy resources. 
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Figure 4.8: Specific biomass concentration (●) as a function of the MgSO4 amount added to M9* 
minimal medium (A) and fermentation profile of E. coli BL21 (DE3) harboring the limonene 
formation pathway in M9* medium supplemented with 118 µmol MgSO4 per liter (B). The biomass 
concentration (●), the limonene yield on biomass (♦) as well as glucose (■), acetate (▲), and pyruvate 
(▼) concentrations are given. The error bars refer to standard deviations obtained from three 
independent cultures (biological replicates). 
4.5 Discussion 
Productivity of resting cells is limited by microbial physiology and operational enzyme 
stability. Critical selection and evaluation of the appropriate whole-cell biocatalyst 
configuration is key for developing an efficient production process (Chapter 6, (Kuhn et al., 
2010; Woodley, 2006)). This study focused on fermentative production with cells subjected to 
growth limitations (resting or nutrient-limited), whereas often the physical state of the cells 
(e.g., naturally or artificially immobilized on surfaces or particles) or the selection of 
appropriate reaction conditions (reactor configuration, two-liquid phase system) are 
considered. A resting-cell configuration has, except for rhamnolipid (Wittgens et al., 2011) 
and perillyl acetate (Chapter 3) production with Pseudomonas putida and E. coli, respectively, 
not been systematically exploited for de novo syntheses involving recombinant 
microorganisms.  
A linear antiproportional correlation between the specific terpene (amorphadiene in this case) 
production rate and the specific growth rate was observed in constraint-based flux analyses of 
E. coli harboring a heterologous terpene formation pathway (Kim et al., 2014). In the present 
study, magnesium sulfate-limited growth of E. coli (pMVAidi, pTAC:LS:AGPPS2) was 
found to increase biomass-specific limonene production as compared to non-limited 
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conditions (Figure 4.8 and Table 4.1). This and the decreased maximal biomass yield on 
glucose in magnesium sulfate-limited fermentations (0.1 vs. 0.27 gbiomass gglcuose-1) points to a 
competition for resources between the heterologous limonene formation pathway and cellular 
growth or maintenance under the conditions investigated. It also indicates that the microbial 
physiology rather than pathway enzyme activity limits limonene production in growing cells. 
Similar conclusions on physiological limitations were reported for the fermentative synthesis 
of erythromycin precursor 6-deoxyerythronolide B from propionate in E. coli (González-
Lergier et al., 2006) as well as the microbial hydroxylations of proline (Falcioni et al., 2013), 
limonene (Cornelissen et al., 2011), and styrene (Kuhn et al., 2013). 
Limonene production in true resting cells suffered from low stability of the limonene 
formation pathway enzymes. This could partially be relieved by the addition of IPTG and 
antibiotics. The effect of IPTG addition can readily be retraced to facilitated heterologous 
protein biosynthesis. Impaired plasmid maintenance or, more likely, the intracellular levels of 
guanosine tetraphosphate (ppGpp) might be possible explanations for the positive effects of 
antibiotics supplementation. ppGpp accumulates in E. coli during nutrient starvation (Irr, 
1972) and represses global cellular processes such as rRNA transcription (Cashel and Gallant, 
1969), translation (Svitil et al., 1993), and DNA replication (Maciag et al., 2010). Bokinsky 
and co-workers showed in a recent study that ppGpp indeed inhibits RNA and DNA synthesis 
(Bokinsky et al., 2013). The addition of chloramphenicol led to 60% decreased ppGpp levels 
within 15 min and, thus, an onset of RNA and DNA synthesis (Bokinsky et al., 2013). The 
exact mechanism of the chloramphenicol-mediated ppGpp degradation remains unclear, 
although this effect has been described in the early 1970s (Lund and Kjeldgaard, 1972). 
However, the degradation of ppGpp might have led to improved protein synthesis and thus 
increased limonene formation rates of resting E. coli (pMVAidi, pTAC:LS:AGPPS2) 
supplemented with chloramphenicol.  
Resting cells as a tool to study environmental perturbations and for productive synthesis 
of chemicals. Environmental perturbations frequently affect both microbial growth and 
heterologous pathway activity. This makes it difficult to discriminate between different 
effects when growing cells are applied. Here, growth (biocatalyst synthesis) and terpene 
production were assessed and optimized individually. An expression temperature of 30°C 
rather than 20, 25, or 37°C was optimal for the balanced synthesis of all heterologous 
pathway enzymes in an experiment using the temperature as variable for gene expression 
(resting-cell fermentations were performed at 30°C). Low expression temperatures have been 
reported to enhance soluble expression of GPP synthase (GPPS) (Chapter 2), nevertheless, 
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increasing the expression temperature to 30°C also increased the specific limonene formation 
rate of resting cells. This observation confirms that the GPPS availability does not limit the 
total limonene formation rate, as it was hypothesized in Chapter 2. The rapid decrease of 
specific limonene formation rate indicated instability of one or more enzymes of the limonene 
formation pathway (Figure 4.5 and Figure 4.6). Operational enzyme instability thus constitutes 
an optimization target for improving terpene production with resting as well as growing cells. 
In addition, a resting cell configuration can also be applied to individually dissect and exploit 
the effects of perturbations/modifications such as medium additives to enhance expression 
(Zhou et al., 2012), carbon sources (Yoon et al., 2009), or (pathway) enzyme 
inhibitors/promotors, e.g., acetate, on growth and product formation.  
The possibility to apply non-growing biocatalysts in a modular fashion by means of mixed-
strain approaches is another advantage. This was useful for biocatalytic cascade reactions that 
profit from environmental conditions that usually are not compatible with microbial growth, 
i.e., micro-aqueous reaction environments (Wachtmeister et al., 2014). Recently, the de novo 
synthesis of the oxygenated limonene adduct perillyl acetate was shown to profit from this 
modularity, employing different strains for limonene biosynthesis and its oxygenation 
(Chapter 3). This mixed-culture resting cell application may serve as a general strategy for 
further application in productive biosynthesis of terpenoids and other chemicals for which 
synthesis is otherwise limited by their growth-inhibiting properties, e.g., phenol (Wierckx et 
al., 2005) or styrene (Mingardon et al., 2015) biosynthesis in Pseudomonas putida S12. 
Physiological advantages and constraints of resting cells for terpene production. The 
transition of conditions where microbes face an excess of all essential nutrients to conditions 
where one or more of these nutrients are depleted is accompanied by severe changes in the 
microbial physiology with respect to intracellular metabolite concentrations and fluxes 
(Brauer et al., 2006). The altered pattern of metabolites and fluxes also affects the 
performance of heterologous biosynthesis pathways, which are fueled by these metabolites. 
The type of nutrient limitation (e.g., nitrogen, sulfur, or phosphate) provokes distinct 
phenotypes. Nitrogen limitation in E. coli for instance results in significantly lower glucose 
uptake rates as compared to magnesium limitation as shown in our case (Figure 4.7) and also 
reported previously (Chubukov and Sauer, 2014). Concomitantly, a very high pyruvate 
secretion rate was observed for magnesium-limited cultures, which was hypothesized to be 
the result of an impaired functioning of the Mg2+ dependent pyruvate dehydrogenase complex 
(Chubukov and Sauer, 2014; Kale et al., 2007). In our experiments, recombinant E. coli 
starved for magnesium and sulfur also showed a similar profile with higher glucose uptake, 
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pyruvate and acetate excretion rates as compared to nitrogen-limiting conditions. Obviously, 
limonene synthesis substantially profited from this pyruvate excretion with respect to the 
stability and final (specific) product concentration. The ATP synthesis rates, as estimated by 
constraint-based flux balance analysis, were highest (roughly 27 mmol gcdw h-1) for 
magnesium starved E. coli cells as compared to other limitations such as nitrogen or 
phosphate (Chubukov and Sauer, 2014). This raised the question whether improved rates for 
ATP synthesis, which is also consumed in the heterologous mevalonate pathway, may have 
contributed to the improved limonene synthesis. However, the same initial specific limonene 
formation rate in nitrogen starved cells, with a lower estimated ATP synthesis rate of 
5 mmol gcdw h-1 (Chubukov and Sauer, 2014) and the fact that growing cells produce (and 
consume) significantly more ATP (Orth et al., 2011) does not comply with this hypothesis.  
The observed accumulation of the overflow products pyruvate and acetate may occur due to a 
reduced activity of the tricarboxylic acid cycle leading to increased availability of acetyl-CoA, 
the starting material for terpene biosynthesis. In accordance with that, elevated acetyl-CoA 
availability was recently hypothesized to be the result of an altered transcription profile in 
response to nitrogen limitation in cultures of E. coli BW25113 (Marzan and Shimizu, 2011). 
However, the gradual transition into the non-growing state (stationary phase in batch 
cultivation) has to be differentiated regarding physiology and gene expression from the active 
generation of resting cells (harvesting from an actively growing culture and resuspension in 
limiting medium), where cells are directly facing depletion of an essential nutrient. The 
observed limonene rates are relatively low in comparison to turnover rates of the reactions of 
the central carbon metabolism. This might raise the question whether limonene biosynthesis 
can at all be limited by the availability of intermediates of the central carbon metabolism. 
However, it should be noted that gene expression and thus flux via the heterologous pathway 
may not be balanced, which may lead to uncoupling of the consumption of cellular resources 
from limonene formation. In view of that it seems reasonable to conclude that the availability 
of intracellular resources was improved by optimization of the resting cell medium from 
simple potassium phosphate buffer to a magnesium sulfate deficient medium. 
4.6 Conclusion 
A yet underrated potential for optimizing the de novo synthesis of valuable chemicals with 
resting recombinant E. coli was revealed by successfully demonstrating that the decoupling 
from microbial growth boosts the formation of the monoterpene limonene. Evaluation of 
resting cells under different medium conditions and growth-limitations allowed the 
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development of an effective limonene production system, in which microbial growth is 
limited by magnesium sulfate availability. The system is characterized by superior terpene 
production capacities, reduced formation of biomass as a side product, and a more efficient 
utilization of resources. In conclusion, controlled reduction rather than maximization of 
microbial growth was identified as a key strategy for efficient monoterpene production. Such 
approaches involving limited growth and resting cells complemented by genetic pathway and 
host engineering strategies may well develop into promising process design strategies with 
relevance for the production of valuable fine chemicals (e.g., oxygenated terpenoids) at scale. 
 
Chapter 5: Continuous synthesis of perillic acid with bacterial biofilms 
   
97 
 
 
Chapter 5 Continuous multi-step synthesis of perillic acid 
from limonene in a segmented-flow biofilm reactor 
 
 
 
 
Christian Willrodt, Babu Halan, Lisa Karthaus, Jessica Rehdorf, Mattijs K. Julsing, Katja 
Buehler, and Andreas Schmid  
 
 
 
 
 
 
Christian Willrodt and Babu Halan contributed equally to this chapter. Lisa Karthaus 
contributed to the biofilm experiments, the assessment of biofilm formation capacity and the 
purification of perillic acid in the context of her bachelor thesis coordinated and supervised by 
Christian Willrodt and Babu Halan. Jessica Rehdorf, Mattijs K. Julsing, Katja Bühler, and 
Andreas Schmid coordinated the project and corrected the manuscript. 
 
 
Manuscript in preparation 
  
Chapter 5: Continuous synthesis of perillic acid with bacterial biofilms 
   
98 
5.1 Abstract 
The efficiency of many biocatalytic reactions involving industrially interesting reactants is 
constrained by toxification of the applied biocatalyst. Here, we evaluated the combination of 
biologically and technologically inspired strategies to overcome toxicity related issues during 
the multi-step oxyfunctionalization of (R)-(+)-limonene to (R)-(+)-perillic acid. 
Pseudomonas putida GS1 catalyzing selective limonene oxidation via the p-cymene 
degradation pathway and recombinant P. taiwanensis VLB120 were evaluated for continuous 
perillic acid production. A tubular segmented-flow biofilm reactor preventing oxygen 
limitation enabling membrane mediated substrate supply and efficient in situ product removal 
was used. Both P. putida GS1 and P. taiwanensis VLB120 developed a catalytic biofilm in 
this system. The productivity of P. putida GS1 was highly dependent on the carbon source 
and reached 35 g Ltube-1 day-1 when glycerol was supplied. Approximately tenfold lower 
productivities than with P. putida GS1 were reached irrespective of the applied carbon source 
when the recombinant P. taiwanensis VLB120 harboring p-cymene monooxygenase and p-
cumic alcohol dehydrogenase was cultivated in a biofilm format under segmented flow 
conditions. The technical applicability for preparative perillic acid synthesis in the applied 
system was verified by purification of perillic acid from the outlet stream using a cationic 
resin. This concept enabled the multi-step production of perillic acid, which might be 
transferred to other reactions involving volatile reactants and toxic end-products. 
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5.2 Introduction 
Many interesting reactants for industrially relevant biotransformations can be classified as 
hydrophobic solvents, which are toxic to the biocatalyst by affecting the cellular viability. In a 
process this will finally lead to reduced biocatalyst efficiency and lower reactor productivities. 
One of the major challenges in whole cell biocatalysis is to overcome process constraints 
caused by solvent toxicity (Heipieper et al., 2007; Xue and Woodley, 2012). Solvent toxicity 
may be counteracted by biologically or technologically inspired strategies. Technologically 
oriented approaches often exploit multiphasic production systems (Lima-Ramos et al., 2014; 
Straathof, 2003) taking advantage of the enhanced solubility of toxic reactants/products in the 
water immiscible phase, while the whole cell biocatalyst resides in the aqueous environment 
(Hack et al., 2000; Stark and von Stockar, 2003). Thereby, the concentration of the respective 
compound is kept below toxic levels in the aqueous biocatalyst environment. Likewise, 
strategies allowing controlled substrate supply and continuous product removal can be 
employed to reduce contact time between the biocatalyst and the toxic product (Hilker et al., 
2006; Schewe et al., 2015). Biologically inspired strategies include the utilization of naturally 
solvent tolerant production strains (Inoue and Horikoshi, 1989). Several Pseudomonas species, 
for instance, feature adaptive mechanisms such as morphological changes, alteration of 
membrane fluidity, or modification of surface properties to overcome toxic effects of solvents 
(Heipieper et al., 2007; Segura et al., 2012). Increased tolerance against toxic compounds can 
also be accomplished by genetic manipulations such as the up-regulation of the expression of 
RND-type efflux pumps in Pseudomonas taiwanensis VLB120 (Volmer et al., 2014) or the 
heterologous overexpression of ABC-type solvent efflux pumps in Escherichia coli (Dunlop 
et al., 2011).  
The exploitation of alternative biocatalyst configurations such as resting instead of growing 
cells or immobilized instead of suspended cells is another powerful strategy to cope with toxic 
reactants (Chapter 6). Naturally immobilized cells on a surface embedded in a self-produced 
matrix of extracellular polymeric substances are referred to as biofilms (Costerton et al., 
1995). Microbial cells that are immobilized in biofilms are described to exhibit significantly 
enhanced tolerance towards antimicrobial agents (Costerton et al., 1995) and organic solvents 
(Halan et al., 2011; Li et al., 2006). This increased tolerance is often attributed to both 
physical parameters such as limited exposure of toxic reactants and biological parameters 
such as adaptive stress responses, lower metabolic activity, or the formation of persister cells 
(Stewart, 2002; Walters et al., 2003). Microbial biofilms have a long-lasting success in 
biological waste water treatment (Qureshi et al., 2005) and bioremediation (Singh et al., 2006), 
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but can also be applied as living biocatalysts in continuous chemical syntheses (Halan et al., 
2012).  
The cultivation of the biofilm forming strain P. taiwanensis VLB120 ∆C achieved 
productivities of up to 46 g Ltube-1 day-1 for the one-step synthesis of (S)-styrene oxide in a 
tubular biofilm reactor setup after relieving the oxygen limitation by introduction of air 
segments (Karande et al., 2014). Very recently also the oxyfunctionalization of cyclohexane 
to cyclohexanol has also been realized in a continuous production system with recombinant 
P. taiwanensis VLB120 (Karande et al., 2015). In addition to biofilms as a catalyst format, the 
substrate and product toxicity was relieved by using a silicone membrane with dual purpose. 
The membrane mediated the substrate supply and simultaneously constituted the growth 
surface. The potential of biofilms combined with the advantages of this technical setup have 
not been investigated yet for multi-step biotransformations. 
In this work, we harness the advantages of both the biofilm catalyst and the segmented flow-
through bioreactor concept for the three-step biooxidation of a readily available volatile 
monoterpene limonene to the high value but toxic compound perillic acid. Perillic acid, which 
is naturally occurring in Perilla frutescens, is an attractive target for the pharmaceutical and 
cosmetic industries due to its cytotoxicity to cancer cells (Boon et al., 2000) and its 
antimicrobial properties (Duelund et al., 2012). An integrated bioprocess for perillic acid 
production with a solvent tolerant P. putida GS1 that catalyzes the limonene oxidation via the 
native p-cymene degradation pathway involving the enzymes cymA, cymB, cymC (Figure 
5.1B) (Mars et al., 2001), however, suffered from process instability due to toxification of the 
biocatalyst. P. putida GS1 accumulates perillic acid as the sole limonene oxidation product, 
which cannot be further degraded, due to lacking aromatic ring structure, which is present in 
the native substrate p-cumate. End-product toxification was overcome by the application of a 
cationic resin entrapping perillic acid (Mirata et al., 2009). By exploiting the performance of 
the native strain P. putida GS1 and a likewise solvent-tolerant recombinant P. taiwanensis 
VLB120 which has been extensively studied under catalytic biofilm conditions (Gross et al., 
2010; Gross et al., 2013; Karande et al., 2014; Schmutzler et al., 2015), we developed a 
biofilm based process concept as an alternative strategy for overcoming toxicity limitations 
and improve process stability during perillic acid production. This approach resulted in 
continuous production of perillic acid as the sole oxidation product and showed the potential 
to perform multi-step biotransformations in a biofilm setup.  
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5.3 Materials & Methods 
Chemicals and oligonucleotides. Anhydrous D-glucose was purchased from Alfa Aesar 
(Karlsruhe, Germany). Custom synthesized oligonucleotides were purchased from Sigma 
Aldrich (Steinheim, Germany). All other chemicals were obtained from AppliChem 
(Darmstadt, Germany), Sigma Aldrich (Steinheim, Germany), or Carl Roth (Karlsruhe, 
Germany) at the highest purity available.  
Bacterial strains and plasmids. Wild-type P. putida GS1 (DSM 12264) was obtained from 
the German Collection of Microorganisms and Cell Cultures (DSMZ). Cloning of genes was 
performed by an in vitro assembly method (Gibson et al., 2009). Reagents were obtained from 
Fermentas (St. Leon-Rot, Germany). Phusion™ high fidelity polymerase was used according 
to the manufacturer’s instructions. E. coli DH5α was used for all molecular biology 
manipulations. Genomic DNA of P. putida GS1 was isolated (peqGOLD Bacterial DNA kit, 
peqLAB, Erlangen, Germany). The primers were designed on the basis of the available 
genome sequence of P. putida F1 (GenBank ID: CP000712.1). The open reading frames 
(ORFs) for the cymene monooxygenase cymAa and the adjacent reductase cymAb were 
amplified from the genomic DNA using the primers PCW085 (5’-GGAACCAGTAC-
TGGAGAATTCCATAATGTGGGAATACATCAAGTAC-3’) and PCW086 (5’-ACGGAT-
CCCGGGCGCGCCAAGCATACAATTAGCCTTTAGGAGTT CC-3’). PCR settings were 
set to 40 seconds elongation time and an annealing temperature of 59.1°C. After DpnI 
treatment of the PCR mix, the 2280 bp amplicon was purified via excision from an agarose 
gel and subsequently recombined with NdeI digested pCom10lac (Lindmeyer et al., 2015) 
leading to the expression plasmid pCom10L:CymA. Expression of the heterologous gene in 
this vector is driven by the IPTG inducible Plac promotor. The ORF for the p-cumic alcohol 
dehydrogenase (cymB) was amplified using PCW093 (5’-AAAGGCTAATTGTATGCTTGG 
CGCGAGGAGGACAGCTAAATGAGACTGAAAGACAAAGTCG-3’) and PCW094 (5’-
TCTCTCATCCGCCAAAACAGAAGCTTGAATGTCGTGGCGAATGAC-3’), an annea-
ling temperature of 58.6°C and an elongation time of 35 seconds. After DpnI treatment of the 
PCR mix, the 804 bp amplicon was purified and recombined with digested (SgsI, HindIII) 
pCom10L:CymA resulting in the plasmid pCom10L:CymAB. Accuracy of all manipulations 
was assessed by sequence analysis and the obtained sequences were identical to the cymAab 
and cymB sequences of the cmt operon of P. putida F1 (GenBank ID: U242215).  
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Cultivation of bacterial strains. Five mL of Lysogeny broth (LB) were inoculated from 
frozen stocks and incubated for 16 h at 30°C (200 rpm, 2.5 cm amplitude). Five hundred µL 
from this culture were used to inoculate a 50 mL M9* (250 mL baffled Erlenmeyer flask) 
preculture supplemented with either 0.5% (w/v) glucose, glycerol or citrate. After overnight 
incubation at 30°C, this culture was used to inoculate the respective M9* (liquid:gas phase 
ratio 1:4) main cultures at an OD450 of 0.2 or the tubular biofilm setup. The cultures for the 
recombinant strains were supplemented with 50 µg mL-1 kanamycin. Gene expression was 
either induced in the early stationary phase (OD450 between 0.6 and 0.8) or, for biofilm 
applications, already during the M9* preculture. 
Analytical procedures. Quantification of the analytes (R)-(+)-limonene, (R)-(+)-perillyl 
alcohol, (R)-(+)-perillyl aldehyde and (R)-(+)-perillic acid (PAc) was performed on a 
TraceGC Ultra (ThermoFisher Scientific Inc., Waltham, MA, USA) gas chromatography 
instrument. Nitrogen was applied as a carrier gas and the gas flow rate was set to 
1.5 mL min-1. The injector (250°C) was operated in splitless mode and the oven profile was: 
80°C (5 min), 80-160°C (7.5°C min-1), 160-300°C (40°C min-1), and 300°C (5 min). To 
assess the respective concentrations, standard curves were prepared using (R)-(+)-limonene, 
and the (S)-enantiomers of perillyl alcohol, perillyl aldehyde, and perillic acid. Standard 
solutions were prepared in M9* medium and subsequently extracted by the addition of an 
equal volume of diethyl ether (Et2O), with 0.2 mM dodecane as an internal standard, and 
vigorous mixing. The phases were separated by centrifugation (room temperature, 17000 g, 
2 min) and the organic phase was dried over anhydrous Na2SO4 prior to GC analysis. 
The concentrations of glycerol and citrate were assessed by HPLC as described elsewhere 
(Gross et al., 2010) and cell dry weight in dispersed cultures was calculated from the 
measured turbidity using the respective conversion factor (LibraS11, Biochrom Ltd., 
Cambridge, UK, OD450 = 1 equals 0.186 and 0.223 gcdw L-1 for P. taiwanensis VLB120 (Lang 
et al., 2014) and P. putida (Ütkür et al., 2011), respectively).  
Limonene toxicity assays. The precultures were incubated as described above and limonene 
toxicity was assessed by adding different amounts (0 - 250 mmol L-1) of (R)-(+)-limonene 
directly after inoculation of the main culture (25 mL M9* medium, 250 mL baffled 
Erlenmeyer flask, 0.5% (w/v) citrate) with M9* overnight cultures of P. taiwanensis VLB120 
or P. putida GS1. In addition to the amounts of limonene added to the aqueous phase, one mL 
of limonene was added to an evaporation container attached to the lid of the flask to saturate 
the gaseous phase and prevent evaporation of the limonene from the aqueous culture. The 
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flask was sealed tightly to prevent evaporation and biomass was assessed after 16 h of 
cultivation at 30°C (after washing twice with 0.1 M potassium phosphate buffer).  
Perillic acid toxicity assays. One gram of (S)-(-)-perillic acid was dissolved in 4 mL aqueous 
2 mol L-1 NaOH. The pH was adjusted to 11.5 by adding 10 mol L-1 sodium hydroxide and 
water was added to a final volume of 20 mL. This solution was diluted to the desired 2.5-fold 
concentrated stock solutions (0 - 150 mmol L-1) with 0.4 mol L-1 NaOH. 0.4 mL of these 
stock solutions were mixed with 0.6 mL M9* medium (1.667-fold concentrated) 
supplemented with 0.8% (w/v) citrate in a 15 mL cultivation tube. Perillic acid was soluble in 
alkaline stock solutions and did not precipitate upon dilution with the medium, although the 
solubility in aqueous systems (~0.8 mmol L-1) was exceeded. Forty µL of a M9* overnight 
culture of P. taiwanensis VLB120 or P. putida GS1 were added and biomass was assessed 
after 16 h of cultivation in a rotary incubator as described above. By preparing appropriate 
perillic acid stock solutions, the NaOH concentration in the different growth experiments was 
kept equal to prevent NaOH triggered growth biases. The pH of the M9* medium remained 
unaltered upon addition of the perillic acid stock solutions.  
Resting cell assays. After incubation of P. taiwanensis VLB120 harboring either 
pCom10L:CymA or pCom10L:CymAB in M9* medium with citrate, 1 mM IPTG was added 
during the early exponential growth phase (OD450 of ~0.6) and incubation was continued for 
4 h. An aliquot of the cell suspension was centrifuged (4°C, 4618 g, 20 min) and resuspended  
to 0.6 – 1.2 gcdw L-1 in potassium phosphate buffer (0.1 M, pH 7.4). From here the assays were 
performed as described elsewhere (Cornelissen et al., 2011).  
Biofilm formation capacity. The determination of the biofilm forming capacity was 
conducted in a tubular reactor setup. M9 minimal medium containing either 0.5% (w/v) 
glucose, glycerol, or citrate was pumped by a peristaltic pump (IPC High Precision 
Multichannel Dispenser, Ismatec, Wertheim, Germany). Silicon tubes (3 mm inner diameter, 
1.5 mm wall thickness, 600 mm length) were used as biofilm surface. Tygon tubes (2.06 mm 
inner diameter, Tygon R 3607, Ismatec, Wertheim, Germany) were used to connect the 
bubble traps and the medium reservoirs to the pumps. Prior to inoculation, the reactor was 
autoclaved and coiled within a flask which was then placed in a 30°C water bath. The reactors 
were inoculated with respective precultures obtained as described above. The reactor was kept 
idle for 2 h without any medium flow. Afterwards the medium flow was set to 0.1 ml min-1 
Chapter 5: Continuous synthesis of perillic acid with bacterial biofilms 
   
104 
and operated for 2 days. Biomass was assessed gravimetrically after drying the sample at 
85°C. 
 
Figure 5.1: Schematic representation of the segmented flow biofilm reactor (A) and the reaction 
scheme for the multi-step bioconversion of (R)-(+)-limonene to (R)-(+)-perillic acid (B). The silicon 
membrane biofilm reactor is supplied with fresh minimal medium and air via Tygon tubes using 
peristaltic pumps. Consecutive air/liquid segments are generated by applying a T-connector. Limonene 
is supplied from a tightly sealed reservoir to avoid substrate evaporation by diffusion through the 
silicon membrane. A cross-section close-up view illustrates the biofilm attachment to the membrane 
and the air/aqueous segmented flow. Abbreviations: cymA (p-cymene monooxygenase), cymB  
(p-cumic alcohol dehydrogenase), cymC (p-cumic aldehyde dehydrogenase), DH (dehydrogenases), 
(R)-(+)-limonene (1), (R)-(+)-perillyl alcohol (2), (R)-(+)-perillyl aldehyde (3), (R)-(+)-perillic acid (4). 
The figure was adapted from Karande and co-workers (Karande et al., 2014). 
Production of perillic acid in a segmented flow biofilm reactor. For the biofilm-based 
perillic acid production, in principle the same setup as described above was applied, but 
silicon tubes with an inner diameter of 2 mm, a wall thickness of 1 mm, and a length of 
1000 mm were used (Figure 5.1). Additionally a second peristaltic pump was installed and 
connected to the system via a T-connector. After 3 days of continuous single phase flow 
(0.1 ml min-1), air segments were introduced at flow rates of 0.4 ml min-1. Sterility of the 
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introduced air segments was ensured by installing a syringe filter (0.2 µm, polyether sulfone 
membrane, VWR, Germany) (Figure 5.1). Upon reactor inoculation, 20 mL (R)-(+)-limonene 
were added to the flask containing the coiled reactor tubing which allowed 20 - 40% of the 
tubing to be submerged into limonene. The perillic acid concentration was assessed after 
extraction of the reactor outflow with Et2O at previously defined time points. Dilution rate: 
2 h-1 (at least 4-5 times higher than the maximum specific growth rate of the strains used). 
Purification of perillic acid. As described before (Mirata et al., 2009), the Amberlite IRA 410 
Cl resin was used to absorb perillic acid from the reactor outflow. Prior to use, the resin was 
treated with ethanol and water (Mirata et al., 2009). Twelve grams of washed resin were 
applied to adsorb 80% of the perillic acid from 0.4 L reactor outflow within 4 h of binding. 
Perillic acid was eluted with a mixture of 4 M HCl and ethanol (40:60, volumetric ratio) at 
30°C. A second elution step was performed via ethyl acetate treatment. The aqueous and the 
organic fraction were combined and subjected to distillation in a rotary evaporator to remove 
ethanol and ethyl acetate. The precipitate was removed by filtration. The filtrate was treated 
with HCl to precipitate perillic acid. 
5.4 Results 
Recombinant P. taiwanensis VLB120 show high perillic acid formation rates. As 
P. taiwanensis VLB120 is not natively hydroxylating limonene, the respective genes had to 
be introduced heterologously. The genes for the monooxygenase (cymAa), the respective 
reductase (cymAb) and the putative p-cumic alcohol dehydrogenase (p-cumic ADH) were 
isolated from the genomic DNA of P. putida GS1 and cloned into an expression vector under 
control of the Plac promoter to construct a P. taiwanensis VLB120 capable of perillic acid 
formation. P. taiwanensis VLB120 harbors a variety of alcohol and aldehyde dehydrogenases 
(Lang et al., 2014) and, therefore, we hypothesized that additional expression of the p-cumic 
aldehyde dehydrogenase would not be necessary. Activity assays have been performed 
supplying the substrate limonene to resting cells of P. taiwanensis VLB120 to verify 
functional expression of both recombinant genes. Indeed, resting cells of P. taiwanensis 
VLB120 harboring only the monooxygenase cymA (pCom10L:CymA) showed perillic acid 
formation (Figure 5.2A) with a rate of approximately 4.5 U gcdw-1 upon addition of 2 mM 
limonene. Apparently, intrinsic dehydrogenases or cymA itself catalyzed further oxidation to 
the acid. Coexpression of the p-cumic ADH, however, led to increased perillic acid formation 
(Figure 5.2B) and doubled the specific production rate.  
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Figure 5.2: Biomass-specific production of oxygenated limonene products during a resting cell assay 
with P. taiwanensis VLB120 harboring either pCom10L:CymA (A) or pCom10L:CymAB (B). Cells 
were harvested six hours after induction of gene expression with 1 mM IPTG. Concentrations of 
perillic acid (■), perillyl aldehyde (♦), and perillyl alcohol (▲) were assessed by GC. After the cells 
were incubated in minimal medium with citrate, the resting cell assays were performed in 0.1 M 
potassium phosphate buffer (pH 7.4) at 30°C and orbital shaking. The error bars were retrieved from 
standard deviations of two independent cultivations and assays (biological duplicates). 
Although perillic acid was the major product in both cases, perillyl alcohol and aldehyde 
accumulated to a molar fraction of more than 50% (sum) when only cymA was expressed, 
whereas they constituted less than 10% when cymA and cymB were expressed simultaneously. 
Therefore, we conclude that concerted activity of cymA and cymB in P. taiwanensis VLB120 
reduced by-product formation. In summary, it was verified that functional recombinant 
expression of the genes cymA and cymB in P. taiwanensis VLB120 was sufficient to produce 
perillic acid as the major product of limonene oxidation. In order to evaluate its 
competitiveness with the native production strain P. putida GS1 in a microbial perillic acid 
production process the impact of the reactants on the physiology of P. taiwanensis VLB120 
and P. putida GS1 towards the reactants had to be investigated. 
P. putida GS1 tolerates higher concentrations of perillic acid and limonene than 
P. taiwanensis VLB120. Toxicity assays were performed to compare the physiological 
response of both P. putida GS1 and P. taiwanensis VLB120 towards limonene and perillic 
acid. P. putida GS1 showed an exceptional tolerance towards the monoterpene limonene 
(logP = 4.46, (Sikkema et al., 1995)). The growth yield of this strain remained unaffected by 
limonene concentrations as high as 225 mM (Figure 5.3A). In contrast, the growth of 
P. taiwanensis VLB120 was completely inhibited by limonene concentrations between 50 and 
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75 mM (Figure 5.3A). The observed effect might have arisen from phase rather than 
molecular level toxicity as limonene is barely soluble in water (less than 0.1 mM).  
 
Figure 5.3: Effect of varying limonene (A) and perillic acid (B) concentration to the final biomass 
yield of P. taiwanensis VLB120 (■) and P. putida GS1 (●). Different concentrations of the 
compounds were added directly after inoculation. For the limonene toxicity evaluation, the gaseous 
phase was saturated with limonene via an evaporation container to avoid limonene loss. Experiments 
were carried out in M9* with citrate as sole carbon and energy source and the error bars refer to 
standard deviations obtained from two independent cultivations (biological duplicates). 
Perillic acid (logP = 3.59) was highly toxic towards both strains, and growth was completely 
inhibited in either case at 60 mM. Interestingly, a different profile of perillic acid dependent 
growth inhibition was observed for P. taiwanensis VLB120 as compared to P. putida GS1 
(Figure 5.3B). Biomass yield first dropped and then stayed constant between 10 and 35 mM 
perillic acid for P. taiwanensis VLB2120 while it continuously dropped in P. putida GS1. A 
similar behavior with respect to the toxicity profile was also observed for the concentration 
dependent toxicity analysis of perillyl alcohol towards P. putida KT2440 (Cornelissen et al., 
2011). It is therefore essential to regulate perillic acid concentrations below 35 mM in the 
aqueous phase for developing an efficient production process. 
Hydroxylation of limonene to perillic acid or perillic acid degradation was not observed 
within the experimental time window with either strain. In conclusion, P. putida GS1 is 
superior in terms of resilience to both limonene and perillic acid as compared to 
P. taiwanensis VLB120. Nevertheless, P. taiwanensis VLB120 is a known biofilm producer 
and has been used successfully for the biofilm-based production of toxic compounds such as 
(S)-styrene oxide (Gross et al., 2010; Halan et al., 2011), octanol (Gross et al., 2013), and (S)-
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3-hydroxyisobutyric acid (Lang et al., 2015). Since P. taiwanensis is very well characterized 
under biofilm conditions and important process parameters have been described, it is 
worthwhile to include P. taiwanensis VLB120 as a potential production strain albeit the lower 
resistance against limonene and perillic acid. Biofilm formation capability of P. putida GS1 is 
unknown and has yet to be investigated. 
Biofilm formation capacity is dependent on the carbon source. In order to investigate 
whether P. putida GS1 is capable of forming biofilms, the strain was cultivated in M9* 
minimal medium with either glucose, glycerol, or citrate as sole carbon and energy source. 
These cultures were then used to inoculate a tubular biofilm reactor.  
 
Figure 5.4: Evaluation of biofilm formation capacity of P. taiwanensis VLB120 (grey bars) and 
P. putida GS1 (white bars) (A). The biofilm dry weight was assessed after cultivation of the respective 
strain with either glycerol, glucose, or citrate (0.5% (w/v)) under single-phase continuous flow 
(0.1 ml min-1) for two days. The error bars refer to standard deviations obtained from three 
independent cultivations (biological triplicates). Panel B shows a photographic image of the freshly 
harvested biofilm of either of P. taiwanensis VLB120 and P. putida GS1 cultivated with citrate as sole 
carbon and energy source. Panel A of the figure is based on data reported in the Bachelor Thesis of 
Lisa Karthaus (Karthaus, 2014). 
For comparison, the well-characterized biofilm forming strain P. taiwanensis VLB120 was 
cultivated as well. The biofilm dry weight was assessed after three days of continuous flow 
with the respective medium. P. putida GS1 formed substantial amounts of biofilm (up to 
7 gbdw mreactor-2, bdw: biofilm dry weight) in the applied setup, independent of the carbon 
source supplied. In contrast, P. taiwanensis VLB120 showed a clear preference for citrate 
regarding biomass formation (15 gbdw mreactor-2) (Figure 5.4). This is in agreement with the 
specific growth rates during batch cultivation in shake flasks of this strain with the respective 
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carbon sources (data not shown). In conclusion, both strains are capable of forming biofilms 
and producing perillic acid and therefore both strains can be investigated regarding their 
potential to produce perillic acid in a continuous flow-through system. 
Biofilm-based perillic acid production is efficient with P. putida GS1 and glycerol as carbon 
source. Mirata and co-workers developed an integrated process for the synthesis of perillic 
acid from limonene with P. putida GS1 (Mirata et al., 2009). The fed-batch based reaction 
setup using controlled feeding of glycerol and limonene, however, suffered from a relatively 
short production time. More than 90% of the perillic acid was produced within the first four 
days of a seven days cultivation (Mirata et al., 2009). Continuous operation of the reactor 
would be desirable to overcome this limitation. Therefore, a production system was developed 
that allowed for the continuous production of toxic perillic acid in a segmented-flow biofilm 
reactor setup (Figure 5.1). The segmented-flow system was harnessed to prevent the limitation 
of oxygen for both cellular growth and the biocatalytic reaction (Karande et al., 2014). 
 
Figure 5.5: Synthesis of perillic acid in a segmented flow biofilm reactor with P. putida GS1 (A) and 
P. taiwanensis VLB120 (pCom10L:CymAB) (B) using either glycerol (●) or citrate (■) as carbon 
source. A single-phase flow of 0.1 mL min-1 was applied during the first two days after inoculation. 
Subsequently, the air flow was started at a flow rate of 0.4 mL min-1 (as indicated by the arrow). The 
perillic acid concentration was assessed by GC after regular sampling from the outlet of the 1 m 
reactor. The error bars refer to standard deviations from at least two independent biofilm experiments. 
The glycerol-based perillic acid formation of P. putida GS1 (Panel A, ●) is based on data reported in 
the Bachelor Thesis of Lisa Karthaus (Karthaus, 2014). 
Both P. putida GS1 (Figure 5.5A) and P. taiwanensis VLB120 (pCom10L:CymAB) (Figure 
5.5B) cultivated on citrate as sole carbon source, showed very little perillic acid formation 
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during the first two days of cultivation (only aqueous flow, 0.1 mL min-1, 0.5% (w/v) citrate). 
Perillic acid formation increased after introducing the air flow (0.4 mL min-1) within the next 
two to three days and reached a plateau productivity value of approximately 5 g Ltube-1 d-1 and 
2.5 g Ltube-1 d-1 for P. putida GS1 and P. taiwanensis VLB120 (pCom10L:CymAB), 
respectively. This productivity remained unaltered high until the experiment was actively 
terminated 12 days after inoculation. Residual citrate concentrations of more than 4 g L-1 were 
detected at the reactor outlet in either case, indicating that availability of the carbon source did 
not limit production during steady state operation. The productivity of P. taiwanensis 
VLB120 (pCom10L:CymAB) biofilms for perillic acid formation remained unaffected by the 
type of carbon source, as cultivation of the biofilm on glycerol resulted in similar 
productivities (2.5 to 3 g Ltube-1 d-1) as compared to the citrate cultivation (Figure 5.5B). This 
however, seems not to match the difference in biomass formation with either citrate or 
glycerol during solely aqueous flow (Figure 5.4A).  
Interestingly, P. putida GS1 cultivated on glycerol produced significantly higher amounts of 
perillic acid at productivities of up to 15 g Ltube-1 d-1 already during the first two days of 
cultivation in single aqueous flow. Additional supply of oxygen via air segments caused a 
drop in productivity due to washout of significant amounts of biomass. Afterwards a second 
generation biofilm was developed. In accordance with that the productivity raised to a peak 
productivity of 35 g Ltube-1 d-1 on the eighth day after inoculation and levels at an average 
productivity of 22 g Ltube-1 d-1 until the end of the experiment (12 days after inoculation). Also 
in this case, the concentration of the carbon source at the outlet of the reactor was higher than 
4 g L-1 and thus not limiting biotransformation. 
In conclusion, the continuous production of perillic acid is feasible with both wild-type 
P. putida GS1 and recombinant P. taiwanensis VLB120 (pCom10L:CymAB) and 
characterized by very high volumetric productivities. P. putida GS1 cultivated on glycerol 
proved to be the favored combination for multi-step biotransformation of limonene into the 
high-value compound perillic acid. 
Adaption of downstream processing yields highly pure perillic acid. Recovery of the 
reaction product from the fermentation broth is often challenging and hampered by low 
aqueous product concentrations (Woodley, 2008). The purification of perillic acid has been 
optimized and reported to profit from a resin-based in situ product removal technique 
applying a cationic adsorption matrix (Mirata et al., 2009). Therefore, a portion of the biofilm 
efflux was collected and the perillic acid was allowed to adsorb to the cationic coating 
(benzyldimethyl-(2-hydroxyethyl)ammonium) of the resin for 24 h. The adsorbed perillic acid 
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was eluted in two steps using 4 mol L-1 HCl/EtOH and ethyl acetate, respectively. After 
removing the solvent, perillic acid was obtained (Figure 5.6) at a purity of approximately 96% 
(GC) and an isolation yield of 60%. This finally proves that the biofilm based production in 
combination with a potent downstream technique can be utilized for the preparative 
production of the high value compound perillic acid. 
 
Figure 5.6: Crystalline (R)-(+)-perillic acid at a purity of approximately 96%. The product at the 
reactor outlet was adsorbed to a cationic resin, eluted with an ethanol/HCl mixture and ethyl acetate. 
After removing the solvents, perillic acid was crystallized by the addition of hydrochloric acid. The 
figure was adapted from the Bachelor Thesis of Lisa Karthaus (Karthaus, 2014). 
5.5 Discussion 
Typically, continuous bioproduction processes are desirable at industrial scale because of 
stable productivities, long running-times, and comparatively low operational maintenance 
requirements (Al-Kaidy et al., 2014). However, the continuous bioproduction of compounds 
with physicochemical properties (e.g., volatility, toxicity) that do not match with native 
microbial products is constrained by both biological and technical parameters (Chapter 6). By 
applying solvent-tolerant Pseudomonas species expressing the perillic acid biosynthesis 
pathway either natively or recombinantly in a segmented flow biofilm reactor both, the 
biological and technical components were exploited. P. putida GS1 and P. taiwanensis 
VLB120 have been isolated based on their capability of degrading toxic agents (Panke et al., 
1998; Speelmans et al., 1998). P. putida GS1 tolerated very high limonene concentrations, but 
growth was completely inhibited at perillic acid concentrations of 60 mM and higher. This 
finding is in contrast to the results of an earlier study showing that growth was completely 
inhibited at 167 mM perillic acid (Mirata et al., 2009). In contrast to Mirata and coworkers 
(Mirata et al., 2009) using a complex medium, we used minimal medium for the toxicity 
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analyses, which has been hypothesized to result in lower expression levels of solvent efflux 
pumps in another Pseudomonas strain (Volmer et al., 2014) and thus a reduced tolerance 
capacity of the microbial cell. P. taiwanensis VLB120 has been found to be generally more 
susceptible to both limonene and perillic acid. In contrast to perillic acid, limonene toxicity 
appeared to be caused by phase toxicity effects. Dissecting the underlying mechanisms for 
this and the difference between both strains would require more sophisticated genotypic and 
phenotypic analyses and was therefore beyond the scope of this study. 
The combination of the biocatalyst configuration of naturally immobilized cells and the 
tubular flow-through membrane biofilm reactor were harnessed for continuous perillic acid 
production and efficient product removal to prevent toxification. The productivity of P. putida 
GS1 for perillic acid production could be increased almost fourfold as compared to the fed-
batch process (Mirata et al., 2009), partially as a result of the increased biomass density 
within the biofilm reactor. However, the comparison of these two systems is biased by the 
small volumes applied in the biofilm-based production setup. The maximally achieved perillic 
acid concentrations at the outlet the biofilm reactor (~5.6 mM) remained below the critical 
concentration for suspended cells (approximately 39 mM for P. putida GS1). Thus, a further 
increase in productivity seems not yet to be limited by toxicity. However, it has to be noted 
that local concentrations in the vicinity of the biocatalyst might be significantly higher 
because the catalytically active biofilm is located close to the silicone membrane.  
The productivity of P. putida GS1 biofilms cultivated on glycerol is up to sixfold higher than 
the productivity of the same strain cultivated on citrate although biofilm formation under both 
conditions was comparable. This implies that limonene availability was not limiting for the 
setup on citrate. Increase of the air flow rate to 0.6 mL min-1 in the glycerol-based cultivation 
did not lead to a further increase in productivity (data not shown). This indicates with citrate 
as carbon source, the oxygen mass transfer was not limiting perillic acid production either. 
This conclusion is in accordance with previous work reporting significantly higher 
productivities of up to 46 g Ltube-1 d-1 for the oxygen-dependent bioconversion of styrene to 
(S)-styrene oxide with P. taiwanensis VLB120∆C using the same technical setup (Karande et 
al., 2014). Therefore, we conclude that the increase in productivity is rather attributed to 
higher expression levels of the genes from the cym operon with glycerol as carbon source 
which is in accordance to previously published results (Speelmans et al., 1998). It might be 
also speculated that expression from of the cym genes is subject to catabolite repression in 
presence of organic acids including citrate (Kurbatov et al., 2006; Wolff et al., 1991).  
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In contrast, perillic acid production with the recombinant strain P. taiwanensis VLB120 
(pCom10L:CymAB) was not affected by the type of the carbon source leading to the 
assumption that cymA and cymB are expressed to the same levels under glycerol and citrate 
conditions. This is further supported by the fact that resting cells retrieved from cultivations 
with either carbon source showed similar perillic acid formation rates. It seems reasonable to 
assume that similar biofilm formation is observed under segmented flow conditions although 
assessing the biofilm capacity under single phase conditions (Fig. 2A) revealed significant 
differences in biomass formation with glycerol or citrate. Besides the efficient delivery of 
oxygen, the introduction of air segments also shifts the otherwise structurally random growth, 
which might lead to blocking of the capillary (Muffler et al., 2014) towards an even and dense 
second generation biofilm layer of constant thickness (Karande et al., 2014). Nevertheless, 
biomass formation has to be evaluated under process conditions in order to allow reliable 
conclusions on the connection of biomass formation and productivity. This is part of ongoing 
work. The overall productivity of P. taiwanensis VLB120 (pCom10L:CymAB) is 
approximately 10-times lower than the productivity of P. putida GS1 during the glycerol-
based cultivation. It might be speculated that the reduced productivity, assuming comparable 
biofilm-formation of both strains, is caused by lower expression levels of the involved 
pathway enzymes in the recombinant host. Furthermore, auxiliary roles of other enzymes, 
such as other dehydrogenases (cymC) or putative uptake proteins (cymD), from the cym 
operon in the native host cannot be excluded (Eaton, 1997). Accumulation of perillyl alcohol 
and perillyl aldehyde during the resting cell assays with P. taiwanensis VLB120 
(pCom10L:CymAB) was observed, although perillic acid was the major limonene oxidation 
product. This points towards kinetic limitations on the levels of the heterologous alcohol 
dehydrogenase cymB and the native aldehyde dehydrogenases. Optimization and balancing of 
the gene expression in the recombinant pathway would certainly improve perillic acid 
production, especially as accumulation of intermediates is not reported for the wild-type 
P. putida GS1 (Mars et al., 2001; Speelmans et al., 1998). Noteworthy, no intermediate 
products were accumulated during the biofilm based production of perillic acid using 
P. taiwanensis VLB120.  
Yet, the achieved concentrations of perillic acid were significantly lower as in the previously 
reported fed-batch process (Mirata et al., 2009). Nevertheless, the small volume of the tubular 
reactor has to be taken into account and considered as a tunable parameter by retaining the 
advantages gained from the miniaturization. Therefore, it seemed logical to increase the 
catalytically active area simply by enhancing the longitudinal dimension of the tubular 
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bioreactor. Using a reactor length of 5 m in instead of 1 m for perillic acid production with 
P. putida GS1 cultivated on glycerol, however, resulted in decreased productivities and only 
twofold increase in total product amount after 20 days of operation (data not shown). Most 
likely this can be attributed to an oxygen limitation, which might be overcome by using 
oxygen enriched air segments. 
Traditional strategies for the scale-up of bioprocesses are based on constant kLa values, 
dimensionless numbers (e.g., Damkoehler number), or geometrical similarities (Marques et al., 
2010). In our case, upscaling without losing the miniaturization advantages (diffusion 
distance, high surface area) might be successful by parallelization (numbering-up) of the 
tubular setup (Warikoo et al., 2012; Wohlgemuth et al., 2015). In that respect a bundle of only 
thirty parallel tubes would be required for the production of 100 g perillic acid with P. putida 
GS1 within one month and increasing the cumulative tube volume to one liter would even 
yield more than 1 kg perillic acid. The combination of the continuous perillic acid production 
with the powerful resin-based in situ product removal (Mirata et al., 2009) would alleviate 
challenges connected to the large and highly diluted outlet stream, which pose typical 
problems in continuous biotechnological syntheses (Stark and von Stockar, 2003), and for the 
production of this high value compound at larger scale. In conclusion, we demonstrated that 
the continuous multi-step biotransformation of limonene to perillic acid is enabled in a tubular 
biofilm reactor at very high productivities. The product could be recovered from the outlet 
stream and purified to be used for downstream applications. The biofilm reactor concept can 
be transferred to other reactions involving volatile reactants and toxic end products to perform 
efficient multi-step biocatalysis. 
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6.1 Abstract 
The recent progress in sustainable chemistry and in synthetic biology increased the interest of 
chemical and pharmaceutical industries to implement microbial processes for chemical 
synthesis. However, most organisms used in biotechnological applications are not evolved by 
Nature for the production of hydrophobic, non-charged, volatile, or toxic compounds. In order 
to overcome this discrepancy, bioprocess design should consist of an integrated approach 
addressing pathway, cellular, reaction, and process engineering. Highlighting selected 
examples, we show that surprisingly often Nature provides conceptual solutions to enable 
chemical synthesis. Complemented by established methods from (bio)chemical and metabolic 
engineering, these concepts offer potential strategies yet to be explored and translated into 
innovative technical solutions enabling sustainable microbial production of non-natural 
chemicals. 
6.2 Introduction 
The application of microbial organisms for the synthesis of chemicals has a long lasting 
history. Especially the production of amino acids, organic acids, alcohols and proteins, from 
carbon sources like glucose via traditional fermentations has been implemented successfully 
and is widespread in industry (Sun and Alper, 2014). These compounds are frequently 
common metabolites of synthetic pathways and reaction environments evolved and optimized 
by Nature. From a physicochemical perspective, these products share properties such as 
hydrophilicity and high water solubility, they are often charged and show relatively low 
toxicities for the production strain. The cellular membrane forms an efficient barrier for these 
molecules and plays a pivotal role enabling chemistry involving compounds with these 
properties. Mass transfer of charged molecules in either direction is only facilitated by active 
or passive transport mechanisms. This allows the cell to maintain intracellular homeostasis 
and osmotic pressure (Silhavy et al., 2010). Many interesting chemicals for chemical or 
pharmaceutical industries, however, are complex molecules with properties such as 
hydrophobicity, low water solubility, a high degree of reduction, and toxicity to 
microorganisms (Figure 6.1). In Nature, synthesis or metabolism of these compounds is often 
restricted to specialized organisms. Frequently, the reactions are confined to parts of 
organisms or organelles, which are seldom of industrial use because of slow growth, 
fastidious nutrient requirements, and limited scalability (Zhang et al., 2011). Nature evolved a 
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system of superordinate conceptual strategies for synthesis, storage, and function of volatile, 
toxic, and hydrophobic chemicals (see Table 6.1). 
 
Figure 6.1: Graphical arrangement of common microbial substrates and metabolites (‘natural’) and 
industrially interesting compounds (‘technical’) based on the physicochemical properties water 
solubility, vapor pressure, and logP value (obtained via www.chemspider.com). The data table for this 
figure is given in chapter 9.2 The development of sustainable and efficient biocatalytic processes 
demands an integrated strategy to bridge discrepancies between microbial metabolites (green) and 
industrially interesting chemicals (blue, red, black). For this, several constraints derived within the 
four levels of bioprocess engineering need to be addressed in a concerted rather than a sequential 
mode. Concepts and solutions to modulate constraints highlighted in red color are specifically 
elaborated in the text. 
Chapter 6: General discussion 
   
118 
Today, methodologies of metabolic engineering and synthetic biology like rapid DNA 
synthesis and assembly allow a fast and straight forward design, optimization, and 
construction of natural and artificial biosynthetic pathways in recombinant microorganisms. 
The potential of these methodologies is exploited for syntheses of value added chemicals and 
natural products with low abundance in Nature (Lee et al., 2012). Consequently, a vast 
amount of useful compounds from different classes of chemicals, i.e., alkanes and olefins (Liu 
et al., 2014), aromatics (Kunjapur et al., 2014), terpenoids (Nowroozi et al., 2014), and 
polyketides (Jiang and Pfeifer, 2013) has been produced from renewable feedstocks with 
genetically modified microorganisms. Despite this impressive progress, the majority of 
processes remained at the proof-of-principle stage yielding product concentrations in the 
milligram per liter range. For the economic production of fine chemicals, however, final 
concentrations and volumetric productivities exceeding 50 g L-1 and 1 g L-1 h-1, respectively, 
are required (Straathof et al., 2002). Porro et al. already addressed this issue recently in an 
excellent review and concluded that the production of valuable compounds in microbial cells 
should be restricted to compounds matching the requirements determined and possibilities 
offered by the microbial biocatalyst (Porro et al., 2014). In principle, we do agree with this 
argumentation. Yet, there are solutions for the synthesis or transformation of compounds, 
which do not directly match with microbial production. Surprisingly, often these technical 
solutions are inspired by or based on natural concepts. Here, we review recent concepts and 
advances beyond genetic pathway optimization aiming at bridging the apparent discrepancies 
(Figure 6.1) between natural evolution of the microbial cell and its technical applicability for 
the conversion or de novo production of hydrophobic, volatile, reduced and/or toxic 
compounds. As product properties affect both, the (recombinant) biocatalyst and the reaction 
setup, we discuss a framework for bioprocess design guided by physicochemical properties of 
products and intermediates of a given pathway and applying the concerted optimization of 
genetic, metabolic, reaction, and process related parameters (Figure 6.1). 
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Table 6.1: Overview of natural conceptual solutions to cope with toxicity, complexity, hydrophobicity, and volatility of (metabolic) intermediates, substrates 
or products. 
Property Conceptual Solution Mechanism Example Reference(s) 
charge, molecular weight membrane structure confinement of cellular 
interior by selective barriers 
lipid-bilayer, asymmetry, fluidity, pores, 
transporters 
(Silhavy et al., 2010) 
toxicity, spatio-temporal 
organization 
cell compartimentalization confinement of (sub)-cellular 
interior by selective barriers 
lysosomes, plastids, mitochondria 
 
(Zecchin et al., 2014) 
 
toxicity, hydrophobicity,  
structural complexity 
enzyme kinetics maintaining low intermediate 
concentrations by variable 
affinity and catalytic 
efficiency of pathway 
enzymes 
decreasing KM with increasing molecular 
mass and hydrophobicity 
(Bar-Even et al., 
2011) 
toxicity degrading enzymes degradation of potentially 
harmful intermediates 
degradation of ROS by catalases, 
peroxidases, and dismutases  
(Imlay, 2008) 
 
specific export ABC-transporter mediated 
export of potentially harmful 
substances 
linKLMN mediated export of 2,5-
dichlorophenol during γ-
hexchlorcyclohexane degradation by 
Sphingobium japonicum 
(Endo et al., 2007) 
 
adhesion bacterial adhesion to surfaces 
and excretion of protecting 
and stabilizing substances 
sessile behavior and biofilm formation 
leads to increased resilience of microbial 
communities against antibiotics 
(Costerton et al., 
1995) 
complexity scaffolding establishing of spatial 
proximity or proper 
arrangement for consecutive 
or concerted non-equivalent 
reactions 
thiotemplated PK or NRP synthesis 
machineries 
(Wang et al., 2014) 
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Property Conceptual Solution Mechanism Example Reference(s) 
complexity protection groups prevention of unwanted side 
reactions by promiscuous 
enzyme activity or chemical 
reactivity 
acetylation of glutamate during arginine 
biosynthesis to prevent undesired 
cyclization 
(Dairi et al., 2011) 
volatility unspecific export diffusive excretion of volatile 
compounds in plants 
plant volatile compounds such as 
monoterpenes, aldehydes and esters are 
passively excreted in order to fulfill their 
function as messenger etc. 
(Pichersky et al., 
2006) 
 
dedicated synthesis compartments synthesis of volatile 
compounds near the place of 
function 
biosynthesis of methylbenzoate in the 
epidermal cells of floral organs 
(subsequent excretion) 
(Kolosova et al., 
2001) 
 
dedicated storage compartments synthesis of volatile 
compounds near the place of 
function and storage  
biosynthesis of monoterpenes in plant 
glandular trichoma cells and storage in oily 
sub-cuticular containers 
(Turner and Croteau, 
2004) 
hydrophobicity specific import hydrophobic pores in the 
outer membrane 
outer membrane protein ompW of E. coli 
facilitates uptake of hydrophobic 
molecules 
(Hong et al., 2006) 
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6.3 Guidance of bioprocess design by physicochemical properties 
As described recently in a review by Volmer et al., microbial production processes for 
chemical syntheses are governed by the specific demands of the applied whole-cell 
biocatalyst in interplay with the so-called technical ecology of the respective reaction 
environment (Volmer et al., 2015). Equally important, bioprocess design is determined by 
intrinsic physicochemical properties of the product (or intermediates) of interest, especially 
for compounds, which do not meet the functional boundaries of the microbial biocatalyst 
designed by evolution. The thermodynamic feasibility and balancing of the chemical 
synthesis in terms of stoichiometry, redox equivalents, and energy are certainly decisive 
features for an economic production process (Porro et al., 2014). Many studies aiming at the 
de novo or multi-step syntheses of industrially relevant compounds, however, focus on 
genetic and metabolic engineering only. For further details, the reader is referred to excellent 
reviews and references therein covering the concepts and tremendous achievements in these 
fields, e.g., (Jones et al., 2015). The successful implementation of an industrial process 
however, relies on more than the genetic and metabolic optimization of the heterologous host 
(Figure 6.1). Engineering within four different but mutually interfering levels, namely 
genetic/pathway, metabolic/cellular, reaction, and process engineering, in a concerted rather 
than in a successive fashion might shift a given bioprocess into an operational window 
making it feasible (Woodley and Titchener-Hooker, 1996). For industrial biotransformations, 
an immense methodical repertoire based on reaction and process engineering strategies is 
available and can be adapted for fermentative and multi-step synthesis strategies in chemical 
biotechnology. In order to cope with challenging physicochemical properties, some of the 
natural conceptual synthesis concepts summarized in Table 6.1 can be translated into 
corresponding technical counterparts in a microbial environment addressing constraints on the 
level of biocatalyst selection, biocatalyst modification, biocatalyst configuration, reaction 
engineering as well as reactor format (see Table 6.2). 
Biocatalyst Selection. Biocatalyst selection primarily focuses on the ability of an organism to 
synthesize the targeted enzymes and to catalyze corresponding reactions at high and stable 
rates with reduced formation of side products. However, certain physiological properties can 
also be exploited to improve production processes. In order to minimize biocatalyst 
toxification, the selection of microbial strains less sensitive for organic substrates and 
products is a vital approach (Heipieper et al., 2007). Solvent-tolerant Pseudomonas strains 
have been successfully applied for the microbial production of isobutyric acid (Lang et al., 
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2014) from glucose. The production of geranic acid from glycerol with recombinant P. putida 
(0.193 g Laq-1) has been reported as well, although the product concentration was probably 
below the toxicity limit (Mi et al., 2014). 
The lipopolysaccharide layer on the asymmetrical outer membrane of Gram-negative bacteria 
is hydrophilic and forms an efficient barrier for hydrophobic molecules. From an evolutionary 
point of view this seems to be a pivotal adaptation, but in a biotechnological application this 
results in a mass transfer limitation for hydrophobic substrates. Therefore, the ability of 
P. aeruginosa to produce and secrete rhamnolipids, which were shown to be involved in 
enhanced hexadecane uptake, might be exploited for biotechnological synthesis suffering 
from insufficient uptake of hydrophobic compounds (Noordman and Janssen, 2002). The 
selection of a Gram-positive host Bacillus subtilis 3C5N featuring a moderately hydrophobic 
surface for the one-step bioconversion of cyclohexene into epoxyhexane resulted in a 3.7-fold 
higher specific reaction rate and an enhanced resistance towards the product compared to 
E. coli (Siriphongphaew et al., 2012). 
In analogy to this approach, the inability of E. coli to take up large hydrophobic terpenoic 
acids inspired the development of a recombinant B. megaterium strain carrying CYP106A2 
for the specific hydroxylation of 11-keto-β-boswellic acid (Bleif et al., 2012). With respect to 
biocatalyst selection, it has to be taken into account that certain issues, especially related to 
toxicity, become relevant when optimization by, e.g., genetic engineering and reaction 
engineering, is already conducted in a host of first choice. Switching the host on a later time 
point in process development is often problematic, which makes early and careful biocatalyst 
selection crucial. 
Biocatalyst Modification. Biocatalyst uptake of hydrophobic substrates has also been 
addressed by biocatalyst engineering approaches. The hydroxylation and subsequent 
oxidation of dodecanoic methyl ester to 12-oxododecanoic methyl ester, a precursor for the 
fabrication of Nylon-12, with recombinant E. coli W3110 harboring the alkane 
monooxygenase AlkBGT was increased 62-fold by coexpression of alkL from P. oleovorans 
GPo1 (Julsing et al., 2012b). 
AlkL putatively forms a hydrophobic pore in the outer membrane (Grant et al., 2014), which 
facilitates mass transfer. Biotransformations of other hydrophobic substrates, i.e. alkanes (C8-
C16) (Grant et al., 2014; Julsing et al., 2012b), limonene (Cornelissen et al., 2013), or 
dodecanoic acid (Scheps et al., 2013) have also been shown to benefit from incorporation of 
AlkL in the outer membrane. 
C
h
a
p
te
r 6
: G
e
n
e
ra
l d
iscu
ssio
n
 
 
 
 
1
2
3
 
 
Table 6.2: Overview of technical conceptual solutions to cope with toxicity, complexity, hydrophobicity, and volatility of (metabolic) intermediates, 
substrates, or products. 
Constraint Property/Issue  Conceptual Solution Reaction Remarks Reference(s) 
Biocatalyst 
Selection 
hydrophobicity gram-positive host cyclohexene → 1,2-
epoxyhexane 
11-Keto-β-boswellic acid → 
15α- hydroxyl-11-keto-β-
boswellic acid 
Bacillus sp. as alternative host 
strain, featuring a moderately 
hydrophobic cell surface to enhance 
uptake 
(Bleif et al., 2012; 
Siriphongphaew et al., 
2012) 
 
toxicity usage of a more tolerant 
host 
production of isobutanol or 
geranic acid from glucose 
solvent tolerant recombinant 
Pseudomonads 
(Lang et al., 2014; Mi et 
al., 2014) 
Biocatalyst 
Engineering 
toxicity efflux pump engineering glucose → (S)-(-)-limonene coexpression of an efflux pump 
from A. borkumensis together with 
the limonene pathway 
(Dunlop et al., 2011) 
 
toxicity efflux pump engineering styrene → (S)-styrene oxide deletion of ttgV (transcriptional 
repressor of TtgHI solvent efflux 
pump), twofold increased 
epoxidation activity 
(Volmer et al., 2014) 
 
toxicity/flux scaffolding glucose → mevalonate mevalonate (MVA) pathway protein 
scaffolds to reduce diffusion of the 
toxic intermediate HMG-CoA, 77-
fold increase in MVA levels 
(Dueber et al., 2009) 
 
toxicity fusion protein glucose → pinene fusion of GPP synthase and pinene 
synthase to relieve GPP toxicity (Sarria et al., 2014) 
Biocatalyst 
Engineering 
hydrophobicity enzyme localization glucose → C12-C14 PHA soluble fatty acyl-CoA synthetase, 
fivefold increase of PHA by 
preventing CoA ligation prior to 
fatty acid excretion  
(Agnew et al., 2012) 
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Constraint Property/Issue  Conceptual Solution Reaction Remarks Reference(s) 
Biocatalyst 
Engineering 
hydrophobicity cell permeabilization terminal hydroxylation of 
dodecanoic acid, dodecanoic 
methyl ester, or limonene 
relieve of the substrate uptake 
limitation by coexpression of the 
outer membrane pore protein AlkL 
from P. putida GPo1 
(Cornelissen et al., 
2013; Julsing et al., 
2012b; Scheps et al., 
2013) 
Biocatalyst 
Configuration 
toxicity adhesive cells styrene → (S)-styrene oxide small scale and scale-up of biofilm 
based styrene oxide production 
using P. taiwanensis sp VLB120 
(Halan et al., 2014; 
Karande et al., 2014) 
 
complexity/enzyme 
promiscuity  
mixed cells 2- alkylidene-
cyclopentanones → (R)-δ-
Lactones 
consecutive biotransformation with 
Acinetobacter sp. RS1 and E. coli, 
separation prevented unwanted 
oxidation of the substrates by E. coli  
(Liu and Li, 2013) 
 
hydrophobicity cell permeabilization abietic acid → 15-
hydroxyabietic acid 
relieved substrate uptake limitation 
by permeabilization via polymyxin 
B 
(Janocha and Bernhardt, 
2013) 
 
hydrophobicity mixed cells benzaldehyde → (1R,2R)-1-
phenylpropane-1,2-diol 
application of mixed resting cells in 
a micro-aqueous reaction 
environment (MTBE) 
(Wachtmeister et al., 
2014) 
 
hydrophobicity/volatility mixed cells  glucose → (S)-(-)-perillyl 
acetate 
mixed-strain resting cell 
fermentation, overcoming of 
limiting limonene availability by 
overrepresentation of limonene 
producing strain 
Chapter 3 
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Constraint Property/Issue  Conceptual Solution Reaction Remarks Reference(s) 
Reaction setup toxicity ISPR: resin (R)-(+)-limonene → (R)-(+)-
perillic acid 
P. putida DSM12264 in STR, ISPR 
via a cationic resin to efficiently 
remove the toxic perillic acid 
(Mirata et al., 2009) 
 
toxicity ISPR: resin glucose → (S)-(-)-perillyl 
alcohol 
selected anion exchange resin that 
preferentially binds the final product 
perillyl alcohol but not the 
intermediary limonene 
(Alonso-Gutierrez et 
al., 2013) 
 
toxicity ISPR:resin ferulic acid → vanillin multi-step biotransformation with 
Amycolatopsis sp. ATCC 39116 in 
solid-liquid two-phase partitioning 
bioreactor 
(Ma and Daugulis, 
2014) 
 
toxicity ISPR: liquid-liquid 
extraction 
glucose → styrene 
glycerol → (S)-(-)-limonene 
two-liquid phase fermentations with 
the water immiscible solvents 
BEHP or DINP 
(McKenna et al., 2015) 
Chapter 2 
 
toxicity/volatility ISPR: pervaporation benzyl alcohol → 
benzaldehyde 
P. pastoris based biotransformation, 
in situ product removal facilitated 
by internal tubing that allows 
pervaporation of benzaldehyde 
(Craig and Daugulis, 
2014) 
 
volatility ISPR: gas stripping glucose → isoprene 
glucose → isobutanol 
fermentation processes from glucose 
to very high levels of isoprene or 
isobutanol, product accumulation 
and recovery from the gas phase 
(Coelho et al., 2014) 
(Baez et al., 2011) 
 
toxicity substrate feed eugenol → vanillin 
 
multistep biotransformations of 
eugenol (30 L scale), eugenol feed 
to maintain volumetric 
concentration of 0.1% (v/v) 
(Overhage et al., 2003) 
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Overexpression of efflux pump genes can be applied to reduce toxic effects of both 
intracellular products as well as organic solvents applied in two-liquid phase systems on the 
biocatalyst (see below). In this respect, a P. taiwanensis VLB120 strain deficient in the 
transcriptional repressor ttgV of the operon encoding the RND-type efflux pump ttgGHI was 
developed. In contrast to the parental strain, the knock-out recombinant grew in the presence 
of 1% (v/v) toluene without the need of tedious adaptation and without an initial lag phase. It 
showed twofold improved specific styrene epoxidation rates (Volmer et al., 2014). The 
fermentative formation of (S)-(-)-limonene from glucose in E. coli harboring an optimized 
limonene biosynthesis pathway was increased by 50% as a result of the overexpression of a 
yet uncharacterized putative efflux pump from Alcanivorax borkumensis. As the achieved 
limonene concentrations were rather low and yet below the toxicity limit (determined via the 
exogenous addition of limonene) it remains questionable whether this improvement is due to 
alleviated toxic effects or the consequence of a metabolic pull by facilitated extrusion of 
limonene (Dunlop et al., 2011). However, the different impact of exogenously added or 
intracellularly produced limonene (or any other toxic compound) remains to be elucidated. 
Another example to reduce toxic effects of reaction intermediates in multi-step pathways is 
linking functionalities spatially. A simple strategy to achieve this is to introduce a protein 
linker in translational fusions forcing the respective fusion partners into spatial proximity and 
thus minimizing the diffusion distance of ,e.g., toxic or volatile intermediates (Chapter 3, 
(Sarria et al., 2014)). However, stoichiometry as a tunable parameter cannot be exploited. 
More sophisticated, but even more complex to implement, is the use of intracellular scaffolds. 
Inspired by conceptual solutions provided by Nature (e.g., polyketide synthases), Dueber et al. 
used a protein scaffold composed of interaction domains from metazoan signaling proteins to 
specifically recruit enzymes from the terpene precursor pathway tagged with appropriate 
binding motifs (Dueber et al., 2009). Impressively, the spatial organization alleviated the 
accumulation of the toxic intermediate 3-hydroxy-3-methyl-glutaryl-CoA and resulted in 77-
fold improved mevalonate levels (Dueber et al., 2009). Apart from using protein-protein 
interactions, the spatial organization can also be achieved by, e.g., RNA structures/scaffolds 
which are recognized by specific protein adapters fused to the pathway proteins of interest 
(Delebecque et al., 2011).  
Biocatalyst Configuration. Whole-cell biocatalysts can be used in different configurations, as 
growing, resting (non-growing but metabolically active), or permeabilized cells, either 
suspended or immobilized. Many biotechnological processes with recombinant microbial 
catalysts are carried out with growing cells to stabilize enzymes in a cellular environment and 
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ensure the supply of redox-equivalents and self-regeneration (Schrewe et al., 2013). However, 
in some cases, the use of resting or permeabilized cells is preferred as it allows a more 
flexible and straightforward optimization of the reaction conditions by separating the growth 
and catalyst production phase from product formation/bioconversion. In addition, resting cells 
also allow the use of substances that are not compatible with microbial growth, such as 
substrates and additives to improve the efficiency of a biocatalytic reaction. Permeabilization 
of recombinant E. coli cells harboring CYP105A2 with polymyxin B or EDTA relieved the 
mass transfer of abietic acid into the cells and resulted in increased hydroxylation rates 
(Janocha and Bernhardt, 2013).  
However, an enzyme-coupled cofactor regeneration system was necessary to supply redox 
equivalents for the reaction, since cofactor regeneration by the cell was not available anymore. 
Exactly, this aspect points out that permeabilization is only suitable for enzymatic reaction 
independent from cell metabolism, which is hardly the case in multi-step catalysis and 
fermentative processes. For metabolism-dependent reactions, resting or non-growing cells 
might be preferred. The rates for the NAD(P)H-dependent epoxidation of styrene (Julsing et 
al., 2012a) and dioxygenation of naphthalene (McIver et al., 2008), were increased two- and 
threefold, respectively, with resting cells as compared to growing cells. This increase might 
be attributed to the absence of the energy requirement for growth (Bühler et al., 2008) and 
therefore characterizes resting cells as important tools in microbial biotechnology. 
A very smart approach applying microbial cells for multi-step biotransformations has been 
reported the by the group of Rother. Spatially separated by solvent-resistant membranes, 
lyophilized cells of two different recombinant E. coli strains harboring either a benzaldehyde 
lyase from P. fluorescens or an alcohol dehydrogenase from Ralstonia sp. were applied for 
the two-step synthesis of (1R,2R)-1-phenylpropane-1,2-diol from benzaldehyde and 
acetaldehyde (Wachtmeister et al., 2014). High substrate loads, the use of a microaqueous 
methyl-tert-butylether environment, high space time yields of up to 3.25 g L-1 h-1, and the 
reusability of the “catalysts in teabags” demonstrate the potential of this approach for 
implementation in a process setting. In general, the application of mixed (resting) cells is an 
attractive idea for biosynthetic cascade reactions as it allows the independent and separate 
optimization of biocatalyst production for different enzymatic steps (e.g. host selection and 
expression conditions) and the adjustment of stoichiometry of the enzymes involved by using 
the different biocatalysts in a defined ratio.  
In a single strain setup with growing or resting cells harboring the entire biosynthesis pathway, 
the availability of limonene as reaction intermediate limited further oxygenation in the 
Chapter 6: General discussion 
   
128 
reaction cascade. In a mixed-strain setup, however, spatial separation of limonene 
biosynthesis from glucose in the first recombinant E. coli strain and limonene oxygenation by 
a second E. coli strain harboring CYP153A6 from Mycobacterium sp. strain HXN-1500 
resulted in the accumulation of perillyl acetate at higher levels (Chapter 3). Production of 
perillyl acetate was enabled by the possibility to increase volumetric limonene synthesis by 
applying ten times more limonene producing cells compared to the amount of limonene 
oxygenating cells. 
The self-immobilization of microbial cells in biofilms as biocatalysts is widespread in Nature 
and provides another promising strategy for the industrial synthesis of chemicals (Halan et al., 
2012). In biofilms, cells are embedded in extracellular polymeric substances (EPS), made up 
of polysaccharides, proteins and DNA. The composition of polysaccharides in EPS 
contributes to change in properties such as electric charge, structure, porosity etc. The 
protective matrix makes microorganisms in biofilms up to 500-fold more tolerant than 
corresponding suspended counterparts (Costerton et al., 1995). Adaptation of the microbial 
life form of biofilms and the concomitant modification of the external environment play a 
crucial role for the survival of microorganisms in varying environments which can be 
exploited in chemical biotechnology. Based on a sixfold higher residual metabolic activity, Li 
et al. showed that Zymomonas mobilis embedded in an EPS matrix are less susceptible 
towards toxic benzaldehyde as compared with their suspended counterparts (Li et al., 2006). 
Thus microbial biofilms provide an elegant concept offered by Nature and to conduct cascade 
reactions involving toxic, hydrophobic, and volatile compounds in a technical context.  
Reaction Setup. Reaction engineering is a major part of bioprocess development, especially 
when non-natural (hydrophobic, toxic, volatile) compounds are involved. One of the most 
frequently applied concepts of reaction engineering aiming to relieve limitations arising from 
toxicity, low solubility, and volatility are multi-phase production systems. The first phase 
(typically the aqueous phase) contains the respective whole-cell biocatalyst and the second 
phase (organic solvent, solid resin, gas) is selected based on the specific properties of the 
product and the tolerance of the biocatalyst. In addition, two-liquid phase systems are 
frequently used for substrate supply and/or in situ product removal. Two factors are 
determining the proper choice of the organic carrier phase: (i) this phase must not be toxic to 
the whole-cell catalyst or volatile itself, and (ii) the preference of the product (substrate) to 
reside in this phase must be much higher as in the aqueous phase (quantified by the partition 
coefficient). As it was shown recently for the fermentative production of styrene from glucose, 
the careful selection of an appropriate organic carrier phase plays a vital role (McKenna et al., 
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2015). The application of bis(2-ethylhexyl)phthalate as organic carrier phase resulted in a 1.6 
or 3.3-fold increased styrene concentration compared to dodecane or the omission of an 
organic carrier phase, respectively (McKenna et al., 2015).  
Besides the use of two liquid phases for in situ product removal (ISPR), several resins were 
successfully applied. The multi-step bioconversion of (R)-(+)-limonene to (R)-(+)-perillic acid 
with P. putida DSM 12264 could be improved by the use of an external loop connected to the 
bioreactor containing an anion exchange resin continuously removing the generated acid from 
the fermentation broth (Mirata et al., 2009). The Amberlite IRA 410 Cl resin efficiently 
lowered the aqueous perillic acid concentration and allowed the cumulative production of 
31 gacid L-1 (Mirata et al., 2009). As limonene is highly volatile and hydrophobic it is 
efficiently removed via the aeration stream of the bioreactor and was therefore used in excess 
(Mirata et al., 2009).  
The recovery of fermentatively synthesized (S)-(-)-limonene has been shown to profit from 
the overlay of the aqueous phase with an organic carrier phase (Chapter 2). For the 
fermentative production of perillyl alcohol, however, the physicochemical properties of the 
intermediate (S)-(-)-limonene limited its hydroxylation. Its extraction into the dodecane 
carrier phase was kinetically favored over the oxygenation (Alonso-Gutierrez et al., 2013). 
Alonso-Gutierrez et al. partially relieved this limitation by omitting the organic phase, which 
led to the formation of perillyl alcohol from glucose (Alonso-Gutierrez et al., 2013). The 
same study reported the removal of the produced perillyl alcohol, which is toxic for the 
applied E. coli strain, from the fermentation broth by selection of a suitable resin selectively 
binding the alcohol and not the limonene intermediate. 
Continuing on the topic of volatility, gas stripping has been successfully applied as an ISPR 
strategy for the production of valuable compounds such as isobutanol at very high titers (Baez 
et al., 2011). For isoprene, a monomer for synthetic rubber production, the combination of 
genetic engineering of the biocatalyst to increase terpene levels with reaction engineering (gas 
stripping) allowed for the formation of industrially significant titers over 60 g L-1 and 
straightforward downstream processing (Coelho et al., 2014). 
Reactor Format. Nature not only remains to be the source of inspiration for biocatalyst 
selection, modification and configuration, but also provides an intuitive insight on how to 
bridge the gap between micro- and macroscopic worlds in a structured and scalable way. In 
addition to classical stirred tank reactor formats and besides numerous other alternatives, 
miniaturization might also offer an opportunity for bioprocess design. The micrometer size of 
a single microbial cell increases the surface area to volume to minimize the diffusion distance 
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and to maximize the nutrient mass transfer essential for cell growth, metabolism, and 
productivity. Other examples include the distribution of air flow in lungs, blood circulation in 
animals, and water transportation in plants. To maximize the mass transfer in these systems, 
larger channels are split in many small channels. The surface areas are thus significantly 
enlarged to minimize the diffusion distance and to maximize mass transfer (Emerson et al., 
2006). Thus, along with the advantages of microfluidics and miniaturization, Nature provides 
a hierarchical and structural strategy to scale biological systems. These designs are stunningly 
different from traditional engineering designs, i.e., stirred tank reactors. Yet, it is important to 
note that industrial process development is also an evolutionary procedure where the fittest 
components are adapted and finally find applications (Weisz, 1973). 
 
Figure 6.2: Selected examples of value added compounds that are obtained at industrial scale via 
fermentative microbial production. In each case, careful synchronization of the bioprocess design with 
the physicochemical properties of intermediates and products led to successful and efficient 
bioproduction. Examples were taken from the references (Sariaslani, 2007) (p-hydroxystyrene), 
(Coelho et al., 2014) (isoprene), and (Paddon et al., 2013) (artemisinin). 
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In a recent example, the use of biofilms as catalyst has been exploited for the 
biotransformation of (S)-styrene to styrene oxide with P. taiwanensis VLB120 in a 
miniaturized system consisting of a tube with a diameter of 2 mm (Gross et al., 2010). The 
biofilm located in the tube was subjected to a biphasic (aqueous:air) flow to ensure sufficient 
oxygen supply and to relieve the mass transfer limitation which significantly increased the 
productivity more that fourfold as compared to a solely aqueous flow (Karande et al., 2014). 
6.4 Conclusion 
The examples highlighted in this review demonstrate that understanding Nature’s solutions 
coping with challenging physicochemical properties can help to overcome current bottlenecks 
and even lead to innovative concepts to design bioprocesses beyond metabolic and genetic 
optimization of microorganisms. The implementation of these concepts is a key step for 
efficient bioprocess design and an inevitable tool for bridging the gap between lab- and 
industrial scale chemical production. Complemented by established methods from 
(bio)chemical engineering, this immense potential is yet to be explored. Three outstanding 
examples providing insight into successful bioprocess design for the de novo synthesis of the 
value added chemicals p-hydroxystyrene (Sariaslani, 2007), isoprene (Coelho et al., 2014), 
and artemisinin (Paddon and Keasling, 2014) are summarized in Figure 6.2. Still, there is a 
long way to go towards a truly bio-based economy, but only systematization (e.g. (Lima-
Ramos et al., 2014)) and combining efforts in genetic, cellular, reaction, and process 
engineering can fuel the realization of economic and ecologically superior industrial processes 
with heterologous microbial production strains.  
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7.1 Conclusion 
The microbial de novo synthesis of biologically active or industrially attractive isoprenoids is 
a rapidly growing research area. A few biotechnological isoprenoid production processes 
(isoprene, artemisinin) have been industrially implemented and are commercialized. Yet, the 
major part of studies report on proof-of-concepts for the synthesis of different isoprenoids by 
enhancing the isoprenoid precursor synthesis by genetic pathway engineering. Often, other 
optimization levels such as reaction engineering are neglected. 
This work aimed at identifying and addressing tunable parameters beyond genetic pathway 
engineering that limit the microbial production of the industrially important monoterpene 
limonene and its value-added oxygenated derivatives. The key findings are concluded in the 
following sections and evaluated within the context of current state-of-the-art microbial 
isoprenoid production processes. 
Microbial isoprenoid production: state of the art. Important process-relevant parameters of 
current microbial isoprenoid production approaches such as final concentration, fermentation 
time, or specific yield are summarized in the introductory chapter of the present work 
(Chapter 1, Table 1.1). A graphical visualization providing a comprehensive survey of current 
isoprenoid production processes is obtained by plotting these parameters (final concentration 
or specific yield) against the fermentation time (Figure 7.1A, B). Both, the industrially decisive 
productivity parameter (Figure 7.1A) as well as the, for strain comparison more meaningful, 
specific catalytic production rate (Figure 7.1B) can be deduced from these plots.  
The best performing process to date is the production of the hemiterpene isoprene with 
recombinant E. coli harboring an optimized heterologous mevalonate pathway. A final 
concentration of more than 60 g Laq-1 and a space time yield of more than 2 g L-1 h-1 were 
achieved (Coelho et al., 2014). The specific yield of this strain was reported to be 
approximately 100 mg gcdw-1, which is significantly higher than the median yield of 
19 mg gcdw-1 of the processes highlighted in Figure 7.1B, but at the same time also significantly 
lower as compared to that of some other hemi-, mono-, or sesquiterpene production 
approaches. In general, the final concentration in the majority of reviewed processes remains 
below 1 g Laq-1 (dashed horizontal line, Figure 7.1A). This is partially attributed to the surplus 
number of small scale (shake flask) proof-of-concept studies but also to the rather low 
specific production yields per gram cell dry weight. Therefore, concentrations exceeding 
1 g Laq-1 can currently only be achieved in bioreactor cultivations featuring higher cell 
densities. 
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Figure 7.1: Graphical representation of the productivity and specific formation rate landscapes of the 
reviewed current isoprenoid production processes (Chapter 1, Table 1.1) and the results of this work. 
The obtained process parameters achieved in this thesis are marked with the specific chapter and 
highlighted with an arrow. The diagonal lines in panel A indicate the minimally required 
productivities for economically feasible fine chemical (dashed line) or pharmaceutical (solid line) 
production (Straathof et al., 2003). The horizontal lines in panel A were chosen arbitrarily and refer to 
final product concentrations of 0.1 (solid) or 1 g Laq-1 (dashed), respectively. The diagonal lines in 
panel B visualize specific production rates of 1 (solid) or 10 mg gcdw-1 Laq-1 (dashed) and were 
introduced to facilitate the assessment the presented values. The horizontal lines in panel B were 
chosen arbitrarily and refer to specific yields of 10 (solid) or 100 mg gcdw-1 (dashed), respectively. 
Color code: Hemiterpenoids (magenta), monoterpenoids (orange), sesquiterpenoids (green), 
diterpenoids (blue), tetraterpenoids (purple). The assignments of the respective numbers are given in 
Chapter 9.3. 
The concentration median of the reviewed processes is 156 mg Laq-1 and, compared to 
concentrations reached in the microbial de novo production of amino acids or alcohols, still 
very low (Sun and Alper, 2014). The type or class of an isoprenoid does not directly influence 
its microbial production, because no significant trends can be observed in either graphical 
representation. This leads to the conclusion that isoprenoid production is not limited by the 
activities of the prenyl transferases and terpene cyclases/synthases. 
Terpene production is limited by precursor availability. Construction of a recombinant  
(S)-(-)-limonene overproducing E. coli strain by introduction of the yeast mevalonate pathway 
increased limonene concentrations more than 60-fold as compared to non-optimized control 
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strains. The high cell density fermentation of this strain in a two-liquid phase setup with 
glycerol as sole carbon and energy source resulted in one of the highest titers reported for the 
production of a monoterpene so far (~1.4 g Laq-1Figure 7.1, Chapter 2). The specific yields in 
the bioreactor were similar to those obtained in shake flask cultivations. This leads to the 
conclusion that limonene production at the bioreactor scale is limited by the biomass 
concentrations and not restricted by physical parameters such as hydrodynamics and mass 
transfer or biological parameters (spatial inhomogeneities). Enrichment of limonene in the 
organic phase allowed the facile purification of enantiomerically pure (S)-(-)-limonene 
(Chapter 2). This provides one of the very few examples demonstrating the preparative 
microbial production of an industrially relevant isoprenoid. Although the achieved product 
titer was rather high, the productivity was still 2.5-fold lower than the reported minimal 
productivity for economically feasible fine chemical production processes of 0.1 mg L-1 h-1 
(Figure 7.1A, dashed diagonal line, (Straathof et al., 2002)). The specific yield with glycerol as 
carbon source (~22 mglimonene gcdw-1) was slightly above the median yield, but significantly 
lower than the average yield (~77 mg gcdw-1) of the reviewed processes. The availability of 
IPP/DMAPP still appeared to be limiting for limonene synthesis, although precursor synthesis 
in the applied strain was enhanced by overexpression of the yeast mevalonate pathway 
(Chapter 2). Many other processes presented in Figure 7.1 featured a higher potential for 
IPP/DMAPP production, because more optimized precursor pathways were harnessed. 
Consequently significantly higher isoprenoid yields were reached. Alonso-Gutierrez and co-
workers achieved an increase of specific limonene production by one order of magnitude 
through the genetic optimization of the heterologous mevalonate pathway (promoter strength, 
genes from different origins) (Alonso-Gutierrez et al., 2013). The achievable titer in high cell 
density fermentations would be almost 15 g Laq-1 when this improvement is transferred to the 
strain and approach applied in this study. This would constitute a very promising starting 
point for the iterative optimization of an efficient industrial production process. Therefore, the 
balanced expression of the involved precursor pathway genes can be considered as a decisive 
factor on the level of genetic engineering for the bioproduction of isoprenoids. 
Limonene availability for oxygenation is alleviated by cellular and reaction engineering. 
The majority of isoprenoid production processes do not include functionalization reactions for 
the aliphatic terpenes produced. In fact, only four of the reviewed processes realized the 
regiospecific oxygenation by coupling of a P450 monooxygenase ((Zhou et al., 2015), 
(Paddon et al., 2013), (Alonso-Gutierrez et al., 2013), (Wriessnegger et al., 2014)), which 
might correlate with the observation that coupling an oxygenation with a P450 
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monooxygenases is a challenging task (Chapter 3). In this work, the physicochemical 
properties (volatility, hydrophobicity) of limonene, favoring its evaporation from the 
cultivation medium, and the rather low limonene synthesis rate were rendered as limiting 
aspects for selective oxyfunctionalization. These aspects were partially counteracted by 
innovative reaction engineering approaches enabling the synthesis of valuable oxygenated 
limonene adducts, which are frequently used in the flavor and fragrance industries. The low 
limonene availability for the P450 monooxygenase was overcome by distributing the 
limonene formation and its hydroxylation amongst two different non-growing but 
metabolically active E. coli strains (Chapter 3). Over-representation of the limonene 
producing strain partially relieved the limitation of precursor availability identified in Chapter 
2 and alleviated the need of laborious genetic engineering strategies. Although the novel 
approach of mixed-culture resting cell fermentations enabled the very fast production of the 
pharmaceutically active oxygenated limonene adduct perillyl acetate, the final concentration 
remained in the lower area (Figure 7.1A, Chapter 3). This is partially caused by rather 
ineffective coupling of limonene synthesis and its oxidation (approximately 0,25 moleperillyl 
acetate per molelimonene) and the overall low limonene production rate. The latter issue can be 
addressed by established methods in genetic pathway engineering, whereas the ineffective 
coupling might be counteracted by the introduction of proteins enhancing limonene uptake, 
i.e., the hydrophic-pore protein AlkL (Cornelissen et al., 2013). Alternatively limonene 
evaporation might be prevented by suitable process design as described for instance in 
Chapter 5. 
Control of microbial growth is a key reaction parameter for isoprenoid production. Many 
studies aiming at the optimization of microbial cell factories for the production of chemicals 
via in silico approaches are often employing biomass objective functions (i.e., in flux balance 
analyses, or COBRA methods) as basis (Feist et al., 2010; Feist and Palsson, 2010). 
Systematic gene knock-out strategies are designed to maximize growth rate and couple the 
formation of the compound of interest to the formation of biomass, e.g, as described for the 
production of vanillin (Pharkya et al., 2004). Also, isoprenoid fermentation processes 
typically rely on growing recombinant microorganisms (Table 1.1, Chapter 1). However, the 
fermentative production of isoprenoids thereby has to compete with cellular maintenance and 
growth for carbon and energy rendering the formed biomass an unproductive sink for carbon. 
On the other hand, the existence of biomass, including biocatalytic proteins, is essential for 
the biocatalytic reaction(s) itself. In Chapter 4, resting cells were applied as an alternative 
reaction engineering approach in order to reduce energy and carbon spilling towards the 
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formation of biomass. This approach resulted in increased limonene yields with respect to cell 
dry weight and glucose (Chapter 4). The stability of the resting cell biocatalyst was initially 
limiting, but was improved by optimization of the fermentation medium leading to high and 
stable limonene production rates for up to 8 h and a high specific yield of more than 
50 mglimonene gcdw-1 (Figure 7.1B), which is more than fivefold higher than the specific yield 
obtained with growing cells applied in Chapter 2. The long term stability and scaling 
opportunities have to be investigated to increase final isoprenoid concentration and specific 
yield using resting cells. Microbial growth was restricted in another, less laborious, attempt by 
supplying limiting amounts of essential magnesium sulfate to the minimal medium. 
Decreased growth rates and biomass yields with respect to the carbon source, but increased 
the specific limonene production fourfold as compared to a non-limited control culture were 
observed. Thus, the control of microbial growth, which in turn affects carbon partitioning, 
was identified as a key regulator on the reaction engineering level for the microbial 
production of limonene and might also be useful to improve the de novo synthesis of other 
valuable chemicals.  
A modular reaction concept provides access to various oxygenated monoterpenoids. The 
combination of the results of Chapter 3 and Chapter 4 constitutes the basis for a generalizable 
modular synthesis concept that allows for the production of various oxygenated 
monoterpenoids requiring only minor efforts in genetic engineering e.g., by replacing the 
genes for the monoterpene synthases or hydroxylases (Figure 7.2).  
The versatility of this approach was demonstrated by harnessing two different limonene 
hydroxylases (Chapter 3). Optimal expression conditions (e.g, genetic control elements, host, 
temperature) for each module can be established by separating the metabolic pathway 
modules amongst different microbial strains (even different species). Very recently, 
Stephanopoulos and co-workers reported a similar approach for coupling the de novo 
production of taxadiene to its oxygenation. Co-culture conditions were created by using a 
xylose consuming and acetate excreting E. coli strain harboring the diterpene formation 
pathway and a S. cerevisiae strain that grows on acetate and harbors the P450 hydroxylase 
genes (Zhou et al., 2015). Despite its elegance, this approach is only applicable for reactants 
with low volatility and intermediate toxicity to the applied microbial organisms, because 
tuning the stoichiometry of the sub-populations is hardly possible. The mixed-culture 
approach relying on resting cells presented in Chapter 3 comes alongside the enormous 
advantage that the stoichiometry between the two pathway modules can be readily adjusted. 
This aspect locates the mixed-culture approach at the interface between in vivo and in vitro 
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biocatalysis exploiting the good of both strategies, e.g., the stoichiometric controllability of in 
vitro systems and the stabilization and regeneration of enzymes in their natural in vivo 
environment. Furthermore, the decoupling of growth and product formation is a very mighty 
tool for more flexible control over the expression conditions with respect to temperature, 
medium, or host as compared to a co-culture based on interdependently growing microbial 
strains. The developed approach can be combined with metabolic pathway engineering 
strategies and the optimization successes described in Chapter 4 and might evolve into a 
powerful modular alternative for the production of highly-valuable oxygenated 
monoterpenoids. 
 
Figure 7.2: Schematic representation of the modular approach for the production of oxygenated 
monoterpenoids with two different non-growing, but metabolically active E. coli strains. The steps 
accomplished in this work are visualized by solid arrow lines, whereas promising future applications 
that can be achieved with minor genetic modifications are visualized by dashed arrow lines. 
A tubular reactor enables continuous limonene oxygenation. Coupling of limonene 
synthesis and its oxidation was shown to be limited by the availability of limonene (Chapter 
3). Although mixed-culture resting cell fermentations enabled the synthesis of perillyl acetate, 
the reaction was still limited by the availability of limonene, which is determined by the rate 
of limonene synthesis, the evaporation rate, and the solubility. The biofilm-based oxidation of 
limonene to the high-value compound perillic acid with native and recombinant solvent-
tolerant Pseudomonas strains expressing the p-cymene monooxygenase gene cymA and the 
alcohol dehydrogenase cymB, acting on limonene was investigated in the last experimental 
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part of this thesis (Chapter 5). For this, the respective biofilms were cultivated under 
segmented flow conditions on a tubular silicon support which was submerged into a bulk 
limonene phase in a sealed vessel. Perillic acid was continuously produced with both strains. 
The native strain P. putida GS1 reached very high volumetric production rates of up to 
35 g Ltube day-1. Perillic acid was successfully purified from the reactor efflux. Initial attempts 
to couple this biofilm-based perillic acid production to the fermentative de novo production of 
limonene by suspended resting recombinant E. coli (described in Chapter 4), however, yet 
remained unsuccessful. Nevertheless, the described miniaturized tubular biofilm reactor (inner 
tube diameter 2 mm) is ideally suited for the bioconversion or even de novo synthesis of toxic 
and volatile isoprenoids for several reasons. First, the bacterial cells embedded in a microbial 
biofilm are less susceptible to toxic reactants and can be cultivated to very high local biomass 
concentrations. Second, evaporation of limonene, which is then not available for the 
oxygenation, is significantly reduced by the tubular geometry of the bioreactor and the use of 
sealed vessels. Limonene diffuses into the biofilm reactor via the silicon membrane and 
necessarily passes the adjacent high cell density biofilm layer expressing the oxygenase. 
Third, reactant toxicity is prevented by the continuous removal of the products with the efflux 
stream. In addition, the toxic product can be removed, concentrated/isolated by selectively 
binding to a resin, or dissolved in a suitable organic phase. Therefore, coupling of limonene 
synthesis with suspended cells to its biofilm-based oxidation in a two-step process would be a 
very interesting and promising target for future process engineering research. 
Bioprocess design is guided by physicochemical properties of reactants. Inspired by our 
research on microbial limonene production, we discussed a framework for bioprocess design 
that is guided by physicochemical properties of the involved reactants. As do isoprenoids, 
many industrially relevant compounds feature challenging physicochemical properties such as 
hydrophobicity, volatility, or toxicity that frequently do not meet the evolutionary boundaries 
of industrially applied organisms and often limit their bioproduction. Therefore, genetic and 
technical strategies on the levels of cellular, reaction, and process engineering to overcome 
these constraints were systematically discussed regarding their applicability in multi-step 
biocatalysis. The conceived framework and the discussed concepts can be utilized as a 
generalized toolbox and adapted to aid bioprocess design for compounds – e.g., isoprenoids, 
alkaloids, polyketides, hydrocarbons, etc. – featuring challenging physiochemical properties 
and thus require concerted efforts in pathway, cellular, reaction, and process engineering.  
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7.2 Retrospect and future impact 
The development of a bio-based economy with environmentally friendly industrial processes 
based on renewable feed stocks made significant progress. However, strategies for the 
substitution of chemical processes with biotechnological processes are not yet defined 
comprehensively, especially with respect to closed substrate/product streams. Today, glucose 
and other organic carbon sources, which production is competing with food/feed supply for 
humans, are used for the biotechnological de novo synthesis of chemicals. This is particularly 
true for the biotechnological manufacturing of isoprenoids or other natural products. 
Impressive progress in the development of microbial cell factories that produce isoprenoids 
from renewable resources – including lignocellulosic biomass or carbon dioxide and 
sunlight – has been made, but the catalytic efficiency of many biological production processes 
is still very low. Whereas the identification of enzymes that produce novel isoprenoids with 
promising properties will be a subject of many future studies (supported by, e.g., genome 
mining or metagenomics approaches), the major challenge for industrial implementation will 
be the mutual complementation of strategies from different disciplines such as synthetic 
biology and metabolic and (bio)chemical engineering. In that view, it appears necessary that 
the integration of these strategies and the intensification of bioprocesses, traditionally 
conducted in the industrial environment, combined with a systematization of bioprocess 
design should become integral parts of application-oriented research also in academic 
laboratories.  
The results and achievements of the present work contribute to the research on microbial 
isoprenoid production processes by the systematic and concerted identification of process 
constraints on different levels of engineering. By shifting the focus from genetic pathway and 
cellular engineering towards a more holistic approach including reaction and process design, 
we demonstrate that the efficiency of an isoprenoid bioprocess with respect to product yield 
on biocatalyst or carbon source is constrained by multiple parameters on different levels. The 
results in this work prove that these constraints can be addressed by a multitude of different 
strategies, resulting in improved efficiencies, higher yields and, simplified workflows. 
However, sometimes these strategies might necessitate a rethinking of classical concepts in 
terms of biocatalyst configuration, reaction operation, or reactor design. But as it is valid for 
biological systems: “engineering process development in a competitive world is also an 
evolutionary process with all forces working for survival of the fittest components” (Weisz, 
1973). Thus, rethinking established concepts might very well be the right way to 
economically and ecologically competitive microbial production processes. 
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9.1 Nucleotide sequences of the truncated and codon-optimized genes 
Limonene synthase (from M. spicata, E57M truncation) 
ATGGAACGCCGCTCCGGTAACTACAATCCTTCCCGTTGGGACGTCAACTTCATCC
AGTCCCTGCTGTCGGACTACAAGGAAGACAAGCACGTCATCCGTGCTTCCGAACT
GGTGACCCTGGTTAAAATGGAACTGGAGAAGGAGACTGATCAGATCCGCCAGCT
GGAACTGATCGACGATCTGCAACGTATGGGCCTGAGCGATCACTTCCAAAACGA
GTTCAAAGAAATCCTGAGCAGCATCTACCTGGACCACCACTACTATAAGAACCCG
TTCCCTAAAGAAGAGCGTGACCTGTACTCCACCTCCCTGGCATTCCGCCTGCTGC
GTGAGCACGGCTTCCAAGTCGCTCAGGAGGTTTTCGACAGCTTCAAGAACGAAGA
GGGTGAGTTCAAAGAAAGCCTGTCGGACGACACCCGTGGCCTGCTGCAGCTGTAC
GAAGCGTCGTTCCTGCTGACCGAAGGTGAAACCACCCTGGAATCCGCTCGTGAGT
TCGCTACCAAATTCCTGGAGGAAAAGGTCAACGAGGGTGGTGTGGACGGTGATC
TGCTGACCCGTATTGCCTACTCCCTGGATATCCCGCTGCACTGGCGTATCAAACGT
CCGAACGCGCCAGTTTGGATCGAATGGTATCGCAAGCGTCCAGACATGAATCCGG
TTGTTCTGGAACTGGCGATCCTGGACCTGAACATCGTCCAAGCGCAGTTCCAGGA
AGAACTGAAAGAATCGTTCCGTTGGTGGCGTAACACTGGCTTCGTGGAGAAACTG
CCTTTCGCTCGCGATCGCCTGGTTGAGTGCTATTTCTGGAACACCGGCATCATCGA
GCCACGTCAGCACGCTTCCGCTCGTATCATGATGGGCAAGGTTAACGCCCTGATT
ACCGTCATCGACGACATCTACGATGTTTACGGCACCCTGGAGGAGCTGGAACAAT
TCACCGACCTGATCCGCCGTTGGGACATCAATAGCATCGACCAGCTGCCAGATTA
CATGCAGCTGTGCTTCCTGGCCCTGAACAACTTCGTTGACGACACCTCGTACGAC
GTCATGAAGGAAAAAGGTGTGAATGTTATCCCATACCTGCGCCAATCCTGGGTGG
ACCTGGCCGACAAGTACATGGTGGAAGCTCGTTGGTTCTACGGTGGTCACAAGCC
GTCCCTGGAAGAGTACCTGGAGAACTCGTGGCAGTCGATCAGCGGTCCTTGCATG
CTGACCCACATCTTCTTCCGTGTCACTGACTCGTTCACTAAGGAAACCGTTGATTC
GCTGTACAAGTACCATGACCTGGTGCGTTGGAGCAGCTTCGTGCTGCGTCTGGCT
GACGACCTGGGCACTAGCGTCGAAGAAGTCTCCCGTGGCGACGTTCCTAAATCCC
TGCAGTGCTACATGTCCGACTACAACGCTTCGGAAGCTGAAGCACGCAAGCACGT
TAAATGGCTGATCGCTGAGGTTTGGAAAAAGATGAACGCTGAACGTGTTAGCAA
GGACAGCCCGTTCGGCAAAGATTTCATCGGCTGCGCTGTGGACCTGGGTCGTATG
GCCCAACTGATGTATCATAACGGTGATGGCCACGGCACCCAACACCCGATCATCC
ACCAGCAGATGACCCGCACCCTGTTCGAACCATTCGCCTAA 
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GPP synthase 2 (from A. grandis, E86M truncation) 
ATGTTCGACTTCAATAAATACATGGACTCGAAAGCTATGACTGTAAACGAGGCTC
TGAACAAAGCTATCCCGCTGCGTTACCCGCAGAAGATCTACGAGAGCATGCGTTA
CAGCCTGCTGGCTGGCGGTAAACGTGTTCGTCCGGTTCTGTGCATCGCGGCTTGC
GAACTGGTCGGTGGCACCGAAGAACTGGCGATCCCAACTGCGTGCGCCATCGAG
ATGATCCACACCATGAGCCTGATGCACGACGATCTGCCGTGCATCGACAATGACG
ACCTGCGCCGTGGCAAACCGACCAACCACAAGATTTTCGGCGAGGATACCGCAG
TAACCGCGGGCAACGCACTGCACTCCTACGCTTTCGAGCATATCGCTGTTTCGAC
CTCCAAGACCGTTGGCGCTGACCGCATTCTGCGCATGGTTTCGGAACTGGGTCGC
GCTACCGGCTCCGAAGGCGTTATGGGTGGTCAAATGGTAGACATCGCTTCCGAAG
GCGACCCGTCCATCGACCTGCAAACCCTGGAATGGATTCACATCCACAAGACCGC
TATGCTGCTGGAATGCAGCGTAGTTTGCGGCGCTATCATCGGTGGTGCTTCGGAA
ATCGTAATCGAACGCGCCCGTCGTTACGCTCGTTGCGTAGGTCTGCTGTTCCAAGT
CGTAGACGACATCCTGGATGTCACTAAGTCGTCGGACGAACTGGGCAAAACCGCT
GGCAAAGACCTGATCTCGGACAAGGCAACCTACCCTAAGCTGATGGGCCTGGAG
AAGGCGAAAGAGTTCTCCGACGAACTGCTGAATCGCGCGAAAGGTGAACTGTCC
TGCTTCGACCCTGTTAAAGCGGCTCCTCTGCTGGGTCTGGCAGATTACGTCGCTTT
CCGCCAAAACTAA 
GPP synthase (from Streptomyces sp. strain KO-3988) 
ATGACCACCGATACCGGTCAGGATGCAGTTGGTCTGGCACGTCGTACCGGTGCAG
ATCTGCTGCATCGTGTTGAAGATCGTCTGCGTAGCCTGCTGGCAGTTGAACGTGA
TGCATGGGCAGCAGTTCATGAACAGGCAGTTGTTCCGGTTGATGCACTGAGCGAA
CTGATTGCAAGCGGTGGTAAACGTATTCGTCCGGCATTTTGTATTACCGGTTATCT
GGCAGCCGGTGGTGATCCGGCAGAGCCTGGTATTGTTGCAGCCGGTGCAGCACTG
GAAATGCTGCATCTGAGCGCACTGGTTCATGATGATGTTCTGGATGATAGCAGCA
GCCGTCGTGGTGTTCCGACCGTTCATACCCAGGCAATGGCACTGCATGAAAGCAG
CGGTTGGCAGGGTGAACCGCGTCGTTATGGTGAAGGTGTTGCAATTCTGGTTGGT
GATCTGGCACTGGTTTATAGCGAAGAACTGATGGCCGAAGCACCGCGTCGTGTTC
TGCCGGAATGGAATAAACTGCGTAGCGAAGTTATGATTGGCCAGTATATGGATGT
TCATGCAGCAGCAGAATTTAGCGTTGATCCGCGTAGCAGCCGTCTGATTGCACGT
ATTAAAAGCGGTCGTTATACCATTCATCGTCCGCTGGTTGTTGGTGCAAAACGTG
GTCGTGGTCGTGGCGATCTGGCACCGGCACTGGAAGAATATGGTGAAGCAGTTG
GTGAAGCATTTCAGCTGCGTGATGATCTGCTGGATGCAAGCGCAACACCGGCAGA
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AACCGGTAAACCGACCGGTCTGGATTTTACCCAGCATAAAATGACCCTGCTGCTG
GGTTGGGCAATGCAGCGTGATGAACATATTCATACCCTGGTTACCGAACCGGGTC 
ATACACCGGATGAAGTTCGTCGTCGTCTGCTGGATACCGGTGTTCCGGCAGATGT 
TGAACGTCATATTGCAGGTCTGGTTGAACGTGGTTGTAAAGCAATTGCAGATGCA 
CCGGTTGATCAGGTTTGGCGTGGTGAACTGGCAGCAATGGCAGGTCGTGTTGCAT 
ATCGTACCGCATAA 
9.2 Supporting Information for Figure 6.1 
The physiochemical properties of reactants that are natural (native) and non-natural (non-
native) to common biotechnological production strains such as E. coli are visualized in Figure 
6.1:. The following data set was used to build the figure. The data for the solubility and the 
vapor pressure were retrieved from www.chemspider.com.  
compound (“natural”) solubility/ 
mol m-3 
vapor pressure/ 
atm 
H2O 26755.5 0.054 
ADP 2340.8 2.71 · 10-14 
L-glutamate 141.3 1.45 · 10-9 
pyruvate 11487.0 9.10 · 10-4 
2-oxoglutarate 5767.5 9.44 · 10-8 
L-aspartate 62.2 3.45 · 10-10 
L-glutamine 288.8 3.35 · 10-10 
H2O2 29398.8 4.80 · 10-3 
glucose 3957.7 2.13 · 10-11 
glyceraldehyde-3-phosphate 5879.4 1.31 · 10-10 
acetate 16936.2 2.30 · 10-2 
oxaloacetic acid 7629.9 6.18 · 10-8 
dihydroxy-acetone-phosphate 5880.4 9.52 · 10-11 
glucose-1-phosphate 3844.1 4.02 · 10-14 
phosphoenolpyruvate 5986.8 1.98 · 10-10 
L-serine 3292.3 3.91 · 10-11 
fructose-6-phosphate 3844.1 4.02 · 10-14 
L-cysteine 2286.3 8.86 · 10-10 
reduced gluthathione 3253.9 1.17 · 10-16 
compound (“non-natural”) solubility/ 
mol m-3 
vapor pressure/ 
atm 
cyclohexane 0.65352 0.123 
cyclohexene 2.59301 0.113 
11-keto-β-boswellic acid 3.46 · 10-4 1.15 · 10-17 
phenol 871.31154 0.0046 
isobutanol 1146.75805 0.018 
geranic acid 1.64654 2.00 · 10-5 
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limonene 0.10129 0.0019 
styrene 2.9765 0.0066 
styrene oxide 24.9692 6.40 · 10-4 
α-pinene 0.01828 0.0053 
perillyl alcohol 7.9155 6.30 · 10-6 
perilly acetate 0.31914 3.42 · 10-5 
dodecanoic acid methyl ester 0.00614 2.50 · 10-5 
dodecanoic acid  0.02403 2.11 · 10-8 
dodecane 2.17 · 10-5 3.10 · 10-4 
octane 0.00578 0.019 
nonane 1.7154 0.0065 
abietic acid 0.1587 4.20 · 10-10 
benzaldehyde 61.85276 0.00144 
perillic acid 1.98536 2.90 · 10-5 
eugenol 14.98164 1.23 · 10-5 
vanillin 72.2985 6.18 · 10-7 
isoprene 9.42496 0.725 
amorphadiene 0.00189 3.80 · 10-5 
p-hydroxysytrene  43.66282 4.70 · 10-5 
pentane 0.52669 0.675 
heptane 0.03393 0.06 
cyclohexanol 419.33326 8.60 · 10-4 
caprolactone 148.18384 2.20 · 10-4 
hydroxydodecanoic acid 1.28515 5.25 · 10-10 
hydroxydodecanoic acid methyl ester 0.15703 1.71 · 10-8 
octanol 4.14657 1.30 · 10-4 
epothilon A 0.40311 1.47 · 10-21 
codeine 30.06374 2.50 · 10-13 
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9.3 Supporting Information for Figure 7.1 
All processes visualized in Figure 7.1 were summarized in Table 1.1. However, due to the 
shortage of space inside the figure, the respective processes are labeled with arabic numbers. 
This section assigns the respective numbers to the cited articles. 
1 (Xue and Ahring, 2011) 
2 (Yang et al., 2012a) 
3 (Zurbriggen et al., 2012) 
4 (Yang et al., 2013) 
5 (Kang et al., 2014) 
6 (Sarria et al., 2014) 
7 (Kim et al., 2015) 
8 (Alonso-Gutierrez et al., 2013) 
9 (Carter et al., 2003) 
10 (Du et al., 2014) 
11 (Jongedijk et al., 2014) 
12 (Kiyota et al., 2014) 
13 (Alonso-Gutierrez et al., 2013) 
14 (Mi et al., 2014) 
15 (Zhou et al., 2014) 
16 (Liu et al., 2013) 
17 (Zhang et al., 2014) 
18 (Wriessnegger et al., 2014) 
19 (Martin et al., 2003) 
20 (Tsuruta et al., 2009) 
21 (Westfall et al., 2012) 
22 (Paddon et al., 2013) 
23 (Asadollahi et al., 2009) 
24 (Peralta-Yahya et al., 2011) 
25 (Peralta-Yahya et al., 2011) 
26 (Albertsen et al., 2011) 
27 (Scalcinati et al., 2012) 
28 (Wang et al., 2010) 
29 (Dai et al., 2012) 
30 (Schalk et al., 2012)31
 (Boghigian et al., 2011) 
32 (Ajikumar et al., 2010) 
33 (Arens et al., 2014) 
34 (Zhou et al., 2015) 
35 (Leonard et al., 2010) 
36 (Nguyen et al., 2012) 
37 (Yoon et al., 2007) 
38 (Kim et al., 2009) 
39 (Alper et al., 2006) 
40 (Kim et al., 2011) 
41 (Jang et al., 2011) 
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